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General Introduction & Outline of the thesis
1.1 General Introduction
During the last decades prostate cancer has attracted an enormous attention in the 
field of scientific research as well as the non-professional press. The discovery of 
prostate-specific antigen (PSA), public prostate awareness and shifting population 
age distributions towards the elderly in many populations has prioritized prostate 
cancer research.
Prostate cancer is the most common human visceral malignancy and the second or 
third major cause of cancer death among men in the European Union.1'2 In 2007 more 
than 9,500 men were diagnosed with prostate cancer and more than 2,400 died of 
prostate cancer in the Netherlands. (www.ikcnet.nl, Association of Comprehensive 
Cancer Centers, the Netherlands) In many ways, prostate cancer is a natural part 
of the aging male. Autopsy studies show that men in the fourth decade of life have 
a one-third risk of harbouring small carcinomas. By the age of 60, this risk reaches 
approximately 60%. Numerous countries worldwide have shown similar rates of 
microscopical prostate cancer at autopsies. However, wide variations in clinically 
significant prostate cancer and prostate cancer death rates among these populations 
are seen.3'4 The lifetime risk of being diagnosed with prostate cancer now approaches 
1 in 10 in the Netherlands.5
Currently, the only established risk factors for prostate cancer are age, family history, 
race and a few dozens of low-penetrance genetic variants. Large geographic variation 
in prostate cancer incidence (with by far the highest rates in the USA and Canada) 
suggest that lifestyle factors related to westernization, are likely to be involved in the 
aetiology of prostate cancer. One particular lifestyle factor related to westernization 
is obesity.
Obesity is one of the most challenging and growing health problems in industrialized 
countries. It is now so widespread within the world's population that it is beginning 
to replace malnutrition and infectious diseases as the most significant contributor 
to ill health. In the United States, over the last 20 years the prevalence of obesity 
among adults has doubled to 30%.6 Although obesity is less common in Europe, the 
prevalence has also more than doubled during the last two decades.7 See figure 1 
for the prevalence of obesity in adults in Europe. According to Netherlands Statistics 
(Centraal Bureau voor de Statistiek, CBS, available at: http://statline.cbs.nl), in 2008 
less than half of the Dutch adult men had a normal weight, 42% had overweight and 
10% was obese. (figure 2)
What is obesity?
Obesity can be defined as a condition in which excess body fat has accumulated 
to such an extent that health may be adversely affected. There is a disbalance
13
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Figure 1 Prevalence of adult obesity in males. International Obesity Task Force.
(available a t: http ://w ww .iotf.org/m edia/europeadults.pdf)
between caloric intake and expenditure. Although genetic differences are important 
(as illustrated by the extremely high occurrence of obesity among Pima Indians in 
the USA), the marked rise in prevalence of obesity is best explained by behavioural 
and environmental changes. Body weight is determined by an interaction between 
genetic, environmental and psychosocial factors8 (figure 3). The transition from an 
active lifestyle during the teens and twenties to a more sedentary lifestyle thereafter 
is also associated with weight gain in many men. The distribution of body fat (visceral 
and nonvisceral, i.e. subcutaneous) is clinically important. Visceral central adiposity 
is associated with a greater risk of metabolic and cardiovascular disorders including 
insulin resistance, type 2 diabetes mellitus, hypertension and coronary heart disease, 
a combination of phenotypes known as the 'metabolic syndrome'. Obesity is not a 
single disorder but a heterogeneous group of conditions with multiple causes.
How to measure obesity?
Currently there is no universally accepted method of measuring obesity. In clinical 
practice, body fat is most commonly and simply estimated by using a formula that 
standardizes weight by height. The underlying assumption is that most variation in
14
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Figure 2 Percentage of Dutch adult men who have overweight or are obese according to the 
Netherlands Statistics (CBS). (availab le a t: http://sta tline.cbs.n l)
Figure 3 Factors influencing the development of obesity.
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weight for persons of the same height is due to fat mass. By far the most widely used 
weight-for-height measure is the body mass index (BMI, also called Quetelet's Index), 
which is defined as weight (in kilograms) divided by height (in metres squared).9 The 
World Health Organization (WHO) expert committee has proposed a classification of 
overweight and obesity.10 (table 1)
The main limitation of BMI is that it does not distinguish fat mass from lean mass. 
For example, BMI may overestimate the degree of obesity in individuals who are 
overweight but very muscular (professional athletes or bodybuilders). Another 
limitation is that the relationship between percent body fat and BMI is different among 
different ethnic groups. In some populations, the level of risk in terms of percent 
body fat is reached at a lower BMI (South Asians), and in others, at a higher BMI 
(blacks), compared to whites. However, population-specific cut-offs are not currently 
available, and therefore the WHO definition has been widely adopted. Despite these 
shortcomings, there is a close relationship between BMI and the incidence of several 
chronic conditions caused by excess fat.8
Other anthropometric measures commonly used in epidemiological studies to quantify 
obesity are the waist-to-hip ratio (WHR) and, more recently, waist circumference 
(WC). WHR and WC try to capture abdominal adipose tissue (or circumference) 
and fat distribution. The waist is defined as the abdominal circumference midway 
between the costal margin and the crest of the iliac. The largest circumference just 
below the iliac crest is defined as the hip. For men a WHR > 0.90 or WC > 94 cm is 
a fairly accurate determination of an increased risk for obesity-related events.11 In 
patients with a BMI > 35 kg/m2, measurement of waist circumference is less helpful 
since it adds little to the predictive power of the disease risk classification of BMI; 
almost all individuals with this BMI also have an abnormal waist circumference.
As mentioned before, obesity is associated with numerous conditions that include 
hypertension, high glucose levels, dyslipidemia, and central adiposity. This cluster 
of conditions refers to the metabolic syndrome.12 This metabolic syndrome is
Classification BMI (kg/m2) Risk of comorbidities
Normal 18.5-24.9 average
Overweight 25-29.9 increased
Obesity > 30
Grade I 30-34.9 moderate
Grade II 35-39.9 severe
Grade III > 40 very severe
Table 1 Classification of body mass index (BMI) proposed by a WHO expert committee and risk 
of comorbidity.
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Figure 4 PubMed search "obesity" AND "prostate cancer". Number o f publications itemized 
by year.
accompanied by numerous chronic diseases, including hypertension, coronary artery 
disease, asthma, diabetes and arthritis.13 In addition to its link to several chronic 
medical conditions, obesity has also been identified as a risk factor for cancer-related 
death for several cancers, like some colon cancers, postmenopausal breast cancer, 
endometrial cancers, kidney cancers, and adenocarcinomas of the oesophagus.14'15 
In Europe obesity accounts for up to 6% of direct health costs and more than 12% 
of indirect health costs like, a reduced life span, reduced productivity, and lower 
incomes.16
Besides the ongoing obesity epidemic, the incidence and prevalence of prostate 
cancer have risen substantially, starting to be a major health problem too. This 
increase in incidence and prevalence began with the introduction of PSA, growing 
prostate awareness and increasing accessibility to public health care.17 Any association 
between obesity and prostate cancer might have important clinical and public health 
implications. This possible association has gained popularity in the field of scientific 
research. In the past five years the number of published scientific papers about this 
topic has risen spectacularly. (figure 4)
Although a relation between obesity and increased risk of several types of cancer 
is described in epidemiological studies, the exact pathophysiology underlying this 
association is not well understood.14'15 Alteration in sex hormones, growth factors 
and cytokines have been postulated. The link between having prostate cancer in 
specific and obesity is inconsistent.18-21 There is, however, evidence that there is an 
association between the role of obesity and the increased risk of having an aggressive 
prostate cancer.22'23 With the increased incidence of both obesity and prostate cancer, 
it is plausible that physicians will be confronted with an obese patient suffering from 
prostate cancer more often. Studies have also suggested that obesity increased the
17
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risk of biochemical recurrence after prostate cancer therapy.24-29All these studies 
are performed in the USA. Compared to Europe, the population of the USA is not 
only more obese but the composition of the population is also different. In these 
studies obesity is measured using BMI. It may be questioned whether obese patients 
(measured using BMI) from Europe have a similar risk of developing biochemical 
recurrence. Furthermore, are other measurements for obesity more appropriate to 
use when studying the association between obesity and the risk of advanced prostate 
cancer or biochemical recurrence?
Besides active surveillance, patients with localized prostate cancer can be treated with 
different treatment modalities like surgery (open or laparoscopic/ robotic assisted) 
and radiotherapy (external or permanent brachytherapy). The exact role of obesity in 
terms of functional outcomes when treated with one of the treatment options is not 
well known and few data about this topic are published. However, knowledge of the 
role of obesity in this respect is of great importance when informing an obese patient 
suffering from prostate cancer about the different treatment options.
1.2 Outline of the thesis
Growing interest in the potential association between obesity and prostate cancer is 
seen, which is reflected in the rising number of articles published in recent years. This 
thesis describes and discusses the clinical implications of obesity on prostate cancer 
in a Dutch population. To shed light over the functional and oncological outcomes of 
prostate cancer patients in relation to obesity, several studies have been performed. 
To obtain more knowledge on how obesity is related to prostate cancer, the literature 
is thoroughly reviewed in chapter 2. As a sequel to obesity, different hormonal changes 
occur. Besides these changes other biological mechanisms potentially affecting the 
prostate take place. The potential link between obesity and the development and 
detection of prostate cancer is also discussed. Finally the impact of obesity on surgical 
outcomes and biochemical recurrence following prostate surgery and radiotherapy 
are summarized in this section.
Urinary incontinence is a well-known complication after a radical prostatectomy and 
feared by both the patient and the urologist. Very few studies are available about 
the impact of obesity on surgical outcomes. The results of a single centre historical 
cohort of 252 men who underwent an open radical prostatectomy are described in 
chapter 3. This chapter provides information whether obesity is a complicating factor 
in terms of incontinence, vesico-urethral strictures and postoperative morbidity 
when performing an open radical prostatectomy.
18
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Different studies carried out in The United States of America revealed a higher 
risk of biochemical recurrence in obese patients suffering from localized prostate 
cancer undergoing a radical prostatectomy. In chapter 4, a multicenter analysis was 
performed to identify if obesity is also a prognostic marker for biochemical recurrence 
in a Dutch cohort of men who underwent a radical prostatectomy.
Permanent prostate brachytherapy is another treatment modality used for patients 
having clinically localized prostate cancer. Chapter 5 deals with another important 
clinical issue: does obesity influence treatment outcomes in patients who underwent 
permanent brachytherapy? In this section we describe the effect of obesity on 
biochemical recurrence and cancer specific survival in a large cohort of Dutch men 
who underwent brachytherapy.
Abdominal, especially visceral fat, is the most active endocrine organ. Almost 
all studies, which studied the effect of obesity on prostate cancer outcome, have 
used BMI to measure obesity. In chapter 6, we conducted a study to assess if the 
distribution of body fat contributes to the prediction of aggressive prostate cancer. To 
test this hypothesis we compared periprostatic fat and subcutaneous fat measured on 
computed tomography with body mass index to identify if periprostatic fat is a better 
marker for aggressive disease in men who underwent brachytherapy. Because this 
study population consisted mostly of patients with low and intermediate risk disease 
we also conducted a similar study in chapter 7, where we also included patients 
who underwent external radiotherapy. By doing so, we created a more mixed group 
consisting of both low/intermediate and high-risk prostate cancer.
It has been hypothesized that blood lipid profiles are associated with prostate 
cancer risk; however, results are fairly inconsistent and underlying mechanisms are 
not fully understood. The aim of the study presented in chapter 8 was to address 
the association between serum total cholesterol, HDL cholesterol, LDL cholesterol, 
triglycerides and prostate cancer risk in a Dutch, prospective cohort study. Finally, 
chapter 9, provides a general discussion and the conclusions of these thesis and 
chapter 10 gives a summary of the thesis.
19
Chapter 1
Reference List
1. Lutz JM, Francisci S, Mugno E et al. Cancer prevalence in Central Europe: the EUROPREVAL 
Study. Ann.Oncol. 2003; 14: 313-22.
2. Levi F, Lucchini F, Negri E et al. Trends in m ortality from major cancers in the European 
Union, including acceding countries, in 2004. Cancer 2004; 101: 2843-50.
3. Yatani R, Chigusa I, Akazaki K et al. Geographic pathology of latent prostatic carcinoma. 
Int.J.Cancer 1982; 29: 611-6.
4. Sakr WA, Grignon DJ, Crissman JD et al. High grade prostatic intraepithelial neoplasia 
(HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 
249 cases. In Vivo 1994; 8: 439-43.
5. http://www.ikcnet.nl/page.php?id=2616&nav_id=114
6. Ogden CL, Carroll MD, Curtin LR et al. Prevalence of overweight and obesity in the United 
States, 1999-2004. JAMA 2006; 295: 1549-55.
7. James PT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future 
prevention strategies. Eur.J.Cardiovasc.Prev.Rehabil. 2004; 11: 3-8.
8. W illett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N.Engl.J.Med. 1999; 
341: 427-34.
9. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and 
proposed mechanisms. Nat.Rev.Cancer 2004; 4: 579-91.
10. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. 
World Health Organ Tech.Rep.Ser. 2000; 894: i-253.
11. Han TS, Sattar N, Lean M. ABC of obesity. Assessment of obesity and its clinical 
implications. BMJ 2006; 333: 695-8.
12. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 
881-7.
13. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity- 
related health risk factors, 2001. JAMA 2003; 289: 76-9.
14. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from 
cancer in a prospectively studied cohort of U.S. adults. N.Engl.J.Med. 2003; 348: 1625-38.
15. Reeves GK, Pirie K, Beral V et al. Cancer incidence and mortality in relation to body mass 
index in the Million Women Study: cohort study. BMJ 2007; 335: 1134.
16. Groves T. Pandemic obesity in Europe. BMJ 2006; 333: 1081.
17. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence 
and mortality. Part I: international comparisons. BJU.Int. 2002; 90: 162-73.
18. Andersson SO, Wolk A, Bergstrom R et al. Body size and prostate cancer: a 20-year 
follow-up study among 135006 Swedish construction workers. J.Natl.Cancer Inst. 1997; 
89: 385-9.
19. Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate cancer: a follow-up 
of 950000 Norwegian men. Br.J.Cancer 2003; 89: 1237-42.
20. Jonsson F, Wolk A, Pedersen NL et al. Obesity and hormone-dependent tumors: cohort and 
co-twin control studies based on the Swedish Twin Registry. Int.J.Cancer 2003; 106: 594-9.
21. Bradbury BD, W ilk JB, Kaye JA. Obesity and the risk of prostate cancer (United States). 
Cancer Causes Control 2005; 16: 637-41.
22. Ma J, Li H, Giovannucci E et al. Prediagnostic body-mass index, plasma C-peptide 
concentration, and prostate cancer-specific mortality in men w ith prostate cancer: a 
long-term survival analysis. Lancet Oncol. 2008; 9:1039-41.
20
General Introduction & Outline of the thesis
23. Wright ME, Chang SC, Schatzkin A et al. Prospective study of adiposity and weight change 
in relation to prostate cancer incidence and mortality. Cancer 2007; 109: 675-84.
24. Amling CL, Riffenburgh RH, Sun L et al. Pathologic variables and recurrence rates as 
related to obesity and race in men w ith prostate cancer undergoing radical prostatectomy. 
J.Clin.Oncol. 2004; 22: 439-45.
25. Freedland SJ, Aronson WJ, Kane CJ et al. Impact of obesity on biochemical control after 
radical prostatectomy for clinically localized prostate cancer: a report by the Shared 
Equal Access Regional Cancer Hospital database study group. J.Clin.Oncol. 2004; 22: 
446-53.
26. Bassett WW, Cooperberg MR, Sadetsky N et al. Impact of obesity on prostate cancer 
recurrence after radical prostatectomy: data from CaPSURE. Urology 2005; 66: 1060-5.
27. Strom SS, Wang X, Pettaway CA et al. Obesity, weight gain, and risk of biochemical failure 
among prostate cancer patients following prostatectomy. Clin.Cancer Res. 2005; 11: 
6889-94.
28. Palma D, Pickles T, Tyldesley S. Obesity as a predictor of biochemical recurrence and 
survival after radiation therapy for prostate cancer. BJU.Int. 2007; 100: 315-9.
29. Strom SS, Kamat AM, Gruschkus SK et al. Influence of obesity on biochemical and clinical 
failure after external-beam radiotherapy for localized prostate cancer. Cancer 2006; 107: 
631-9.
21

The impact of obesity on prostate cancer
Based on a review article:
The impact of obesity on prostate cancer
World J Urol. 2007 Oct; 25:491-7
JGH van Roermund 
JA W itjes
PROSTATE CANCER. CLINICAL IMPLICATIONS OF OBESITY
Chapter 2
24
Impact of obesity on prostate cancer
This chapter reviews the most relevant hormonal and adipokines alterations 
caused by obesity and the possible effect of these changes on prostate cancer (PC) 
development and progression. In relation to PC treatment, the impact of obesity 
and its influence on functional and oncological outcomes of the different treatment 
modalities for PC are discussed.
2.1 Potential biochemical mechanisms affecting the prostate
Adipose tissue constitutes a large, active endocrine and metabolic organ. Adipocytes 
contain the cytochrome P450 aromatase enzymes, which are encoded by the CYP19 
gene. These enzymes are responsible for catalyzing the conversion of androgens to 
estrone and estradiol. Adipocytes can also secrete a myriad of peptides (adipokines) 
that intervene in the framework of a complex network of endocrine, autocrine 
and paracrine signals.1 Although the exact biochemical processes underlying the 
association between PC and obesity are unknown, several potential mechanisms 
have been proposed and will be discussed in this paragraph.
2.1.2 Androgen pathway
PC is a sex steroid (estrogens, androgens and progesterone) sensitive disease. Thus, 
steroid hormone alterations associated with obesity may play some role. Obesity 
has an important impact on the synthesis and bioavailability of endogenous sex 
steroids and is associated with increased serum estradiol and decreased serum 
concentrations of free testosterone. Increased levels of estradiol are caused 
by peripheral conversion of testosterone to estradiol by increased aromatase 
activity secondary to the accumulation of adipose tissue. Obesity also reduces the 
concentrations of sex-hormone-binding globulin (SHBG). Both phenomena increase 
the fraction of bioavailable estradiol and lead to a reduction in total testicular 
testosterone production.2'3
Although estrogens have been proven to be an effective therapy for metastatic 
PC treatment, it is not used anymore due to its higher mortality rate, caused by 
cardiovascular complications. It is well known that most prostatic carcinomas are 
hormone dependent and that approximately 70-80% of men with metastatic PC 
respond to various forms of androgen deprivation therapy by lowering testosterone 
levels to castration levels. Nowadays this is the first choice for patients with 
metastatic PC. At first sight obesity (increased levels of estrogens and lower levels of 
testosterone) might seem protective for PC. However, reports have shown a lower 
preoperative total testosterone correlated with a poorer pathological stage at the 
time of surgery.4-6 Also, a large prospective case-control study nested in cohorts in 
Finland, Norway and Sweden, found a modest, but significant decrease in PC risk 
for increasing levels of total testosterone.7 Although estrogen was used as an anti­
25
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androgen in the treatment of PC, the role of estrogen in PC aetiology is unclear. Several 
lines of evidence suggest that estrogens may enhance prostate carcinogenesis. First, 
through the actions of SHBG, estrogen has direct and indirect effects on epithelial 
cell differentiation and proliferation.8 Second, estrogens may interact with the 
SHBG receptor in the stroma of the prostate gland to activate insulin-like growth 
factor (IGF) synthesis and direct stromal proliferation (through IGFs), to mediate the 
response to epithelial cells to androgens.9 Third, experimental studies addressed that 
induction of prostate tumours by administration of testosterone in laboratory rats 
was considerably enhanced by the addition of estradiol, suggesting that estrogens in 
conjunction with androgens may stimulate the development of PC.10 Finally, prenatal 
exposure to an extremely low dose of diethylstilbestrol (DES) and other estrogenic 
compounds significantly affected mouse prostate development in vivo and in vitro in 
the presence of androgens and increased the risk of PC in offspring of DES-exposed 
mothers.11'12 Together, although estrogen has been used as an anti-androgen in the 
treatment of advanced PC, these data suggest that estrogens may enhance the risk 
of PC earlier in life.
2.1.3 Adipokines
Beyond alterations in sex steroid hormones, obesity is also associated with increased 
levels of several adipokines, such as leptin, insulin-like growth factor-1 (IGF-1), 
tumour necrosis factor a (TNF-a), interleukin 6 (IL-6), vascular endothelial growth 
factor (VEGF), and decreased level of adiponectin.
Leptin
Leptin, first described by Zhang et al. in 199413, is a 16-kD adipokine produced by 
adipocytes in white adipose tissue and plays a major role in controlling body weight 
homeostasis. Circulating leptin concentrations exhibit a positive correlation with the 
degree of obesity and leptin receptors have been identified in the prostate gland, 
suggesting a plausible biological role in this gland.14'15
Recently, leptin has been shown to stimulate the in vitro growth of hormone refractory 
PC cell lines.16'17 In both reports leptin caused a significant proliferation in both the 
PC-3 and DU145 cell lines when compared with untreated control cells.
The proliferative response of PC cells to leptin has been shown to involve intracellular 
signalling molecules such as phosphatidyl-inositol 3-kinase (p13-K) and c-Jun NH2- 
terminal kinase (JNK).16'18 Alterations in these signalling pathways are not only critical 
in processes of prostate carcinogenesis and malignant transformation, but also 
important in obesity, diabetes, and insulin resistance.19
Results of clinical studies addressing the relation between leptin and PC are not 
consistent. A Chinese case-control study reported an increased risk of PC, but the 
trends were not statistically significant.20 After adjustment for age, men in the highest
26
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tertile of leptin levels had an approximately twofold risk of PC (Odds ratio, OR=1.78, 
95% confidence interval (CI)=1.07-2.95). However, a Norwegian case-control study 
found no support for this hypothesis (OR=0.9, 95% CI=0.6-1.6).21 Although the risk 
for PC in individuals with higher levels of leptin is not clearly proven, some studies 
showed that higher levels of leptin were linked to tumour progression and advanced 
disease. Saglam et al.22 noticed in a cross-sectional study that elevated leptin was 
significantly associated with poorly differentiated cancer and a greater frequency 
of extraprostatic cancer. Chang et al.23 reported men with elevated plasma leptin 
concentrations had an increased risk of being diagnosed with high-volume PC that 
was attenuated after adjustment for body mass index (BMI) (OR=2.41, 95% CI=0.93- 
4.58). One study, a cohort of 225 men, did not find a relation between serum leptin 
and advanced pathological stage (pT3a, extraprostatic extension; OR=1.14, 95% 
CI=0.76-1.71). However this study was done in predominantly white men with mainly 
low risk disease (28% of the patients had a pT3a).24 In all, these observations suggest 
that leptin may play no role in initiation of PC but may rather play some part in the 
progression of PC.
Insulin-like growth factor-1
The metabolic (or insulin resistance) syndrome is characterized by a cluster of 
biochemical abnormalities and associated clinical conditions, not all of which are 
necessarily present in a given case, but which include disturbed glucose metabolism 
and insulin bioactivity resulting in hyperglycaemia and hyperinsulinemia, dyslipidemia 
(hyper-triglyceridemia and low levels of HDL cholesterol), hypertension and type 2 
diabetes.25 Central obesity is often present, but the syndrome does occur in its absence. 
In obesity, different endocrine and metabolic signals lead to insulin resistance, resulting 
in a chronic compensatory hyperinsulinaemia and increased levels of bioavailable 
IGF-1. In their turn, insulin and IGF-1 promote cellular proliferation and inhibit 
apoptosis in many tissue types.2 These effects may be responsible for tumorigenesis 
of PC in obese patients. In an in vitro study a significantly lower proliferation rate 
of androgen-independent PC-3 prostate cells was seen in IGF-1 deficient hosts in 
comparison to IGF-1 expressing hosts.13 Recently, Cox et al. discovered the presence 
of insulin receptors on human prostate cancers. The findings are relevant because 
this may explain the hypothesis that obesity associated hyperinsulinemia mediates 
the adverse effect of obesity on PC prognosis.26 In addition several prospective 
cohort and case-control studies have shown positive associations between PC risk 
and circulating IGF-1 level in men.27-29
Tumour necrosis factor a
Human TNF-a is a 17 kDa pleiotropic cytokine produced by a variety of cells including 
macrophages, monocytes, T cells and nonhematopoietic cells. It can regulate a wide
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variety of cellular responses including proliferation, differentiation, inflammation 
and cell death. In obese men higher levels of TNF-a were seen in those with a higher 
BMI.30 Although several studies have documented the ability of TNF-a to promote 
development of neoplasia, 31-34 studies that investigated the effect on PC are sparse. 
No study investigated the direct effect of obesity on TNF-a and the development of 
PC. Few studies have examined associations between TNF polymorphisms and PC 
risk. Results have been mixed, with one observing significant associations with PC 
risk35 while three others did not.36-38
Interleukin 6
IL-6 circulates in multiple glycosylated forms ranging from 22 to 27 kDa and is involved 
in regulation of multiple cellular functions like proliferation, apoptosis, angiogenesis, 
and differentiation. Many different cell types, including adipocytes, immune cells, 
fibroblasts, endothelial cells, monocytes and a variety of endocrine cells, produce 
it. Adipocytes only produce 10% of the total tissue production and it circulates at 
high levels in the peripheral blood.39'40 Interestingly, studies have shown a positive 
correlation between circulating levels of IL-6 and obesity.41-43
Adler et al. reported that IL-6 is also produced by human prostate cancer cells and is 
elevated in patients with PC.44 In vitro studies using androgen-independent prostate 
cancer cell lines show they secrete high levels of IL-6 into the culture medium, 
suggesting a function of IL-6 as an autocrine or paracrine regulator of PC growth.45'46 
More importantly, results of several reports demonstrate that higher levels of IL-6 
in patients with advanced PC were associated with poor prognosis compared to the 
patients with lower IL-6 levels.47-49 Obesity-related increases in IL-6 levels could thus 
potentially interfere and enhance this mechanism and further promote prostate 
carcinogenesis.
Vascular endothelial growth factor
Angiogenesis is a process by which new blood vessels are formed from pre-existing 
vasculature. VEGF is the most prominent cytokine responsible for endothelial cell 
differentiation, migration, proliferation, tube formation, and vessel assembly.50 VEGF 
regulates physiological angiogenesis, but also plays a crucial role in pathological 
angiogenesis associated with PC and facilitates local invasion of malignant cells and 
the development of distant metastases.51 Studies have shown a correlation between 
obesity and the level of VEGF. In their turn, plasma VEGF levels have shown positive 
correlation with tumour stage, grade and clinical outcome.52-54 
Although no studies have reported the direct correlation between obesity, VEGF 
plasma levels and PC risk, it is attractive to speculate that PC cells may also be 
influenced by increased VEGF plasma levels secreted by adipocytes in obese 
patients.
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Adiponectin
Adiponectin, a 30 kDa collagen-like protein, is exclusively synthesized in adipocytes 
and circulated in the peripheral blood at a concentration which amounts to 0.05% of 
the total serum proteins.55 It plays an important role in regulating energy metabolism 
and inflammation. In contrast to other adipokines, plasma levels are negatively 
correlated with obesity and especially visceral fat accumulation. The regulation of 
adiponectin secretion is complex and poorly understood. Multiple hormones appear 
to have a role, including TNF-a, IGF-1, glucocorticoids and ß-adrenergic agonists.56 
It is secreted with a diurnal variation, attaining a nadir in the early morning. The two 
putative adiponectin receptors (AdipoR1 and AdipoR2) have not only been expressed 
in metabolically active organs but also in the LNCaP-FGC, DU145 and PC-3 prostate 
cancer cell lines.18 Thus, in addition to its insulin-sensitizing role, adiponectin may also 
regulate cell proliferation and specific signalling pathways in cancer cells. Recently an 
oligomer of adiponectin inhibited proliferation of an androgen-dependent (LNCaP- 
FGC) as well as two androgen-independent (DU 145 and PC-3) prostate cancer cell 
lines. It should be noted that this study was performed under serum-free conditions, 
which may favour a decrease in cell proliferation and/or inhibit cell growth.57 A small 
case-control study of PC patients, patients with benign prostatic hyperplasia (BPH), 
and healthy subjects found significantly reduced adiponectin concentrations in men 
with PC relative to BPH and healthy controls.58 Another case-control study found a 
marked reduction in PC risk in patients with higher serum adiponectin levels.59 The 
relationship between serum adiponectin and PC aggressiveness was investigated by 
two studies.60'61 Both studies found an inverse relation between serum adiponectin 
and high grade PC. However, the direction of the association may depend on the 
extent of obesity.
In summary, possible mechanisms by which obesity may impact upon PC include 
altered serum steroid hormones, leptin, insulin, IGF-1, TNF-a, IL-6, VEGF levels 
and decreased levels of adiponectin. (figure 1, gives an overview of the possible 
mechanisms for obesity-related PC progression) Most studies of hormone levels and 
PC risk have evaluated each hormone individually. Difficulties comparing these studies 
are caused by complex interrelationships between hormones, binding proteins and 
their receptors and the moment of exposure. In addition, most studies on adiposity 
usually reflect a single evaluation in time, while cumulative effect of fat content (all­
life exposure) may be of greater importance in prostatic disease development.
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2.2 The risk of obesity on the development of prostate cancer
Large studies have addressed the association of obesity and the risk of PC. However, 
inconsistent results are reported. Two large historical cohort studies, one among 
135,000 Swedish construction workers and a large Norwegian cohort of 950,000 
men, reported a positive relation between BMI and PC,62'63 while another prospective 
population-based cohort study found no association.64 In contrast, in two recent 
studies an inverse relation between BMI and PC risk was found.65'66 It should be noted 
that non-biological explanations may contribute to the apparent disparate results
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among epidemiological studies. For example, some studies were done before the 
prostate-specific antigen (PSA) era and different BMI categorizations were used.
One of the limitations is that most of these studies have been focused on recent 
BMI, which mainly means obesity late in life. This is important, because obesity in 
preadolescent years might be more critical for the development of PC later in life. 
An Australian population-based, case-control study reported no association between 
BMI measured at the age of 21 and the risk of developing PC later in life.67 However, 
Robson et al. and the Health Professionals Follow-up Study, who addressed the effect 
of obesity before the age of 30, found an inverse relation of preadolescent and early- 
adult obesity with a diagnosis of advanced PC later in life.68'69 
Another difficulty comparing the epidemiologic studies is that most of the 
epidemiologic studies accept all PCs as one biological entity when it is probable that 
PC is biologically heterogeneous, not only in terms of grade and stage but also with 
respect to its clinical behaviour.70
In summary, obesity is associated with endocrine changes and hormonal factors have 
been implicated in the cause of PC. A link between BMI and the risk of developing 
PC may be expected. However, the results of the large studies were inconsistent 
and do not permit definite conclusions. It demonstrates the difficulty to interpret 
epidemiologic data when it comes to obesity and PC risk.
2.3 Obesity and prostate cancer aggressiveness
The relation between obesity and PC risk is complex. Although it has been studied 
extensively, it remains inconclusive. Studies that have linked obesity with PC mortality, 
advanced stage disease, and high grade Gleason score, however, have produced 
more consistent results.
In the Physicians' Health Study, which has a prospective design, 2,546 men developed 
PC and 281 (11%) died from PC during the 24-year follow-up. Compared with normal 
weight men, obese men had a 2.66 (95% CI 1.62-4.39) higher risk to die from their 
disease.71 Unfortunately, data on different choices of treatment for the PC patients 
were not available. In another prospective study of obesity in relation to PC mortality, 
obesity was not related to PC incidence, but a 2.12 (95% CI 0.92-2.33) higher risk of 
PC mortality was seen in the highest BMI category.72 The correlation between obesity 
and fatal PC is also confirmed by other authors.62'72-74 In line with PC mortality, studies 
have been published about the increased risk of advanced PC in obese patients.74-77 
The Cancer Prevention Study II Nutrition Cohort is a very large prospective study that 
enrolled 86,404 males and investigated the link between aggressive PC and obesity.74 
During the 12 years of follow-up 5,252 incident primary PC cases were diagnosed.
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The results of the study suggested that obese patients were at increased risk to 
develop more aggressive PC compared to the normal weight men.
These observations suggest that the relationship between obesity and PC is the 
result of its biological effects in promoting an aggressive phenotype rather than the 
transformation of the prostatic epithelium per se.
2.4 The effect of obesity on screening and detection of prostate 
cancer
Transrectal ultrasonography (TRUS) guided prostate needle biopsy has become 
the cornerstone in the detection of PC. A biopsy is performed when patients have 
an abnormal digital rectal examination (DRE) and/ or elevated PSA level and/ or 
abnormal TRUS. Factors that alter PSA, DRE or influence TRUS guided biopsies can 
have an impact on the detectability of PC, unrelated to cancer biology.
When considering the likelihood of detecting PC in glands of various sizes, several 
factors must be considered, e.g. the prevalence of cancer in prostates of different 
sizes, tumour volume, distribution of the lesion or lesions, and the overall size of 
the biopsy specimen in relation to that of the gland. Several authors have studied 
the impact of prostate volume. In a study by Eskicorapci et al., 503 men with an 
abnormal DRE and, or elevated PSA level (>2.5 ng/ml) were included.78 The cancer 
detection rates decreased significantly from 50% to 28% for patients with a prostate 
volume between 14.9 to 35.0 cc and 35.1 to 50.0 cc, respectively. Uzzo et al. stated 
that patients with a prostate volume of 50 cc or lower had significantly higher cancer 
detection rates than patients with a prostate volume of higher than 50 cc (38% vs 
23%).79 Karakiewicz et al. confirmed these findings.80 With this in mind, studies have 
shown variations in prostate size with increasing degrees of obesity. An American 
case-control study of black men found that BMI was directly associated with the 
prostate volume.81 Additionally, in two other studies, the prospective Veterans Affairs 
Normative Aging study and a second one carried out in a population of men with 
lower urinary tract symptoms, obesity was also directly associated with prostate 
volume.82'83 Recently, a prospective cohort study composed of community volunteers 
found that obesity and abnormal glucose homeostasis potentially influence prostate 
growth through mechanisms other than testosterone.84
DRE, is harder to perform in obese men, so palpable nodules can be missed. The 
difficulties in performing the DRE, however, have been challenging to quantify. 
Furthermore, nowadays, most PC's are detected on biopsy following an abnormal 
PSA. Multiple studies have shown an inverse relationship between serum PSA levels 
and BMI. A recent population-based study examined the association between BMI 
and PSA levels in nearly 3,000 men without PC.85 The authors found that the mean
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PSA level decreased with increasing BMI, such that the mean PSA level in men with 
a normal BMI was 1.01 ng/ml and the mean PSA level in morbidly obese men (BMI > 
40 kg/m2) was 0.69 ng/ml. In the multivariate model, age and race did not attenuate 
the association between PSA levels and BMI. The authors hypothesized that PSA 
production is androgen-dependent and that obesity is associated with lower levels 
of circulating androgens. Recent studies found the same association between BMI 
and PSA.86;87 In the study of Banez et al.86 patients underwent a radical prostatectomy 
(RP). After controlling for clinicopathological characteristics, higher BMI was also 
associated with higher plasma volume. They concluded that hemodilution might be 
responsible for the lower PSA levels among obese men with PC.
Taken together, lower PSA levels result in possible delayed biopsies because it takes 
longer for PSA levels to rise above a given threshold. The combination of this delay 
and larger prostates seen in obese patients may affect PC detection and may result 
in a postponed diagnosis and poor outcome. To examine this hypothesis Freedland 
et al. conducted a historical cohort study of 1,375 and 2,014 men treated by RP 
between 1988 and 2007 using the Shared Equal Access Regional Cancer Hospital 
and Duke Prostate Center database, respectively.88 Obese men with PSA-detected 
cancers (cT1c) and treated with RP since 2000, were at significantly greater risk of 
biochemical recurrence (BCR), while obese men treated before 2000 or diagnosed 
with an abnormal DRE were not at significantly greater risk of progression. These 
findings support the hypothesis that current PSA-based screening is less effective at 
finding cancers in obese patients.
In a study of a referral-based biopsy population in the United States, Presti et al. clearly 
explored the relation between BMI and PC detection. On the one hand a normal BMI 
correlated with a higher cancer detection rate and larger cancers in men referred 
for prostate biopsy.89 On the other hand, a referral-based biopsy population in Asia 
found no significant differences among the BMI groups in the PC detection rate.90 
Different racial distributions, population selections and study sizes could explain this 
disparity. Interestingly, two studies found that overweight and obese men living in 
the United States are more likely to receive a PSA test than their counterparts in the 
healthy weight range.91'92 Fontaine et al. found that among men aged 50 years and 
older, overweight and obese men were significantly more likely to have had a PSA 
test in the past year,91 possibly due to more health seeking behaviour of obese men.
In summary, lower PSA levels, a more difficult DRE and larger prostates seen in obese 
patients may negatively influence the detection rate of PC in obese patients. Although 
some authors suggest that the PSA cut-points used to recommend biopsy need to be 
adjusted for the degree of obesity, further investigations are needed to determine 
the exact role of obesity in the detection of PC.88;93
33
Chapter 2
2.5 Influence of obesity on treatm ent outcomes
It is generally held that obesity makes many urological procedures technically more 
challenging. Not surprisingly, obesity makes anatomical dissection of the apex difficult 
and has a higher likelihood of postoperative complications such as postoperative 
incontinence or stricture of the anastomosis. Besides technical difficulties during 
an intervention in achieving good mucosa-to-mucosa apposition, obesity itself may 
poorly influence healing at the vesicourethral anastomosis. However, few data are 
available on the exact impact of obesity on the different surgical techniques. Of the 
existing studies many comprise small numbers of patients.
A retropubic RP can be more technically challenging in obese patients. Eastham 
et al. reported that weight was a significant risk factor for urinary incontinence on 
univariable analysis. Multivariable analysis, however, was not performed due to the 
large number of missing values.94 Few reports investigated the impact of obesity and 
postoperative incontinence. Three retrospective studies found no association between 
obesity and incontinence and used questionnaires to evaluate the incontinence with 
a response rate varying from 55% to 70%, which may have biased the results.95-97 
Another difficulty in comparing studies on incontinence is the different definitions 
used in the studies.
Elliott et al. examined the incidence of stricture after multiple forms of PC therapy 
(RP, permanent prostate brachytherapy (PPB), external beam radiotherapy (EBRT) 
and cryotherapy) in more than 6,500 men, using the Cancer of the Prostate Strategic 
Urological Research Endeavor (CaPSURE) database.98 The overall stricture treatment 
rate was 5.2% and in the multivariate model primary treatment type, age at PC 
treatment and BMI were significant predictors of stricture treatment.
Perineal RP has gained renewed interest in obese patients. Anatomically this makes 
sense because the surgeon can excise the prostate without traversing the abdominal 
fat and to avoid the dorsal venous complex. Three studies addressed the feasibility 
of perineal RP in obese patients. Retrospective series by Dahm et al.99 and Bockzo et 
al.100 have suggested that perineal RP is both safe and feasible, not only in obese, but 
also in morbidly obese patients. Dahm et al. reviewed a cohort of 18 morbidly obese 
men and Bockzo et al. analysed 7 obese patients. The numbers of obese patients 
in both reports were too small to draw firm conclusions. However, a recent control 
study of 71 severely obese and 71 non-obese patients, who were matched by age, 
addressed an increased risk of both surgical and anesthesia-related perioperative 
complications in obese men. Transient neuropraxia in the lower extremities was the 
most common complication in obese men.101 The study did not provide information 
about late complications and functional outcomes.
Laparoscopic prostatectomy is gaining popularity. The magnification of a laparoscope 
makes an apical dissection and sparing of the striated sphincter easier when
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compared to conventional open prostatectomy. In a prospective study by Singh et al., 
no significant differences were seen between operative and peroperative morbidity 
in obese patients who underwent a laparoscopic prostatectomy compared to non- 
obese men.102 Although prostatectomy in an obese patient was found more technically 
challenging due to the significant amount of intra-abdominal tissue, the continence 
rate did not have any correlation with BMI or prostate size. Except for a longer 
mean operative time in obese patients, same conclusions were reported by three 
other reports.103-105 Brown et al. used both the transperitoneal and extraperitoneal 
technique in 151 patients and reported a 16-minute longer operative time in obese 
men compared to non-obese men.103 No differences were seen in continence rate 
and erectile function. However, patients travelled a distance to undergo surgery and 
consistent follow-up data (erectile function, continence rate) were not available. 
Likewise Eden et al. reported a 15-minute longer operation time in 532 patients who 
underwent both transperitoneal (first 111 cases) and extraperitoneal laparoscopic 
RP.104 Although there was no statistically significant difference in outcome between 
the non-obese and obese patients, erection rates were lower in obese compared 
with the non-obese patients. In line, a recent study by Liatsikos et al. who used 
the extraperitoneal approach in 500 patients, found also a 20-minute significantly 
longer operative time.105 In contrast with the other studies they used validated 
questionnaires for urinary and sexual function. An analysis of the functional data 
before and after surgery showed a similar baseline status regardless of the BMI. 
The comparison among the groups showed no statistical significance, but there 
was a trend to a slower recovery in the obese patients. Data on erectile function 
showed comparable results. Although the erectile function rates were lower 
in the obese group there were too few patients who had potency-preserving 
procedures and thus the influence was difficult to assess. All obese men required 
the use of phosphodiesterase-5 inhibitors to achieve an erection sufficient for sexual 
intercourse.
A novel approach of laparoscopic surgery is robotic assisted laparoscopic 
prostatectomy (RALP). Besides magnification, it provides the surgeon a three- 
dimension image and a more ergonomic position during the operation. In a 
prospective study reported by Mikhail et al.106 obesity did not increase perioperative 
and postoperative morbidity, except for operative time and estimated blood loss. After 
one year of follow-up, 74% of the obese patients returned to baseline continence. 
However the response rate of the validated questionnaires was only 22% after 12 
months. Ahlering et al.107 reported on their results for 100 RALP's in the presence 
and absence of obesity. They noted that blood loss during RALP was greater and the 
operative duration longer in 19 obese patients than in 81 who were not obese. Among 
the obese group there was also a significantly higher incidence of complications (26% 
vs 5%) and they required more time to return to baseline urinary function compared
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with their non-obese counterparts. At 6 months only 47% of obese patients had 
achieved urinary continence. Maybe the different length of follow-up, definition of 
urinary incontinence and very low response rate can explain the discrepancy of the 
continence rate between both studies.
A prospective study by Khaira et al. collected duration for different steps during the 
robotic procedure of 285 patients.108 The study population consisted of 49 patients 
who had a BMI > 30 kg/m2. The authors also found that blood loss, transfusion rate 
and complications during RALP did not differ between the non-obese and obese 
group. However the time of urethral dissection, anastomosis and port closure 
was significantly longer in the obese patients. It was harder to perform a urethral 
anastomosis in obese patients due to intra-abdominal fat and omental tissue falling 
into the visual field, unfortunately functional data were not available. In two reports, 
obesity was a risk factor for positive surgical margins.109'110 The positive surgical 
margin rate varied between 21% and 27% in the obese men, and 11% and 13% in the 
non-obese men treated with RALP.
Although the primary goal of cancer treatment is to cure the patient from his 
disease, not less important is the influence on quality of life by different treatment 
options. Several studies have addressed the role of BMI in health-related quality 
of life (HRQOL) before and after RP. Comparing obese men with their normal or 
overweight counterparts, lower postoperative HRQOL measures might be partially 
attributed to lower baseline HRQOL scores and might not be completely attribute 
to more severe postoperative morbidity. Anast et al. retrospectively evaluated 672 
men in the CaPSURE database and found that increased BMI did not predict worse 
HRQOL outcomes after RP, with the exception of very obese men (BMI > 35 kg/m2) 
who had worse urinary bother and functional scores at 24 months compared with 
men who had a BMI < 35 kg/m2.111 In line, Freedland et al. reported, after adjusting 
for age, baseline HRQOL and nerve-sparing status, that obese men did not have 
significant differences in HRQOL compared with non-obese men.112 Overweight men 
however, had significantly lower urinary function scores than men with normal BMI at 
24 months. In contrast, Montgomery et al. evaluated in a prospective study 376 men 
who underwent RP.113 They reported that obesity adversely affect HRQOL before and 
after the RP. The use of different questionnaires and regional variation in practitioner 
expertise and patients factors may affect these outcomes. One study by Sanda et al. 
measured HRQOL outcomes reported by 1,201 patients who underwent different 
treatment modalities (RP, PPB, EBRT) for PC.114 The factor that was associated with 
worse patient-reported outcomes was obesity. Symptoms related to vitality and 
hormonal function were adversely affected by obesity in patients who underwent 
EBRT or PPB.
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Davies et al. evaluated the effect of BMI on PC treatment choice for patients 
with clinically localized PC using a large, prospective community-based database 
(CaPSURE).115 After adjusting for clinical status, age, race, number of comorbidities, 
and level of education in the multivariable analysis, BMI continued to be significantly 
associated with type of treatment. Compared with normal BMI, very obese patients 
(BMI > 35 kg/m2) were more likely to receive primary androgen therapy only (OR
1.77, 95% CI 1.12-2.81), PPB (OR 1.59, 95% CI 1.01-2.52), and EBRT (OR 1.29 95% CI
0.73-2.26) rather than RP. Physician perception of obesity has been found to influence 
patterns of medical care.116'117 In addition, health professionals tend to perceive obese 
persons more negatively than those who are not obese, viewing obese individuals as 
unattractive, unmotivated and noncompliant.118'119 If such perceptions and attitudes 
exist in the urologic community, it may help to explain some of the trends.
In summary, obesity makes a radical RP procedure technically more challenging. 
However, few data are available on the exact role of obesity on the different 
treatment options for localized PC. Since treatments other than open RP are 
available for clinically localized PC, possible postoperative complications can affect 
the decision of choosing a therapy. To date, only small study samples with low 
response rates have investigated the effect of obesity on operative outcomes 
in patients who underwent an open or perineal RP. More studies in the field of 
obesity and its effects on laparoscopic RP's are performed. Although it was more 
technically challenging to perform an RP in an obese patient, only one report 
showed a higher incidence of complications. Future comparative prospective 
studies are necessary to delineate the cancer-related and functional outcomes of 
obese patients undergoing the different treatment options.
2.6 Biochemical recurrence after surgery and radiotherapy in obese 
patients
Although the majority of men newly diagnosed with PC will have early-stage disease, 
little is known about the impact of obesity on oncological outcomes of primary 
therapy for clinically localized disease. Compared to non-obese men, two recent 
large American multi-institutional studies observed a significant higher biochemical 
failure rate among obese men treated with RP.120'121 In the study by Amling et al. 
several interesting racial observations were made. In comparison with whites, Afro- 
Americans were significantly more likely to be obese, had significantly higher PSA 
levels, and had significantly higher-grade cancers. They were also more likely to have 
positive surgical margins at the time of RP. In a multivariate analysis including all 
pathologic tumour factors (stage, grade, surgical margin, and seminal vesicle status),
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black race remained among these as a significant independent predictor of cancer 
recurrence, whereas BMI did not. In the study of Freedland et al., obesity was also 
significantly related to race. BMI, whether categorical or continuous, was a significant 
predictor of BCR and was associated with higher-grade tumours. Although previous 
studies found a relation between obesity and BCR, Mallah and co-workers found weak 
associations with disease progression for BMI, which was of negligible prognostic 
value in men who received surgery.122 However, the definition of disease progression 
used, as well as the statistical approach, makes their results hard to compare with 
the reports mentioned before. The discrepancies between these studies also suggest 
that obesity may affect BCR but is not the only prognostic factor when determining 
whether PC will recur after surgery.
In a retrospective analysis of 436 patients, obese men were likely to lose significantly 
more blood during a retropubic RP, compared to non-obese men.123 Taking this 
into account, Oefelein et al. found intraoperative blood loss as a risk factor for PC 
recurrence.124 Perioperative transfusion with allogeneic blood may impair immune 
response and has proved to have a detrimental effect on the recurrence of curable 
colorectal cancers.125 This may play a role in the higher BCR rates seen in obese patients 
with PC. A reduction of peroperative bloodloss in obese patients with PC may have a 
positive impact on cancer recurrence. It is possible that the pneumoperitoneum and 
magnification of the scope during laparoscopy in obese patients may allow better 
hemostasis compared to the open surgical approaches. Despite the possible clinical 
relevance, no comparative data are available.
Additionally, compared to non-obese patients, more positive surgical margins 
were seen in obese men who underwent an r p .109'110'120'121'126'127 Studies showed 
that a positive surgical margin after RP is associated with an increased risk of PC 
recurrence.128'129 Positive surgical margins may be due to bad surgical technique and/ 
or from extension of tumour beyond the planned limits of resection. Jayachandran 
et al.127 addressed the risk of positive surgical margins by anatomic location after 
RP in 1,434 men, using the Shared Equal Access Regional Cancer Hospital (SEARCH) 
database. Obesity was associated with an increased risk of positive margins at all 
anatomical locations. It was suggested that extreme obesity (BMI > 35 kg/m2) was 
more strongly associated with positive apical and bladder neck margins (OR 3.11 and 
3.74, respectively). Of note, the 95% CI's overlapped with the estimates for the other 
site-specific positive margins.
To hypothesize if similar technical difficulties were seen in open RP and perineal 
RP Fitzsimons et al. retrospectively analysed 1,006 patients treated with open RP 
or perineal RP. They found that obese men, after adjusting for clinicopathologic 
characteristics, were likely to have positive margins as normal-weight men more than 
twice, regardless of prostatectomy type. The data did not provide evidence that open 
RP should be preferred to perineal RP in mildly obese men.
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Elevated BMI has been associated with BCR after RP. Whether this is due to aggressive 
disease biology or to technical limitations is not fully clear, Freedland et al. attempted 
to determine whether the increased rate of BCR in obese patients was due to 
technically inferior surgery. 130 Using capsular incision on the pathological specimen 
as a proxy for a technically worse operation, they found that mildly obese patients 
had a 30% increased chance of capsular incision and moderately to severely obese 
men had a 57% increased risk. Several other studies have further noted a trend 
towards increased positive surgical margins in the overweight and obese patients. 
Interestingly, however, in a study of RP patients with negative surgical margins, 
the SEARCH database study group still found an increased risk of BCR in patients 
with elevated BMI. This observation led to the conclusion that a technically inferior 
operation cannot fully account for the differences in outcome, but more aggressive 
PC seen in obese patients also plays a role in BCR.
Morbidly obese men (BMI >40 kg/m2) with PC are frequently not good candidates 
for general anaesthesia and surgical procedures such as RP. Radiotherapy, which 
is also challenging in this kind of patients, may be the first choice of treatment. 
Unfortunately, little is known about the oncological results in obese patients with PC 
who underwent radiotherapy. Radiotherapy is also used in the treatment of localized 
PC. In obese patients delivery of precision high-dose EBRT is more difficult because of 
a greater chance of daily setup errors and excessive intra-abdominal adipose tissue, 
which may increase organ motion.131 Three reports also found a higher risk of BCR 
in obese patients who underwent EBRT compared to non-obese patients.132-134 The 
problem comparing these studies is the different definition used for BCR. In 1996 the 
American Society for Therapeutic Radiology and Oncology (ASTRO) defined BCR as 
three consecutive PSA rises after a nadir with the date of failure as the point halfway 
between the nadir and the first rise of PSA. In 2005 the ASTRO definition was revised 
by the Radiation Therapy Oncology Group in Phoenix. The panel recommended a 
rise by 2 ng/mL or more above nadir PSA as BCR.135'136 Two studies used the Phoenix 
definition132'134 while the other one133 used the ASTRO definition. Palma et al. found 
that obese patients had a higher risk of PC specific death after EBRT. In the EBRT 
studies, intraprostatic gold markers, which may improve the targeting of the prostate 
gland and minimize daily setup errors due to organ motion especially in obese 
patients, were not used.
PPB is considered an established treatment option for low-risk PC.137-139 PPB 
maybe less affected by obesity and is technically feasible in obese patients with 
postoperative dosimetry and quality of life outcomes comparable to those of 
non-obese patients.140'141 Two recent studies addressed the link between BCR and 
obesity.142'143 In both studies BMI was not associated with PSA failure. Merrick et al.143 
reported the cancer specific survival as well and found that BMI was not associated 
with higher risk to die from PC.
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Figure 2 Summary of the possible mechanisms why obese patients are at higher risk to 
develop biochemical recurrence. (EBRT= External beam  rad io the rapy)
In summary, various studies suggested that obesity may result in higher recurrence 
rates after RP. The question remains, are the differences in outcome predominantly 
driven by biologically worse features or technical difficulties during the surgical or 
radiotherapy procedure? The possibility that PPB is a preferred management option for 
obese patients is intriguing and warrants further investigation. Possible explanations 
why obese patients are at higher risk for BCR are summarized in figure 2.
2.7 Conclusion
Obesity, related to multiple chronic diseases, is a growing problem in Western 
countries. Autopsy studies from numerous countries worldwide, however, have 
shown similar rates of latent or clinically insignificant PC, despite markedly different 
PC death rates among these populations.144'145 These findings suggest that although 
clinically insignificant PC may be common to all races and ethnic groups, some as yet 
unknown factor or factors may promote progression of these latent tumours into 
clinically significant cancers. Recent international trends show that PC incidence is
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increasing in low-incidence countries such as China and Japan. At the same time 
these countries are adopting westernized lifestyles associated with higher rates of 
obesity. These observations suggest that obesity may be a risk factor for PC. However, 
by adopting a westernised lifestyle, it is also possible that more Asian men tested 
their PSA, resulting in a higher detection rate. In any case, epidemiological studies 
are showing conflicting results between obesity and the development of prostate 
diseases. In contrast, more consistent findings have linked obesity with PC mortality, 
advanced stage and higher Gleason score.
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Abstract
Objective: The increasing incidence of both obesity and prostate cancer detection 
will confront the urologist more often with obese men having prostate cancer. It is 
unknown whether obesity affects the surgical and oncological outcomes following 
open radical retropubic prostatectomy (RRP). Knowledge concerning this issue is 
relevant when counselling obese patients with prostate cancer for RRP.
Patients and methods: A single institution cohort study was performed including 
252 men who underwent a RRP between 1992 and 2003. The surgical complications 
(perioperative complications, post-RRP urinary incontinence, vesico-urethral 
strictures (VUS)) were compared between obese (BMI > 30 kg/m2) and non-obese 
(BMI < 30 kg/m2) men.
Results: Compared to non-obese (N=221), obese men (N=31) developed more 
frequently wound infections (16.1% vs. 4.5%; p<0.05), urinary incontinence (25.8% 
vs. 8.7%; p<0.05) as well as VUS (45.2% vs. 12.3%; p<0.05). The pathology results 
and the 5-year cumulative risk of PSA recurrence were comparable between both 
groups.
Conclusion: Compared to non-obese, obese men suffered more frequently from 
post-RRP urinary incontinence and VUS following open RRP
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Introduction
The reported incidence of prostate cancer is highly variable throughout the world 
owing to multiple factors.1 In The Netherlands, like most countries in Western 
Europe, prostate cancer is the most common cancer and second leading cause of 
death among men. On the one hand, the increased public prostate cancer awareness 
and rising use of prostate-specific antigen (PSA) testing, resulted in a higher amount 
of clinically localized prostate cancer, amenable to curative surgery.2 
On the other hand, obesity, a rapidly growing worldwide epidemic, is beginning 
to replace malnutrition and infectious diseases as the most significant contributor 
to ill health.3 In Europe, the prevalence of obesity - according to the World Health 
Organization (WHO), obesity is defined as the body mass index (BMI; weight in 
kilograms divided by height in meters squared) over 30 kg/m2 - has more than 
doubled during the last two decades. At present, more than half of all adults are 
categorized as having overweight (according to the WHO, BMI, between 25 and 30 
kg/m2), and in some European areas up to 30% are obese.4 In summary, it is expected 
that urologists will increasingly be confronted with obese men having a localized 
prostate cancer
Generally, radical retropubic prostatectomy (RRP) is one of the treatment options 
for localized prostate cancer. Obesity, however, may be a complicating factor when 
performing an RRP resulting in higher complication rates, and worse functional 
results. It is unknown whether obesity affects the surgical outcomes following RRP 
Knowledge concerning this issue is relevant when counselling obese prostate cancer 
patients for RRP
In order to be informed about the possible impact of obesity on surgical outcomes 
following RRP, a historical cohort study was conducted including a single centre 
consecutive series of men who underwent an open RRP
Patients and methods
The records were reviewed of a consecutive series of 252 men treated by a RRP 
between 1992 and 2003 at the Canisius-Wilhelmina Hospital in Nijmegen, The 
Netherlands.
The pre-biopsy serum PSA concentrations and transrectal ultrasonography prostate 
volume measurements were recorded. The perioperative complications, length of 
hospital admission, vesico-urethral strictures (VUS), urinary stress incontinence, as 
well as postoperative PSA-levels were evaluated. During follow-up visits patients 
were asked about their urinary continence status. We defined continence if no pads 
were required.
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Non-obese
(N= 221)
Obese
(N=31)
p-value
Age (± IQR) (yr) 65.0 ± 9 63.0 ± 10 0.128a
BMI (± IQR) (kg/m 2) 25.4 ± 3.6 31.4 ± 2.9
Preoperative PSA (± IQR) (ng/mL) 8.7 ± 6.8 9.4 ± 6.9 0.402a
Prostate volume (± IQR) (mL) 37.5 ± 21 38.0 ± 20 0.365a
Clinical stage (%)
T1 145 (65.6) 26 (83.9) 0.042b
T2 76 (34.4) 5 (16.1)
ASA-classification (%)
I 152 (68.8) 15 (48.4) 0.053c
II 0 (27.6) 13 (41.9)
III 8 (3.6) 3 (9.7)
Comorbidities (%)
None 137 (62.0) 14 (45.2) 0.024c
Preoperative TUR-P 16 (7.2) 3 (9.7) 0.71c
Diabetes 4(1.8) 3 (9.7) 0.042c
Cardiopulmonary history 64 (29.0) 16 (51.6) 0.014c
Follow-up (± IQR) (months) 54.7 ± 39.4 42.6 ± 35.6 0.254a
Gleason score (± IQR ) 6.0 ± 1 6.0 ± 1 0.347c
< 6 (%) 161 (72.9) 22 (71.0)
7 (%) 41 (18.5) 4 (12.9)
8-10 (%) 19 (8.6) 5 (16.1)
Pathological stage
pT2 (%) 147 (66.5) 20 (64.5) 0.841b
pT3 (%) 74 (33.5) 11 (35.5) 0.841b
pN+ (%) 5(2.3) 0 (0) 1 .000b
Positive surgical margins (%) 64 (29.0) 11 (35.5) 0.530b
Table 1 Demographic, clinical and pathologic characteristics.
Data presented as m edian, w ith  in te rq u a rtile  ranges, o r num ber w ith  percentages in parentheses. IQR= 
In te rq u a rtile  range (=P25-P75); ASA= Am erican Society o f  Anaesthesiologists. 
a = M ann -W h itn e y  U test 
b = Two-sided Fisher's exact test 
c = Chi-square test
The patients' American Society of Anaesthesiologists (ASA) classification, height, 
weight, estimated blood loss, and operative time were retrieved from anesthesiology 
reports. Gleason score, the pathological stage and surgical margin status were 
obtained from the pathology records.
The frequency of follow-up visits was every 3 months in the first year, every 6 months 
until the 5th year and annually thereafter. During these visits, serum PSA levels were 
determined and patients were asked about urinary continence. An urethrocystoscopy 
was performed if a VUS was suspected.
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Non-obese
(N= 221)
Obese
(N=31)
p-value
Operation time (± IQR) (hours) 3.5 ± 1.00 4.0 ± 1.00 0.144a
Estimated blood loss (± IQR) (mL) 1700 ± 1100 2000 ± 1750 0.146a
Hospital stay (± IQR) (days) 8.0 ± 5 9.0 ± 8 0.061a
Perioperative complications (%) 28 (12.7) 8 (25.8) 0.059b
Major: Died 2 (0.9) 0 1 .000b
Minor: Lymfocele 5 (2.3) 1 (3.2) 0.549b
Pneumonia 1 (0.5) 0 1 .000b
Pulmonary embolism 2 (0.9) 1 (3.2) 0.327b
Wound infection 10 (4.5) 5 (16.1) 0.025b
Epididymitis 2 (0.9) 0 1 .000b
Gross haematomas 2 (0.9) 0 1 .000b
Fever o f unknown origin 3 (1.4) 0 1 .000b
Prolonged ileus 1 (0.5) 0 1 .000b
Post-RRP urinary incontinence (%)c 19 (8.7) 8 (25.8) 0.009b
Vesico-urethral strictures (%)c 27 (12.3) 14 (45.2) 0 .000b
Table 2 Surgical characteristics and complications.
Data presented as m edian, w ith  in te rq u a rtile  ranges, o r num ber w ith  percentages in parentheses. 
a = M ann -W h itn e y  U test 
b = Two-sided Fisher's exact test
c = O nly 219 patien ts w ere  su itab le  fo r  m easuring  th e  long te rm  com plications, because 2 pa tien ts died 
sh o rtly  a fte r surgery.
Patients were stratified into two groups: obese (BMI > 30 kg/m2) and non-obese (BMI 
< 30 kg/m2) for data analysis.
Statistical analysis
Because of non-normal distributions, all variable distributions are summarized using 
the median values with the interquartile range (IQR, i.e., the range between the 25th 
and the 75th percentile of the distribution). In the univariable analysis of categorical 
variables (e.g., perioperative and long-term complications as well as Gleason score, 
pathological stage, tumour grade and surgical margin status) differences between 
obese and non-obese subjects were tested by a Chi-square test (in cases of more 
than two categories) or Fisher's exact test (in case of two categories). Differences in 
continuous characteristics were tested by the Mann-Whitney U test. Kaplan-Meier 
survival analysis (with a log-rank test) was used to calculate the cumulative risk of 
PSA recurrence between both groups. Differences were considered to be statistically 
significant if p <0.05.
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Results
Out of 252 patients, 221 (88%) were categorized as non-obese, and 31 (12%) as obese. 
For demographic, clinical and pathologic characteristics see table 1. Gleason score, 
pathological stage, and prevalence of positive surgical margins were not different 
among obese and non-obese men.
For surgical characteristics and complications see table 2. Two non-obese patients 
died immediately postoperatively; 1 patient, classified as ASA 3, died from heart 
failure, while another ASA 3 patient died from a pulmonary embolism.
Twenty-seven non-obese men developed a VUS. Five patients were managed 
conservatively by urethral dilatation, whereas 22 needed an urethrotomia. In 4 non- 
obese patients the stricture recurred. Of the 14 obese men who developed a VUS, 3 
patients were managed conservatively by urethral dilatation, whereas 11 needed an 
urethrotomia. In this group, no strictures recurred.
During a median follow-up of 54.7 months, 2 non-obese patients died from prostate 
cancer and 12 died from non-prostate cancer related causes. None of the obese men 
died from prostate cancer, whereas one patient died from a non-prostate cancer 
related cause. The follow-up in this group was 42.6 months. In both groups, the 
5-year progression-free survival was 64%. (figure 1) Patients who required additional 
therapy are listed in table 3.
Non-obese 
(N= 219)
Obese
(N=31)
p-value
First PSA (ng/mL) postoperatively (%)
< 0.1 
> 0.1
192 (87.7) 
27 (12.3)
27 (87.1) 
4 (12.9)
1 .000b
Patients with PSA recurrence 88 (40.2) 12 (38.7) 0.53c
Last PSA (ng/mL) postoperatively (%)a 
< 0.1 
> 0.1
161 (73.5) 
58 (26.5)
21 (67.7) 
10 (32.3)
0.521b
Primary additional radiotherapy (%) 
Primary additional hormonal therapy (%) 
Hormonal therapy after radiotherapy (%)
47 (21.5) 
19 (8.7)
7(3.2)
7 (22.6) 
2(6.5)
1 (3.2)
0.820b
1 .000b
1 .000b
Table 3 Postoperative PSA levels and additional therapy.
N um bers in parentheses deno te  percentages. Only 219 patien ts  w ere  su itab le  fo r  m easuring  th e  PSA 
levels postopera tive ly , because 2 pa tien ts d ied sh o rtly  a fte r surgery.
a = Irrespective  o f  any add itio na l therapy. M edian  fo llo w -up ; non-obese 54.7 m onths, and obese 42.6 
m onths.
b = Two-sided Fisher's exact test 
c = K ap lan-M eijer log-rank te s t (figu re  1)
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Figure 1 PSA recurrence-free survival.
Blue line: non-obese. Green line: obese
The 5-year risk developing a PSA recurrence is 36% (95% CI 28%-44%) for the non-obese and 36% (95% CI 
14%-58%) for the obese (Kaplan-Meijer log-rank p value is 0,53).
Discussion
Obesity is one of the fastest growing health problems in industrialized countries. 
According to Dutch Statistics (www.cbs.nl) 10% of Dutch adult men are obese. With 
the introduction of PSA testing in the 1980s, the detection rate of localized prostate 
cancer has increased enormously. The increasing incidence of both obesity and 
prostate cancer suggests that urologists will be confronted frequently with obese 
patients having a potentially curable prostate cancer.
In the present study, the incidence of perioperative complications (14.3%) is 
comparable to the incidence reported in the literature (6.3%-28.6%).5;6 A larger 
number of complications (predominantly wound infections) was observed in obese 
compared to non-obese men. Obese patients had significantly more comorbidities 
such as diabetes mellitus and cardiopulmonary diseases. This could be an explanation 
why obese patients suffered more frequently from wound infections.7
Urinary incontinence is a particularly vexing problem after RRP with social as 
well as personal implications. Reported rates range between 2.5% and 87%, and 
differ considerably according to its definition, follow-up, and surgical technique.8
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Although this complication is feared by both the patient and the urologist, less is 
known about the impact of obesity on the development of urinary incontinence 
postoperatively. In the present study, obese men suffered more frequently from 
post-RRP urinary incontinence in comparison to non-obese men (25.8% vs. 8.7%, 
p=0.009). Only four reports investigated the impact of obesity and postoperative 
incontinence9-12 (table 4). In contrast with the present study, most of these studies 
reported no association between obesity and incontinence. Of note, all studies used 
self-administered and not validated questionnaires concerning urinary symptoms 
to evaluate the incontinence.
A second well known complication of RRP is the development of a VUS. Rates of VUS 
after RRP are 5% to 25.7% and they vary with the definition of stricture and practice 
setting (university vs community).13'14 In the present study, obese men developed 
significantly more VUS (45.2% vs. 12.3%, p=<0.005) in comparison to non-obese men. 
Only one other study also examined the influence of obesity and the development of 
a VUS after primary treatment for prostate cancer.15 In accordance with the present 
study, in the RRP-treated group, obesity was a predictor of the development of a 
VUS.
One of the reasons for the higher incidence of incontinence and VUS in obese men 
can be explained from a surgical viewpoint. Obese men have a relatively deep pelvis, 
making a proper preparation of the striated sphincter, a fine apical dissection, as well 
as the construction of urethrovesical anastomosis, more difficult. The combination of 
sphincter damage and increased intra-abdominal pressure, in obese men,16 can make 
obese patients prone to develop postoperative urinary stress incontinence.
Another reason can be the experience of the surgeon. In this study 252 patients 
were treated over 12 years by 3 surgeons. The majority, 72% of all patients and 84% 
of all obese patients, however, have been operated in the last 6 years of the present 
study. In this time frame an average of 10 RRPs a year per surgeon was performed. 
In theory, the low-volume of prostatectomies per surgeon may be associated with 
higher prevalence of complications in obese men. To the best of our knowledge, 
no minimum volume threshold regarding the performed number of RRPs a year per 
surgeon has been determined and related to any RRP outcome. Interestingly, in a 
self-reported study of Denberg et al.,17 a considerable number (37%) of the urologist 
in the US performed < 10 RRPs a year. Although no threshold has been determined, 
it is an evolving topic that has major health policy implications. Nowadays, all RRPs 
in our hospital are performed by a single surgeon.
A comparison of complication rates of different surgical modalities used in obese 
patients with prostate cancer should be done to make an informed treatment 
selection for those patients. However, data are lacking. An alternative approach
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References Eastham et al.9 HSU et al.10 Wille et al.11 Mulholland et
al.12
Present
study
Number of 
patients
581 1024 742 268 252
Period of 
series
1983-1994 1994-2000 1989-2003 19 98-1999 1992-2003
No of 
surgeons
1 1 5 14 3
Continence 
rate,%
91 91 70 68 89
Definition of 
continence
0 to 1 pad 0 to 1 pad 0 to 1 pad Never or 
occasional 
incontinence, 
no m ore than  
once w eekly
No pad
Data
assessment
MR/SAQ MR/SAQ SAQ SQA MR
RR, % NA NA 76 68 -
Patient weight 
(continuous) 
significant risk factor 
(univariable analysis)
Patient weight 
(categorical) 
was not a risk 
factor*
BMI < 30 vs. 
BMI > 30, CR 
76% vs. 75% 
(NS)
No relationship 
between BMI 
(continuous) and 
incontinence
BMI < 30 vs. 
BMI > 30, CR 
74% vs. 91% 
(p<0.05)
Table 4 Obesity as a risk-factor for postoperative incontinence after radical prostatectom y of 
several series.
MR= medical record; SAQ= self-administered questionnaire; No= number; RR= response rate; NA= not 
available; NS= not significant; CR= continence rate.
*= continence status was evaluated for 422 men
for RRP could be the perineal one. Three studies addressed the feasibility of radical 
perineal prostatectomy in obese patients. Small case series by Bockzo18 and Dahm et 
al.19 retrospectively reviewed the surgical results of 7 and 18 (morbid) obese patients, 
respectively. In the study reported by Bockzo et al. 4 patients were continent after 
one year of follow-up. Dahm and associates evaluated morbid obese men (BMI > 40 
kg/m2). Long-term follow-up data were only available for 10 patients, and 9 were 
urinary continent. Although both studies were too small to draw firm conclusions, 
both authors have suggested that radical perineal prostatectomy is both safe and 
feasible, not only in obese but even in morbidly obese patients. The most recent 
matched-controlled study of 71 severely obese (BMI > 35 kg/m2) and 71 non-obese 
patients, however, did find an increased risk of both surgical and anesthesia-related 
perioperative complications, e.g. laryngospasm requiring reintubation, myocardial 
infarction, rectal injury and pulmonary oedema.20 This study did not provide 
information about late complications and functional outcomes.
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The most recent surgical approach is laparoscopy. Since the laparoscopic approach 
is obviously less hindered by obesity, it is not surprising that in a prospective 
study no significant relation was established between operative and peroperative 
morbidity (including incontinence) in obese patients who underwent a laparoscopic 
prostatectomy compared to non-obese men.21 These data are confirmed by others.22'23 
Another form of laparoscopy is robotic-assisted surgery. In contrast, Ahlering et al.24 
reported significantly more complications in obese men who underwent robotic- 
assisted laparoscopy and they required more time to return to baseline urinary 
function. At 6 months, 47% of 19 obese patients had achieved urinary continence. 
Theoretically, with the magnification of a laparoscope, the apical dissection and the 
preservation of the striated sphincter may be more appropriate in a deep pelvis, 
compared to the conventional open RRP. In all, few data are available about the 
impact of obesity on the different surgical techniques and randomised studies are 
lacking.
Recently, obesity was identified as a risk factor for cancer-related death for several 
cancers.25 For prostate cancer different studies suggested a positive association 
between BMI and grade, stage, positive surgical margins and PSA recurrence after 
RRP.26-28 The exact link between obesity and increased risk of developing aggressive 
prostate cancer, is not well understood. Development and progression of cancer in 
obese men may be elicited by alterations in sex hormones (testosterone, estradiol), 
and elevated levels of adipokines like insulin-like growth factors, leptin, and 
interleukin-6.29 Although obese men suffered more from a worse Gleason score (>7) 
and an increased number of positive surgical margins compared to non-obese, the 
present study could not demonstrate a significant association between BMI and 
the pathological characteristics, as well as the progression-free survival. However, 
the overall number of obese patients was too small for a firm interpretation of the 
aforementioned association.
Several limitations of the present study need to be mentioned. First, the numbers 
of obese patients were small as far as statistical power was concerned. Particularly, 
a multivariable analysis to adjust for potentially significant co-variables could not be 
performed in a meaningful way. Second, information was collected retrospectively 
and functional outcomes were not obtained by self-reported validated questionnaires. 
Third, other treatment modalities like brachytherapy and external beam radiotherapy 
are becoming more popular in the last few years. It is possible that more obese 
patients were shunted into these treatment options. This would bias the obese men 
in this study towards incontinence. Fourth, compared with the literature, the current 
study showed a high proportion of ASA 1 patients. Possibly ASA classifications were 
not well documented or a selection bias may have been occurred by referring ASA 2 
patients with prostate cancer easier to a radiotherapist.
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Conclusion
This study suggests that obese patients are at higher risk for developing urinary 
incontinence and VUS following RRP. These present findings can help when counselling 
obese patients who are prepared to undergo a radical prostatectomy.
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Abstract
Objective: To investigate whether body mass index (BMI) is a prognostic factor for 
biochemical recurrence (BCR) in Dutch men after radical prostatectomy (RP). Although 
epidemiological studies of obesity in relation to prostate cancer have provided 
conflicting results, recent studies from The United States of America suggest that a 
higher BMI as a risk factor for progression of prostate cancer.
Patients and methods: Of the 1,417 patients with prostate cancer who had RP at two 
university hospitals, 1,302 patients were included in the study. BMI (kg/m2) classes 
were defined as normal (<25), overweight (25-30) and obese (>30). The median 
follow-up was 59 months and clinical data were obtained retrospectively from charts. 
BCR was defined as two consecutive prostate-specific antigen (PSA) levels of >0.10 
ng/ml.
Results: In all, 600 patients were classified as having normal weight (43.9%), 665 
as overweight (48.6%), and 103 as obese (7.5%). Overall, 297 patients developed 
BCR after RP; the 10-year risk (95% confidence interval) of BCR was 31.9% (26.6­
37.2), 30.5% (25.8-35.2) and 23.9% (14.9-32.9) for patients in the three categories, 
respectively (p=0.836). Multivariable proportional hazard regression analyses of BMI 
and established prognostic factors for BCR did not change these results.
Conclusion: BMI appeared to have no prognostic value for BCR in Dutch patients with 
clinically localized prostate cancer treated with RP.
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Introduction
Prostate cancer and obesity are among the most common health problems currently 
affecting European men. Obesity is now so common among the world's population 
that it is beginning to replace under-nutrition as the most significant contributor to 
ill health.1 Moreover, obesity has enormous public health consequences because it 
not only increases the risk of several chronic diseases like diabetes, hypertension, 
coronary heart diseases, and certain cancers, but it also imposes a large burden on 
healthcare use and costs.
The relationship between obesity and prostate cancer is debatable, with some studies 
indicating that obesity is associated with a decreased risk of prostate cancer2'3 and 
other studies suggesting an increased risk.4'5 However, recently two large American 
multi-institutional studies addressed a significantly higher biochemical recurrence 
(BCR) rate among obese men treated with radical prostatectomy (RP).6;7 
Nearly all studies on obesity and the risk of death from prostate cancer or BCR are 
conducted in The United States of America (USA); this might be important, because 
not only is the incidence of obesity much higher in the USA than in Europe, but the 
mean body mass index (BMI) of obese patients is also higher.8 In addition, the USA 
population partly consists of African-Americans, who are more prone to be obese 
and have higher-grade prostate cancers. Therefore, the USA population has a distinct 
composition and characteristics compared to the European population. Thus we 
analysed men who had RP for clinically localized prostate cancer at two university 
hospitals (Radboud University Medical Centre, Nijmegen and Erasmus MC, University 
Medical Center, Rotterdam) in the Netherlands to evaluate the relationship between 
obesity and risk of BCR.
Patients and methods
Patients
The study population consisted of patients who had RP and for whom the medical 
records were reviewed retrospectively; 542 patients were treated at the Radboud 
University Medical Centre between 1992 and 2005, and 875 at the Erasmus 
University Medical Center between 1988 and 2007. Excluded were patients who 
had preoperative androgen deprivation or radiotherapy, and those with missing 
data for height or weight; in all, 49 patients were excluded. For an analysis of risk of 
BCR, patients with incomplete follow-up data, positive lymph nodes or PSA values 
that did not reach a nadir of < 0.1 ng/mL were also excluded (N=66). This resulted 
in a study population of 1,302 patients. Preoperative height and weight data were 
collected retrospectively by reviewing anaesthesia records. The BMI was calculated
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as usual (kg/m2), and according to the World Health Organization categories9, 
patients were stratified into three groups, i.e. normal weight (<25), overweight 
(25-30) and obese (> 30).
Follow-up
In general, patients were seen every 3 months during the first year, every 6 months 
during the second and third year, and yearly thereafter unless there was evidence of 
cancer recurrence, in which case more frequent follow-up visits were necessary. The 
serum PSA level was obtained before surgery and at every follow-up visit. BCR was 
defined as two subsequent PSA levels of >0.10 ng/mL or if a second treatment after 
RP was needed. The time to BCR was measured from the date of RP until the date of 
first PSA level of >0.10 ng/mL.
Pathologic evaluation
All RP specimens were fixed overnight, inked, embedded and processed according to 
well-established protocols.10 Pathological staging and examination (seminal vesicle 
invasion, extracapsular extension, margin status and Gleason scores) were done 
by two specialised genitourinary pathologists (CAHK, GJL). The presence of tumour 
cells in the inked resection margin was considered a positive surgical margin. All 
stages were converted to the TNM staging criteria, using the 2002 American Joint 
Committee on Cancer classification.
Statistical analysis
Associations between the predefined BMI subgroups and clinical or pathological 
characteristics were examined using Chi-square tests in case of categorical 
characteristics and Mann-Whitney U tests or Kruskal-Wallis tests in case of continuous 
characteristics. The risk of BCR was assessed with the Kaplan-Meier method, using 
the log rank-test to compare subgroups. Cox proportional hazard model was used for 
multivariable analyses. Differences were considered to be statistically significant if 
p<0.05. Data were analysed using SPSS for Windows (version 15.0)
Results
Table 1 summarizes the clinical and pathologic characteristics of the study population 
stratified by preoperative BMI groups. The median (range) age of the patients at the 
time of RP was 63.1 (42.4-75.0) years, and the median BMI was 25.5 kg/m2. In all, 600 
patients were classified as having normal weight (43.9%), 665 as overweight (48.6%), 
and 103 as obese (7.5%). The median follow-up was 59.3 months and the median 
Gleason score was 6.
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Variable Normal Weight
N =600 (43.9% )
Overweight
N=665 (48.6% )
Obese
N=103 (7.5% )
p-value
Median (IQR)
Age, years 63 .0  (59 .0 -67 .1 ) 63.3 (58 .6 -67 .1 ) 62.1 (58 .3 -65 .0 ) 0 .1 27
BMI, kg /m 2 23 .5 (22 .5 -24 .3 ) 26 .9  (25 .8 -27 .8 ) 31 .4  (30 .5 -32 .3 )
Pre-operative PSA 
level, ng/m l
7.1 (4 .8 -11 .1) 7 .1 (4 .6 -11 .8) 7.2 (4 .6 -10 .2) 0 .815
Follow-up, months 58 .9 (23 .7 -100 .4 ) 52 .9  (18 .0 -98 .2 ) 54 .8  (21 .5 -102 .8 ) 0 .191
N (%)
Pathological stage,
T2
T3
T4
404  (67.4) 
167 (27.9) 
28 (4 .7)
419  (63.3) 
213 (32.3) 
30 (4 .5)
68 (66.0) 
28 (27.2) 
7 ( 6.8)
0 .402
Gleason Score
2-6
7
8-10
278 (56.2) 
170 (34.3) 
47  (9 .5)
299 (52.7) 
221 (39.0) 
47  (8 .3)
39 (47.6) 
37 (45.1) 
6 (7 .3)
0 .3 10
Positive margins 208 (34.9) 256 (38.7) 42 (40.8) 0 .2 76
Seminal vesicle 
involvement
67 (11.2) 55 (8 .3) 10 (9 .8) 0 .7 76
Extracapsular
extension
174 (29.5) 217 (33.3) 32 (31.7) 0 .3 47
Lymph node 
involvement
18 (3 .0) 11 (1 .7) 2 (2.0) 0 .2 77
Table 1 Patients and pathological characteristics. 
IQR= Interquartile range
Overall, 297 patients developed BCR after RP. The 10-year Kaplan-Meier risk (95% 
CI) of BRC was 30.5% (27.2-33.8). Patients in the obese group had slightly lower 
recurrence rates than those in the normal weight group, but this was not statistically 
significant. The 10-year risk (95% CI) of BCR was 31.9% (26.6-37.2), 30.5% (25.8-35.2) 
and 23.9% (14.9-32.9) for patients in the normal, overweight and obese groups, 
respectively (p=0.836; figure 1).
Using Cox proportional hazards regression models, prognostic factors for the risk 
of BCR were evaluated by using univariable and multivariable analyses (table 2). 
Univariable regression analysis showed no significant association between the risk 
of BCR and obesity in obese (HR=0.94; 95% CI 0.59-1.48, p=0.78), and overweight 
patients (HR=1.05; 95%CI 0.83-1.34, p=0.67) compared with normal weight patients. 
Likewise, in multivariable regression analysis for risk of BCR, BMI did not appear to 
have an independent prognostic value.
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Follow-up, months
Figure 1 Risk of biochemical recurrence following radical prostatectomy represented by Kaplan­
M e ie r curves for normal weight (blue), overweight (green) and obese (red) patients (p=0.836).
Discussion
Obesity is a growing problem in Western countries; in Europe, the prevalence of 
obesity has more than doubled during the last two decades. Obesity accounts for up 
to 6% of direct health costs and more than 12% of indirect health costs of shortened 
lives, reduced productivity, and lowered incomes in Europe.11 Simultaneously, since 
the introduction of PSA and the growing awareness of prostate cancer in men, the 
incidence and prevalence of localized prostate cancer is substantially increased and 
has become a major health problem.12 Several biological mechanisms have been 
proposed to explain the relation between adiposity and the risk of prostate cancer. 
Adipose tissue is an active endocrine and metabolic organ. Beyond alterations in 
sex steroid hormones (increased serum concentrations of oestradiol and decreased 
serum concentrations of testosterone) it produces adipokines like leptin, insulin-like 
growth factor-1, interleukin 6 and vascular endothelial growth factor. Alterations in 
sex steroid hormones and adipokines might contribute to the molecular basis of the 
association between obesity and prostate cancer. However, the exact role of obesity 
as related to the development of prostate cancer is not yet clear, although recent 
evidence does suggests a particular role for obesity in prostate cancer progression.
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Univariable HR
(95% CI)
Multivariable HR
(95% CI)
Age (continuous) 1.03 (1.01-1.05)
Preoperative PSA (continuous) 1.05 (1.04-1.07)
Gleason score
< 6 1 1
7 3.11 (2.28-4.25) 2.33 (1.68-3.22)
> 8 7.72 (5.24-11.38) 3.90 (2.54-5.98)
Pathologic stage
T2 1 1
T3 (vs.T2) 3.44 (2.69-4.40) 1.21 (0.87-1.70)
T4 (vs. T2) 5.49 (3.75-8.02) 2.03 (1.23-3.36)
Positive surgical margins, yes (vs. no) 3.95 (3.12-5.00)
Seminal vesicle invasion, yes (vs. no) 5.46 (4.15-7.19)
Extracapsular extension, yes (vs. no) 3.50 (2.77-4.42)
BMI, kg/m2 (categorical)
25 1 1
25-30 1.05 (0.83-1.34) 0.98 (0.74-1.29)
> 30 0.94 (0.59-1.48) 0.72 (0.40-1.30)
BMI (continuous) 1.00 (0.97-1.04)
Year of surgery (continuous) 0.94 (0.91-0.97)
Table 2 Univariable and m ultivariable Cox proportional hazard analyses
Mechanisms and the effect of obesity on prostate cancer have been reviewed in 
more detail elsewhere.13'14 Two large European historical cohort studies reported 
a positive relation between BMI and risk of prostate cancer,4'5 while others found 
a protective influence of obesity on the development of prostate cancer.3'15 Most 
studies examined incident prostate cancer cases regardless of stage or grade. 
However, prostate cancer has a highly variable natural history, which can range from 
fast disease progression in months to a more indolent tumour in which survival can 
be measured in decades.
Although the relation between obesity and prostate cancer risk has been indistinct, 
recently more consistent results were published on the positive association between 
obesity and prostate cancer mortality.16'17 Recent reports, all from the USA, showed 
poorer cancer control after RP, with a significantly greater propensity for higher 
grade disease, positive margins, and nodal and seminal involvement than in non- 
obese patients; the results of these studies are summarized in table 3.6;7;18-20 This 
suggests that obesity has a more prominent role in aggressiveness and progression 
rather than in the development of prostate cancer. These five studies from the USA,
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Am ling e t al.6 Freedland et 
a l.7
Bassett e t al.18 Magheli et
al.19'"
Strom e t al.20
No o f patients 3162 1106 2131 5631 526
Mean FU, months 31 46 23 54 54
Mean BMI NA 27.5 27 NA 27.8
Afro-Am erican, % 21.4 25.9 24.9 7.0 13.7
Obese, % 19.0 22.4 22.0 33.3 24.9
Positive margins, %
Normal 29.3c 28.5 NA 11.1 15.0
Obese 35.0 36.3 NA 18.0 18.6
Positive nodes, %
Normal 3.0c 1.8 NA 2.3 3.1
Obese 3.8 0.4 NA 2.5 2.3
Positive SV, %
Normal 8.0c 8.8 NA 2.8 7.8
Obese 10.0 8.5 NA 4.0 13.8
Gleason score >8, %
Normal 44.3bc 3.9 5.8 5.3 20.3
Obese 52.4b 8.1 5.1 6.8 19.2
BCR at 5 years, %
Non-obese 32.5 32.0 22.0 10.0 18.3
Obese 37.5 40.0 30.0 22.0 28.5
Cox proportional BMI (>30 vs. BMI (cont.) BMI (cont.) BMI (>30 vs. BMI (cont.)
hazards ratio, <30) 1.03 (1.01-1.06)d 1.20 (1.02-1.41)e <25) 1.07 (1.02-1.13)e
(95% CI) 1.20 (1.02-1.42)d BMI (30-35 vs. <25) BMI (>30 vs. <30) 2.04 (1.61-2.58)d BMI >30 vs. <25
1.19 (0.86-1.64)*,d 1.31 (1.00-1.71)e 1.91 (1.51-2.44)e at 40 yrs
BMI (>35 vs. <25) BMI (>35 vs. <25) 2.35 (1.43-3.86)d
1.99 (1.21-3.27)d 1.69 (1.01-2.84)e
Table 3 A comparison o f American studies reporting a relationship betw een BCR and obesity. 
Abbreviations: No= number; FU= follow-up; BMI= body mass index; SV= seminal vesicles; BCR= Biochemical 
recurrence; NA=not available; CI= Confidence interval; cont= continuous.
* = Not significant
a = Patients in the normal weight and overweight cohorts were matched 1:1 to  the cohort o f obese 
patients on the basis o f propensity scores 
b = Pathologic Gleason score >7 
c = Normal and overweight groups are combined 
d = Univariable hazard ratio 
e = Multivariable hazard ratio
reported a higher risk of BCR in obese than in non-obese patients within the first 5 
years. Combining these studies, the risk of BCR within 5 years was, 23.1% for the 
non-obese and 31.8% for the obese patients. The present study could not confirm 
this relationship, as the 5-year risk of BCR was 23.9% for obese patients vs. 20.7% in 
the normal-weight patients. There are several explanations for this difference. First, 
all five previous studies mentioned were done in the USA; by contrast with these 
studies, in which 20 to 25% of men were obese, the present study had only 7% of 
obese patients in the study population. This is not surprising, when assessing the
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National Health and Nutrition Examination Survey; in 2004 the prevalence of obesity 
among American men was around 32%.21 According to the Netherlands Health 
Interview Survey the prevalence of obesity in Dutch adult men was only 9%.22 The 
present study population had not only fewer obese patients, but more importantly, 
the obese patients in the study weighted less than those in the American studies 
listed in table 3. The higher degree and frequency of obesity might translate into 
more 'fatter' fat cells, which might produce a greater quantity of adipokines.23 This 
in their turn might result in a higher risk of BCR. Secondly, by contrast with the Dutch 
population, the population of the USA included African-American men. As an ethnic 
group, African-American men, who are also more obese, have significantly higher 
incidence of prostate cancer and of mortality rates than white men.24 For example, 
in the study of Amling et al.6 black race and BMI were associated with higher BCR in 
the univariable analysis, but in multivariable only black race remained significant. It 
is tempting to speculate that increased rates of African-American men might in part 
explain the differences in BCR after RP, especially because African-Americans are on 
average more obese and are more prone to have aggressive tumours.
In the present study, obese men more often had (although not significant) positive 
margins (40.8%) and T4 tumours (6.8%) than men had with normal weight (34.9% 
and 4.7%, respectively). Nevertheless, the risk of BCR was no higher in the obese 
men. This might be related to the rather few obese patients in the present study 
than in others. Interestingly, if there was BCR, the mean time to develop BCR was 
much shorter in the obese men, at 19.9 months, than in normal weight men, at 37.7 
months.
The limitations of the present study are, first, the use of BCR as a surrogate of cancer- 
specific survival. This is important because it was previously reported that BCR can 
occur late in the postoperative course, and that the presence of BCR is not always 
a good predictor of prostate-cancer-specific death.25 A 10-year cohort study by 
Siddiqui et al.26, reported that despite worse pathologic features at the time of RP in 
obese patients, the long-term cancer-specific survival remained the same regardless 
of BMI. Second, additional quantitative measures of obesity, such as waist-to-hip 
ratio (calculated as the ratio of waist circumference, at the level midway between 
the lower rib margin and iliac crest, over the hip circumference at the maximum 
circumference over the buttocks) and waist circumference were not available. In 
clinical practice and epidemiological studies, body fat is most commonly estimated 
using BMI. Abdominal fatness, which is more metabolic active, is best measured by 
waist-to-hip ratio or waist circumference. This is particularly true in patients older 
than 75 years.27 In the present study most patients were much younger. Third, the 
height and weight data used were recorded from the anesthesia records, as reported 
by the patients at the time of surgery and introduced the possibility of a bias.
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Conclusion
Obese patients undergoing RP in two Dutch academic hospitals, had no worse 
pathological characteristics, and had no significantly greater risk of developing BCR.
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Abstract
Objective: Given the limited information regarding the impact of obesity on 
treatment outcomes for prostate cancer, we sought to examine the relation between 
body mass index (BMI) and biochemical recurrence (BCR), cancer-specific (CSS) and 
overall survival (OS) in men treated with brachytherapy.
Patients and Methods: In all, 1,530 patients with clinically localized prostate cancer 
who underwent brachytherapy were studied. Clinical and pathological data were 
retrospectively obtained from medical records. The BMI was classified as normal 
(<25 kg/m2), overweight (25-30 kg/m2) and obese (>30 kg/m2). BCR was defined as 
a rise in PSA of > 2 ng/mL after the nadir had been reached. The cause of death was 
determined for each deceased patient. Patients with metastatic prostate cancer who 
died of any cause were classified as prostate cancer deaths.
Results: 617 (40.3%) patients were classified as having a normal weight, 754 (49.3%) 
overweight and 159 (10.4%) were obese. The Kaplan-Meier 8-year risk of BCR (95% 
CI) was 33.3% (27.2-39.4), 29.2% (23.5-34.9) and 29.3% (12.4-46.2) for patients 
with a BMI of <25 kg/m2, 25-30 kg/m2 and >30 kg/m2, respectively. The 8-year CSS 
was 88.2% (83.1-93.3), 88.6% (83.7-93.5) and 90.6% (79.9-100.0) and the 8-year OS 
was 70.1% (63.6-76.6), 72.9% (66.6-79.2) and 81.8% (69.3-94.3) for these 3 groups, 
respectively. Multivariable proportional hazard regression analyses of BMI and 
established prognostic factors for BCR confirmed the absence of any prognostic value 
of BMI on BCR, CSS and OS.
Conclusion: BMI did not appear to have any prognostic value for BCR, CCS or OS in 
with patients with clinically localized prostate cancer treated with brachytherapy.
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Introduction
Obesity and prostate cancer are two major health concerns in Western communities. 
In The Netherlands, like most countries in Western Europe, prostate cancer is one 
of the top three causes of cancer-related death among men. The increased public 
awareness of prostate cancer and increased prostate-specific antigen (PSA) testing 
has resulted in a higher incidence of clinically localized prostate cancer.1 Obesity is 
a fast growing epidemic worldwide. With the increasing prevalence of obesity and 
prostate cancer, the urologist and radiation oncologist will be confronted more 
frequently with obese patients having a potentially curable disease. However, the 
exact impact of obesity on treatment outcome of different treatment options for 
patients with prostate cancer is not well understood. Interestingly, in a study by Davies 
et al.2 obese patients were more likely to receive permanent prostate brachytherapy 
(PPB) compared with patients who were not obese.
Obesity, usually measured by body mass index (BMI, weight in kilograms divided 
by height in meters squared) has been linked to several chronic conditions such 
as cardiovascular disease, diabetes mellitus and hypertension. Obesity has also 
been identified as a risk factor for certain types of cancers, e.g. colorectal cancer, 
postmenopausal breast cancer, kidney cancer and endometrial cancer.3 The 
relationship between BMI and development of prostate cancer is less clear, with 
some studies showing an increased risk, but others reporting no association or 
even a protective effect.4-6 More consistent data exist on the association between 
increased BMI and 'aggressive' prostate cancer, i.e. higher grade tumours, higher 
rate of positive surgical margins and a greater risk of biochemical recurrence (BCR) 
after radical prostatectomy (RP)7-9 or external beam radiation therapy (EBRT).10'11
Obesity and prostate cancer are being increasingly addressed reflected by the 
increasing number of articles published on this topic in the recent years. However, 
to date, few data have been reported on the treatment of obese patients with 
prostate cancer, especially on PPB. Besides, most of these studies are conducted 
in the USA; this might be important because the USA population differs from the 
European population. Therefore, we investigated the relationship between BMI 
and biochemical recurrence (BCR), cancer-specific survival (CSS) and overall survival 
(OS) in a historical cohort of Dutch patients treated with PPB for clinically localized 
prostate cancer. To the best of our knowledge, this is the largest European study 
investigating the relation between BMI and prostate cancer outcome after PPB.
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Patients and methods
Patients
Between 1991 and 2008, 1,730 patients with low-stage prostate cancer (stage cT1 or 
cT2) were treated with PPB at the department of Radiotherapy, University Medical 
Center Utrecht. Patients with no data on height or weight (N=154), missing follow-up 
data (N=13) or patients who received salvage PPB after EBRT (N=33) were excluded. 
This resulted in a study population of 1,530 patients. Height and weight data were 
collected retrospectively by reviewing anaesthesia records. According to the World 
Health Organization, patients were stratified into three groups, normal weight (<25 
kg/m2), overweight (BMI 25-30 kg/m2) and obese (BMI > 30 kg/m2).12 
Patients underwent clinical staging by medical history, digital rectal examination and 
serum PSA measurement. Bone scans, pelvic lymph node dissection and computed 
tomography (CT) of the pelvis were obtained as clinically indicated.
Because Gleason grading was performed by different pathologists, Gleason scores were 
divided into three groups to minimize possible inconsistencies: low grade (Gleason 
score < 6), intermediate grade (Gleason score 7), and high grade (Gleason score > 8). 
Patients were also classified into three risk groups according to Ash et al.13: low-risk 
disease (cT1b-cT2a [2002 American Joint Committee on Cancer system], low grade, 
and PSA level of <10 ng/mL), intermediate-risk disease (cT2b-cT2c or intermediate 
grade or PSA level between 10-20 ng/mL) and high-risk disease (>cT3 or high grade 
or PSA level of > 20 or > two intermediate risk factors).
Treatment
Patients underwent prostate implantation using I-125 seeds by three brachytherapists. 
Different treatment techniques were used throughout the study period (1989-2008), 
as previously described14'15. Initially I-125 brachytherapy treatment consisted of 
transperineal implantation using single seeds, the latter being replaced by stranded 
seeds by July 1996. From 1998 onwards, routine volume study and pre-planning were 
performed in all patients. After that, in December 2000, a real-time intraoperative- 
planned approach was introduced, namely the Sonographic Planning of Oncology 
Treatment (SPOT) system and from 2002 the Fully Integrated Real-time Seed Treatment 
(FIRST) system (Nucletron B.V., Veenendaal, The Netherlands) was used. According to the 
Radiation Therapy Committee Task Group No. 43 of American Association of Physicists in 
Medicine, the planned dosage consisted of 144 Gy.16 Specific dose constraints, like D90 
(minimal dose received by 90% of the prostate gland) and V100 (percentage of prostate 
volume receiving 100% of prescribed minimal peripheral dose) were not available for the 
early years of I-125 treatment. Since 2004, a post-planning CT and magnetic resonance 
imaging, on which these values were determined, are routinely performed. Because of 
the large amount of missing values before 2004, they were not used in the analysis.
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N o rm a l W e ig h t
N =617 (40.3% )
O v e rw e ig h t
N =754 (49.3% )
O bese
N =159 (10.4% )
p -va lue
M e d ia n  (IQR)
Age, years 67.0 (62.0-71.0) 66.0 (61.0-70.0) 64.0 (60.0-70.0) <0.001
B ody  M ass Index, k g /m 2 23.5 (22.4-24.3) 26.7 (25.8-27.8) 31.3 (30.4-33.1)
P re tre a tm e n t PSA, n g /m L 9.1 (6.3-13.0) 8.8 (6.2-13.0) 8.8 (6.1-12.4) 0.62
F o llo w -u p , m o n th s 47.0 (23.0-78.0) 47.0 (23.0-74.0) 37.5 (18.1-64.8) 0.08
P ros ta te  v o lu m e , cm 3 33.1 (27.0-41.0) 35.0 (28.0-43.0) 35.0 (30.1-42.0) 0.006
N u m b e r o f  seeds 70 (58-81) 73 (61-83) 73 (66-82) 0.008
N (%)
T re a tm e n t p e r io d
I 1989- June 1996
II Ju ly  1996-2001
III 2002- p resen t
50 (8.1) 
168 (27.2) 
397 (64.3)
44 (5.8) 
187 (24.8) 
519 (68.8)
4 (2.5) 
35 (22.0) 
118 (74.2)
0.03
C lin ica l stage 
T1 
T2
378 (61.3) 
238 (38.6)
483 (64.1) 
271 (35.9)
113 (71.1) 
45 (28.3)
0.06
P a th o lo g ica l G ra d ing
1
2
3
326 (52.8) 
277 (44.9) 
9 (1.5)
397 (52.7) 
349 (46.3) 
3 (0.4)
95 (59.7) 
60 (37.7) 
1 (0.6)
0.09
A sh Risk g ro u p
Low
In te rm e d ia te
High
189 (30.6) 
234 (37.9) 
191 (31.0)
224 (29.7) 
321 (42.6) 
206 (27.3)
50 (31.4) 
71 (44.7) 
36 (22.6)
0.19
PLND
Yes
No
35 (5.7) 
582 (94.3)
30 (4.0) 
724 (96.0)
5(3.1) 
154 (96.9)
0.22
AD T
Yes
No
82 (13.3) 
532 (86.2)
165 (21.9) 
588 (78.0)
34 (21.2) 
124 (78.2)
<0.001
P re o p e ra tive  TURP
Yes
No
49 (7.9) 
568 (92.1)
40 (5.3) 
714 (94.7)
9 (5.7) 
150 (94.3)
0.13
Table  1 Patients and pathological characteristics.
Abbreviations: N= number; IQR= interquartile range (P25-P75); PLND= pelvic lymph node dissection; ADT= 
androgen deprivation therapy; TURP= trans urethral resection o f the prostate.
In all, 281 patients (18.4%) received androgen deprivation therapy (ADT) for 6 months 
before their PPB. ADT was initiated if patients had a large prostate (>50 cm3) to achieve 
prostate volume reduction before the planned PPB. The ADT consisted of a luteinizing 
hormone-releasing hormone agonist. No patients received supplemental EBRT.
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Log Rank, p=0,79 Log Rank, p=0,91
Follow -up, months 
Log Rank, p=0,58
Follow -up, months
Figure 1 BCR-free, Cause-specific and 
Overall survival fo llowing perm anent 
brachytherapy represented by Kaplan­
M e ie r curves. 
normal weight (blue) 
overweight (green) 
obese (red)
Follow -up, months
Follow-up
Generally, patients were seen every 3 months during the first year, every 6 months 
during the second and third year and yearly thereafter unless there was evidence 
of cancer recurrence, in which case more frequent follow-up visits were deemed 
necessary. The serum PSA level was obtained before PPB and at every follow-up visit. 
According to the Phoenix Consensus Conference BCR was defined as a rise in PSA of 
>2 ng/mL after the nadir had been reached.17 Time to BCR was measured from date 
of PPB until date of a PSA level of nadir plus >2 ng/mL was reached. The cause of 
death was determined for each deceased patient. Patients with metastatic prostate 
cancer who died of any cause were classified as prostate cancer deaths.
Statistical analysis
Associations between predefined BMI subgroups and clinical or pathological 
characteristics were examined by Chi-square tests in case of categorical characteristics 
and Kruskal-Wallis tests in case of continuous characteristics. The risk of BCR, cause 
specific and overall survival was assessed with the Kaplan-Meier method using the
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Normal weight Overweight Obese
Biochemical 
recurrence, (%)
33 .3 (27 .2 -39 .4 ) 29 .2 (23 .5 -34 .9 ) 29.3 (12 .4-46 .2 )
Cancer-specific 
survival, (%)
88 .2 (83 .1 -93 .3 ) 88.6 (83 .7 -93 .5 ) 90 .6  (79 .9 -100 .0 )
Overall survival, (%) 70 .1 (63 .6 -76 .6 ) 72 .9  (66 .6 -79 .2 ) 81 .8  (69 .3-94 .3 )
Table 2 8-year risk o f biochemical recurrence, cancer-specific and overall survival (95%  
confidence interval).
log rank-test for the comparison between subgroups. Univariable and multivariable 
Cox's proportional hazard models were used to determine if any of the clinical or 
treatment variables predicts BCR, CSS and OS. The PSA level before PPB, pathologic 
stage and grading were not included in the multivariable analyses, because the 
variable risk group is based on these parameters. Differences were considered to 
be statistically significant if p <0.05. Data were analysed using SPSS for Windows 
(version 15.0).
Results
Table 1 summarizes the clinical and pathological characteristics of the study 
population stratified by preoperative BMI. At time of PPB, the study population had 
a median age of 67.0 years and a median BMI of 25.7 kg/m2. In all, 617 (40.3%) 
patients were classified as having a normal weight, 754 (49.3%) were overweight, 
and 159 (10.4%) were obese. The median PSA level before PPB was 8.9 ng/mL and 
the median Gleason score was 6. Compared to patients that were not obese, obese 
patients were significantly younger and received PPB more frequently during the 
most recent treatment period (2002-present). Obesity was significantly associated 
with prostate volume, adjuvant ADT and number of seeds needed during PPB. Over 
time there was a significant increase in BMI, each year the BMI increased with 0.09 
kg/m2.
As expected, patients whose prostate cancer progressed were more likely to have 
more advanced disease (highest risk group) than those who did not progress 
(data not shown). After a median follow-up of 47.0 months 249 patients (16.3%) 
developed BCR and 193 (12.6%) died after the PPB, of which 61 died of prostate 
cancer. The overall 8-year Kaplan-Meier risk (95% CI) of BCR, CSS and OS was 32.2% 
(28.1-36.3), 88.6% (85.3-91.9), 72.3% (68.0-76.6), respectively. The 8-year risk of 
BCR, CSS and OS did not differ significantly within the three BMI groups. (figure 1; 
table 2)
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Biochemical Progression-free survival
Variable Univariable HR
(95%  CI)
p-value Multivariable HR
(95%  CI)
p-value
Age 1.03 (1 .01 -1 .05 ) 0.001 1.00  (0 .98 -1 .02 ) NS
Preoperative PSA 1.05 (1 .04 -1 .06 ) <0.001
Pathological stage
(T1 vs. T2) 1.98 (1 .55 -2 .55 ) <0.001
Pathological grade
Good
Interm ediate (vs. good) 
Poor (vs. good)
1
1.42 (1 .09 -1 .84 ) 
4 .5 8  (2 .21 -9 .50 )
0 .0 09
<0.001
Risk group
Low
Interm ediate (vs. low) 
High (vs. low)
1
2 .08  (1 .28 -3 .39 ) 
7.83  (5 .02 -12 .24 )
0 .003
<0.001
1
2 .30  (1 .41 -3 .75 ) 
7.45 (4 .69 -11 .82 )
0.001
<0.001
Prostate volume (cm 3) 0 .9 9  (0 .98 -1 .00 ) NS
Preop PLND (yes vs. no) 2.35 (1 .60 -3 .43 ) <0.001 1.14  (0 .76 -1 .71 ) NS
ADT (yes vs. no) 0.88 (0 .62 -1 .26 ) NS
BMI
< 25 kg /m 2 
25 -30 kg /m 2 
> 30 kg /m 2
1
0 .91  (0 .70 -1 .19 ) 
0 .93  (0 .59 -1 .46 )
NS
NS
1
1.00  (0 .77 -1 .31 ) 
1.15 (0 .72 -1 .85 )
NS
NS
BMI (continuous) 0 .9 8  (0 .94 -1 .02 ) NS
Treatment period
1989-June 1996  
July 19 96-2001  
2002-present
1
0 .5 7  (0 .41 -0 .80 ) 
0 .2 7  (0 .18 -0 .39 )
0.001
<0.001
1
1.22 (0 .74 -2 .00 ) 
0 .6 4  (0 .38 -1 .08 )
NS
NS
Number of seeds 0 .9 9  (0 .98 -0 .99 ) <0.001 0 .83  (0 .97 -1 .00 ) NS
Table 3a Univariable and m ultivariable Cox proportional hazard analyses of Biochermical 
Recurrence-free Survival.
Abbrevations: PSA= prostate-specific antigen; Preop = preoperative; PLND= pelvic lymph node dissection; 
ADT= androgen deprivation therapy; BMI= Body Mass Index; NS=non significant.
Using univariable proportional hazards regression analysis, there was no significant 
association between the risk of BCR, CSS or OS and obesity. (table 3) Likewise in 
multivariable regression analysis for risk of BCR, CSS and OS, BMI did not appear to 
have an independent prognostic value.
As listed in table 3, in univariable analyses, age, preoperative PSA level, pathological 
stage and grade, risk group, treatment in the first period and number of seeds were 
significantly associated with increased risk of BCR, CSS and OS. In multivariable 
analyses only patients in the highest risk group were significantly associated with 
increased risk of BCR, CSS and OS. In multivariable analysis, age was a strong 
prognostic factor for OS.
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Cause-specific survival
Variable Univariable HR
(95%  CI)
p-value Multivariable HR
(95%  CI)
p-value
Age 1.06 (1.02-1.10) 0 .007 1.02 (0 .98 -1 .06 ) NS
Preoperative PSA 1.04 (1 .03 -1 .06 ) <0.001
Pathological stage
(T1 vs. T2) 2 .97  (1 .72 -5 .14 ) <0.001
Pathological grade
Good
Interm ediate (vs. good) 
Poor (vs. good)
1
3 .20  (1 .81 -5 .65 ) 
6 .30  (1 .39 -28 .67 )
<0.001
0.017
Risk group
Low
Interm ediate (vs. low) 
High (vs. low)
1
I .7 8  (0 .46 -6 .90 )
I I . 5  (3 .59 -37 .0 )
NS
<0.001
1
1.80  (0 .46 -7 .00 )
8.81 (2 .65 -29 .2 )
NS
<0.001
Prostate volume (cm 3) 1.00 (0 .97 -1 .02 ) NS
Preop PLND (yes vs. no) 2 .20  (1 .11 -4 .39 ) NS
ADT (yes vs. no) 0 .5 6  (0 .20 -1 .54 ) NS
BMI
< 25 kg /m 2 
25 -30 kg /m 2 
> 30 kg /m 2
1
0 .9 4  (0 .56 -1 .60 ) 
0 .8 0  (0 .28 -2 .28 )
NS
NS
1
1.07  (0 .60 -1 .88 ) 
1.46  (0 .50 -4 .28 )
NS
NS
BMI (continuous) 0 .9 6  (0 .88 -1 .04 ) NS
Treatment period
1989-June 1996  
July 19 96-2001  
2002-present
1
0 .35  (0 .20 -0 .61 ) 
0 .13  (0 .04 -0 .40 )
<0.001
<0.001
1
1.05 (0 .41 -2 .71 ) 
0.53  (0 .14 -2 .08 )
NS
NS
Number of seeds 0 .9 8  (0 .69 -0 .99 ) 0.001 0 .9 8  (0 .95 -1 .00 ) 0.08
Table 3b Univariable and m ultivariable Cox proportional hazard analyses of Cause-specific 
Survival.
Abbrevations: PSA= prostate-specific antigen; Preop = preoperative; PLND= pelvic lymph node dissection; 
ADT= androgen deprivation therapy; BMI= Body Mass Index; NS=non significant.
Discussion
The exact role of obesity in the development and progression of prostate cancer is not 
well understood. Several biological mechanisms have been proposed. Adipose tissue, 
especially abdominal visceral fat, is an active endocrine and metabolic organ. Besides 
alterations in sex steroid hormones (increased serum concentrations of estradiol and 
decreased serum concentrations of testosterone) it produces adipokines, e.g. insulin­
like growth factor-1, interleukin-6, vascular endothelial growth factor and leptin. 
Two large European historical cohort studies reported a positive correlation between 
BMI and prostate cancer risk,5'18 while others found a protective effect of obesity on
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Overall survival
Variable Univariable HR 
(95% CI)
p-value Multivariable HR 
(95% CI)
p-value
Age 1.09 (1 .06 -1 .11 ) <0.001 1.07 (1 .04 -1 .10 ) <0.001
Preoperative PSA 1.02 (1 .01 -1 .04 ) <0.001
Pathological stage
(T1 vs. T2) 1.56 (1 .16 -2 .08 ) 0.03
Pathological grade 
Good
Interm ediate (vs. good) 
Poor (vs. good)
1
1.63 (1 .21 -2 .20 ) 
4 .75  (2 .05 -11 .00 )
0.01
<0.001
Risk group
Low
Interm ediate (vs. low) 
High (vs. low)
1
1.03 (0 .66 -1 .61 ) 
2 .38  (1 .61 -3 .53 )
NS
<0.001
1
0 .9 4  (0 .60 -1 .49 ) 
1.59  (1 .04 -2 .44 )
NS
0.03
Prostate volume (cm 3) 0 .9 9  (0 .98 -1 .00 ) NS
Preop PLND (yes vs. no) 1.41 (0 .88 -2 .28 ) NS
ADT (yes vs. no) 0 .5 9  (0 .35 -1 .01 ) NS
BMI
< 25 kg /m 2 
25 -30 kg /m 2 
> 30 kg /m 2
1
0 .8 9  (0 .66 -1 .19 ) 
0 .7 7  (0 .43 -1 .39 )
NS
NS
1
0 .9 8  (0 .72 -1 .33 ) 
1.09  (0 .59 -2 .01 )
NS
NS
BMI (continuous) 0 .95  (0 .91 -1 .00 ) NS
Treatment period
1989-June 1996  
July 19 96-2001  
2002-present
1
0 .45  (0 .32 -0 .62 ) 
0 .3 0  (0 .19 -0 .48 )
<0.001
<0.001
1
0 .9 6  (0 .57 -1 .61 ) 
0 .7 8  (0 .42 -1 .45 )
NS
NS
Number of seeds 0 .9 8  (0 .97 -0 .98 ) <0.001 0 .9 8  (0 .96 -0 .99 ) 0.08
Table 3c Univariable and m ultivariable Cox proportional hazard analyses o f Overal Survival. 
Abbrevations: PSA= prostate-specific antigen; Preop = preoperative; PLND= pelvic lymph node dissection; 
ADT= androgen deprivation therapy; BMI= Body Mass Index; NS=non significant.
prostate cancer.4'19 Although the relation between obesity and prostate cancer risk is 
indistinct, there is more consistency in published papers about a positive association 
between obesity and prostate cancer mortality.20'21 This suggests that obesity might 
play a more prominent role in the progression than in the development of prostate 
cancer.
Recently, reports have shown a higher risk of BCR in obese patients who underwent 
RP or EBRT compared those who were not obese.7'8'10'11'22'23 The hazard ratio (HR) 
varied between 1.04 (95% CI, 1.02-1.07) to as high as 1.99 (95% CI, 1.21-3.27) when 
comparing obese patients with normal weight patients. This may be explained by 
technical difficulties during dissection of the prostate in obese patients resulting
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in more positive margins. Also, in obese patients receiving EBRT, daily treatment 
is often compromised by set up errors because of the increased organ motion by 
excessive intra-abdominal adipose tissue. However, in the present study there was 
no significant association between the risk of BCR and obesity. The 8-year risk of BCR 
was 29.3% for obese patients compared with 33.3% in the normal weight patients. 
The present findings are consistent with three other published reports evaluating the 
relationship between obesity and BCR after PPB. Notably, 13% to 54% of the patients 
received adjuvant EBRT in these studies.24-26
By contrast with the RP and EBRT studies, several explanations can be given as to why 
BMI did not influence BCR in the present study. First, compared with patients who 
were not obese, in the present study obese patients were more frequently treated 
in the most recent treatment period (2002-present). Patients treated in this period 
had a significantly smaller risk of BCR after PPB (HR=0.27, 95% CI 0.18-0.39) in the 
univariable analysis. However, in the multivariable analysis treatment period did not 
have an independent prognostic value. Second, there has been less enthusiasm for 
the use of PPB in men with high-risk disease. On the one hand, the present PPB 
patient group might very well be a selected and more homogeneous group of patients 
with a better prognostics profile. It is attractive to speculate that obese patients with 
high-risk prostate cancer are more often treated with RP or EBRT. As a result, patients 
who are treated with other methods might be more at risk of developing BCR. On 
the other hand, in the present study a smaller percentage (although not statistically 
significant) of obese men had high-risk disease compared with normal weight men. 
Third, the studies that evaluated the risk of BCR after RP consisted of many more Afro- 
Americans (average 21%) compared with the PPB studies (< 5%). Afro-Americans are 
more prone to be obese and more frequently have aggressive tumours compared 
with white men. In the study of Amling et al.7 black race and BMI were associated 
with higher BCR after RP in the univariable analysis; however, in multivariable only 
black race remained significant. Differences in BCR risk in obese patients, treated by 
RP or PPB, may be partly explained by the differences in the distribution of race seen 
in the aforementioned studies.
Fourth, obese patients significantly more often received ADT in the present study 
(table 1); this may have improved prognosis in patients with a higher BMI. Fifth, 
older age correlates with worse disease. In the present study, the obese patients 
were significantly younger and the follow-up among the obese patients was tending 
toward significance. Although these differences are small, it should be considered 
whether these factors in concert could mask an effect.
It is important to notice that BCR is a surrogate of CSS. BCR can occur late in the 
postoperative course and the presence of BCR is not always a good predictor of CSS. 
A 10-year cohort study by Siddiqui et al.27 reported that despite worse pathological
89
Chapter 5
features at time of RP in obese patients, long-term CSS remained the same regardless 
of BMI. In the present study BMI was not related with CSS. Only one other study 
by Merrick et al.26 examined the relation between BMI and CSS in patients who 
underwent PPB, and same conclusions were drawn.
To determine if obesity was an independent predictor for BCR, Freedland et al.28 
investigated patients who underwent RP and had organ confined disease and negative 
surgical margins. After controlling for the higher pathological Gleason grades among 
obese men, BMI remained a significant predictor of BCR with moderately and severely 
obese men (BMI > 35 kg/m2) having nearly a four-fold increased risk for BCR. In that 
study, surgical technique (margin status) could not fully explain the worse outcomes 
among obese patients, suggesting that obesity may be associated with a biologically 
more aggressive prostate cancer.
Limitations of the present study are the following. First, the retrospective nature 
of this study. Second, additional quantitative measures of obesity, such as waist- 
to-hip ratio and waist circumference were not available. Abdominal fat is the most 
metabolic and endocrine active fat in the human body and best measured by waist- 
to-hip ratio or waist circumference. Third, specific dose constraints, like D90 and V100 
were not available for the whole study population. Fourth, the cohort of obese men 
was only 10%. It is possible that some of the associations that were tending towards 
significance might reached significance with a few more men in the obese group. 
However, according to the Netherlands Health interview Survey the prevalence of 
obesity in Dutch men is only 9%.29
Urologists and radiation oncologists will be confronted more often with obese men 
with clinically localized prostate cancer. However, to date there is no consensus about 
what the best treatment option (RP, EBRT, PPB) should be for an obese patient with 
localized prostate cancer. Although accrual might be difficult, randomised prospective 
studies are needed to clarify this problem.
Conclusion
The present study is the largest single institution series to describe the possible 
impact of BMI on BCR, CSS and OS in patients who underwent PPB for clinically 
localized prostate cancer. BMI was not a prognostic marker for BCR, CSS or OS.
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Abstract
Objective: Several reports found that obesity was associated with prostate cancer 
aggressiveness among men treated with radical prostatectomy or radiotherapy. 
Studies concerning this issue have basically relied on body mass index (BMI), as a 
marker for general obesity. Because visceral fat is the most metabolic active fat, we 
sought to evaluate if periprostatic fat measured on a computed tomography (CT) 
is a better marker than BMI to predict prostate cancer aggressiveness in a Dutch 
population who underwent brachytherapy for localized prostate cancer.
Patients and methods: Of the 902 patients who underwent brachytherapy, 725 CT 
scans were available. Subcutaneous fat thickness, periprostatic fat area (cm2) and 
periprostatic fat density (%) were determined on the CT scan. Patients were stratified 
into 3 groups: <25, 25-75 and > 75 percentile of the fat-density. Associations between 
the three fat-density subgroups and BMI and prostate cancer aggressiveness were 
examined.
Results: 237 patients were classified as having normal weight (37.2%), 320 as 
overweight (50.2%) and 80 as obese (12.6%). There was a strong significant association 
between BMI and periprostatic fat density and subcutaneous fat thickness. The 
strongest correlation was seen between BMI and subcutaneous fat thickness (Pearson 
r coefficient=0.71). Logistic regression analysis revealed no statistically significant 
association between the different fat measurements and the risk of having a high­
risk disease.
Conclusion: Periprostatic fat and periprostatic fat density as measured with CT 
were not correlated with prostate cancer aggressiveness in patients receiving 
brachytherapy. However, 31% of the patients with a normal BMI had a periprostatic 
fat density of >75 percentile of the periprostatic fat density.
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Introduction
Obesity and prostate cancer are two major health concerns. On the one hand, obesity 
is a rapidly growing worldwide epidemic and it increases the risk of several chronic 
diseases and certain cancers.1'2 On the other hand, prostate cancer is diagnosed more 
often in the prostate-specific antigen (PSA) era and the disease is often diagnosed in 
a localized stage suitable for curative treatment.3
The relationship between obesity and prostate cancer is debated, with studies finding 
an inverse, a linear correlation with prostate cancer, or no relation at all.4'6 However, 
several studies found a link between obesity and disease aggressiveness.7'9 
Recently, the classical perception of adipose tissue as a storage place of fatty acids 
has been replaced by the notion that adipose tissue produces a large number of 
hormones and cytokines, e.g., tumour necrosis factor-a, interleukin-6, leptin 
and adiponectin.10 The exact role of these cytokines in prostate carcinogenesis, 
however, is not known. Most of the studies that investigated the role of obesity on 
prostate cancer used body mass index (BMI, the weight in kilograms divided by the 
squared height in meters) as a marker of general obesity. Although there is a strong 
correlation between BMI and waist-circumference, the most metabolic active fat is 
the abdominal visceral fat and a better way to measure this is by waist-hip ratio or 
waist-circumference. Therefore, waist-circumference as an indicator of abdominal fat 
may be a better predictor for prostate cancer risk than BMI alone, especially in men 
with a low BMI. Computed tomography (CT) is another technique which measures 
visceral fat even more accurately.11'12
The aim of this study was to investigate whether periprostatic fat, measured on a CT 
scan, is a better marker for prostate cancer aggressiveness in patients who underwent 
brachytherapy for localized prostate cancer compared to BMI. We also evaluated the 
relation between BMI and different fat measurements. To the best of our knowledge 
such a study has never been performed.
Patients and methods
Patients
Between April 2004 and August 2008, 902 patients with biopsy-proven localized 
prostate cancer (stage cT1 or cT2) were treated with transrectal ultrasonography guided 
transperineal permanent mono brachytherapy at the department of Radiotherapy, 
University Medical Center Utrecht, The Netherlands. Due to the very short follow-up 
of this cohort of men we only focused on prostate cancer baseline characteristics. 
Patients underwent clinical staging by medical history, digital rectal examination and 
serum PSA measurement. Bone scans were obtained and pelvic lymph node dissection
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was performed when clinically indicated. A CT was performed to determine specific 
dose constraints 4 weeks after brachytherapy. A CT was performed one day after the 
brachytherapy to determine specific dose constraints. The CT was not performed in 
153 patients and in 24 patients the quality of the CT was poor due to hip prostheses. 
This resulted in a study population of 725 men.
Because different risk classifications are used in the literature we decided to use two 
different risk classifications, one according to Ash et a.13 and the other according to 
D'Amico et al.14 Tumour stage was described according to the 2002, TNM, American 
Joint Committee on Cancer system.
Fat measurement
Preoperative height and weight data were collected retrospectively by reviewing 
anaesthesia records. The BMI (kg/m2) was calculated and stratified into three groups 
according to the WHO, i.e. normal weight (<25), overweight (25-30) and obese (>30). 
Only one patient had a BMI value of < 18.5 kg/m2, this patient was included in the 
normal weight group. The CT scans were acquired on a single slice CT (Aura, Philips 
Medical Systems, Best, The Netherlands), and had an in-plane slice resolution of
0.49 X 0.49 mm with a slice thickness of 3 mm. We used an in-house developed 
software tool for delineation of the pelvic fat region and the measurement of the 
subcutaneous fat thickness (figure 1).15
Because there are no comparable studies available we chose to delineate along 
established lines (figure 1). The fat contained within the delineated contours of the 
CT, is segmented by thresholding on the Hounsfield Units (HU). We differentiated 
between fat (-190 to -30 HU), air (< -500 HU) and other soft tissue types.16 Since the 
delineated contours did not contain bony structures, we did not include a threshold 
for segmenting the bones separately. The total contour area (cm2) was calculated by 
the total number of voxels within the contour minus the number of air voxels and 
the periprostatic fat area (cm2) by counting 'fat' voxels within the total contour area. 
The periprostatic fat density (%) was calculated by dividing periprostatic fat by the 
total contour area.
Patients were stratified into 3 groups: <25 percentile (group 1), between 25 and 75 
percentile (group 2) and >75 percentile (group 3) of the fat-density.
Statistical analysis
Associations between the predefined three fat-density subgroups and clinical or 
pathological characteristics were examined by Chi-square tests in case of categorical 
characteristics and Kruskal-Wallis tests in case of continuous characteristics. The 
Pearson correlation coefficient was used to quantify correlations between BMI and 
the different fat measurements. Binary logistic regression analyses were performed to
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Figure 1 Images dem onstrate our m ethod for determ ining visceral fa t distribution and 
subcutaneous fa t thickness on a CT scan.
A: Tranverse section is made at the level o f the femoral head and the greater trochantor o f the femur. The 
red line, outlines the tota l contour area (cm2), in which attenuation is measured. The line is drawn at the 
back side o f the pubic bone, fo llow ing the border o f the internal obturatorius muscle, anterior side o f the 
gluteus maximus muscle and coccyx bone. W ithin the region o f interest the periprostatic fa t area (cm2) 
and the periprostatic fa t density (%, dividing periprostatic fat by the tota l area w ith in the red countour) 
was calculated.
B: Transverse section is made at the level o f superior pubic ramus. The red line outlines the subcutaneous 
fa t thickness by which the distance between the skin and pubic bone is measured (cm).
evaluate the independent effect of each variable on the risk of having high-risk disease 
versus low- or intermediate-risk (according to Ash et al.13 and D'Amico et al.14). 
Differences were considered to be statistically significant if p<0.05. Data were 
analysed using SPSS for Windows (version 15.0).
Results
The median age (range), BMI and periprostatic fat density at the time of brachytherapy 
was 66 years (45-81), 25.8 kg/m2 (17.6-56.8) and 31.8% (10.0-52.2), respectively. 
In 88 (12%) patients the BMI was not available. In all, 237 patients were classified 
as having normal weight (37.2%), 320 as overweight (50.2%) and 80 as obese 
(12.6%). Table 1 summarizes the clinical and pathological characteristics of the study 
population stratified by periprostatic fat density.
Patients in group 3 were significantly older. The median prostate volume was 
statistically different between the 3 groups but the differences were not clinically 
relevant. A clear significant association was seen between the periprostatic fat density 
groups and BMI, subcutaneous fat thickness and periprostatic fat. Figure 2 shows
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G roup 1
N=181  
< 25 percentile
G roup 2
N =363  
25-75 percentile
G roup 3
N=181  
> 75 percentile
p-value
M e d ian  (IQR):
Age, years 64 .0  (59 .0 -68 .0 ) 66 .0  (61 .0 -70 .0 ) 68 .0  (63 .0 -71 .0 ) <0 .001a
Follow  up, months 18.0 (11 .0 -30 .5 ) 16.5 (11 .0 -28 .8 ) 18 .0 (11 .0 -29 .0 ) 0 .97a
Prostate vo lum e, cm3 37 .0  (30 .0 -44 .0 ) 34 .3  (28 .0 -41 .0 ) 34 .0  (27 .8 -40 .0 ) 0 .02a
In itia l PSA, ng/m l 8.4 (6 .3 -12 .2) 8 .5 (6 .3 -11 .7) 9 .0  (6 .9 -12 .5) 0 .20a
B M I, kg /m 2 24.5 (22 .8 -26 .4 ) 26 .0  (24 .6 -27 .8 ) 26 .8  (24 .8 -29 .4 ) <0 .001a
Total periprostatic fa t, cm2 23 .7  (19 .3 -25 .9 ) 31 .3  (28 .0 -34 .5 ) 40 .5  (36 .9 -43 .5 ) <0 .001a
Fat density, % 24 .0  (21 .3 -26 .0 ) 31 .8  (29 .2 -33 .9 ) 38 .5 (37 .1 -40 .9 )
Subcutaneous fa t, cm 3.9 (3 .2 -4 .7 ) 4 .7  (3 .9 -5 .5 ) 5.1 (4 .1 -6 .1 ) <0 .001a
N (%)
W H O-classification <0 .001b
Norm al w eight 88 (57.9) 109 (33.5) 40  (25.0)
O verweight 60 (39.5) 175 (53.8) 85 (47.0)
Obesity 4 ( 2.6) 41 (12.6) 35 (19.3)
Clinical stage 0 .21b
T1 112 (61.9) 252 (69.4) 119 (66.1)
T2 69 (38.1) 111 (30.6) 61 (33.9)
Grade 0 .4 6b
Low 111 (61.3) 231 (64.2) 114 (64.0)
In term ediate 70 (38.7) 129 (35.8) 64 (36.0)
Ash risk group 0 .9 6b
Low 69 (38.1) 141 (39.2) 67 (37.4)
In term ediate 76 (42.0) 154 (42.8) 75 (41.9)
High 36 (19.9) 65 (18.1) 37 (20.7)
D'Amico risk group 0 .4 0b
Low 72 (39.8) 145 (39.9) 70 (38.7)
In term ediate 99 (54.7) 200 (55.1) 95 (52.5)
High 10 (5 .5) 14 (3 .9) 12 (6.6)
Lymph node dissection 0 .1 4b
Yes 7 (3 .9) 5 (1.4) 3 (1 .7 )
No 174 (96.1) 358 (98.6) 178 (98.3)
Table 1 Baseline characteristics.
Patients were stratified by fa t density. IQR= interquartile range; a = Kruskal-Wallis-test; b = X2-test.
the correlation between BMI and the different fat measurements. The strongest 
correlation was seen between BMI and subcutaneous fat thickness (Pearson r 
coefficient=0.71, p<0.001).
Logistic regression analysis revealed no statistically significant association between the 
different fat measurements and the risk of having high-risk disease (table 2). Only age 
was significantly associated with increased risk of having a high-risk disease, however 
in the multivariable analysis (data not shown) this significance disappeared.
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Subcutaneous fat thickness (cm) Fat density (%)
Figure 2 Correlation betw een body mass 
index and different fa t m easurem ents.
The linear regressive line is shown w ith  95% CI. 
The vertical line represents the median.
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The urologist and radiation oncologist will be confronted more frequently with obese 
patients having a localized prostate cancer. Although the association between obesity 
and the risk of prostate cancer risk is controversial4'17'18, a stronger link between 
obesity and increased risk for higher pathologic grade and higher rates of biochemical 
recurrence compared with normal weight patients was seen in several studies.9'19'20 Of 
note, all these studies were done in the USA. We conducted a study in The Netherlands 
where we evaluated 1,302 patients who underwent a radical prostatectomy. In that 
study BMI did not appear to have any prognostic value for biochemical recurrence 
or worse pathologic features.21 Same conclusions were drawn by Pfitzenmaier et al.22 
In contrast with the USA, where 30% of the population is obese, only 9% to 14% of 
the European population was obese.23'24 Thereby, obese patients are less obese than 
the obese men in the USA and a relatively large proportion of the USA population 
consists of Afro-Americans who are more prone to be obese and more frequently 
have aggressive tumours compared with white men.
A question may present itself: are we measuring obesity in the right way? In most 
studies investigating obesity in relation to prostate aggressiveness and biochemical 
recurrence, BMI is used as a criterion for general obesity. The most metabolic active
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Variable Odds Ratio (95% CI) p-value
Age 1.07 (1.03-1.11) <0.001
Prostate volume, cm3 1.00 (0.98-1.02) 0.68
BMI (continuous) 0.97 (0.92-1.03) 0.37
BMI
<25 kg/m2 1
25-30 kg/m2 0.80 (0.53-1.21) 0.29
>30 kg/m2 0.51 (0.24-1.06) 0.07
Periprostatic fat density (continuous) 1.00 (0.97-1.03) 0.94
Periprostatic fat density
Group 1 1
Group 2 0.89 (0.56-1.40) 0.61
Group 3 1.05 (0.63-1.76) 0.85
Subcutaneous fat thickness 0.96 (0.85-1.10) 0.56
Periprostatic fat area 1.00 (0.976-1.02) 0.76
Table 2a Univariable logistic regression analysis o f factors predicting high-risk disease according 
to Ash.
Variable Odds Ratio (95% CI) p-value
Age 1.06 (1.00-1.13) 0.06
Prostate volume, cm3 1.01 (0.97-1.05) 0.57
BMI (continuous) 0.89 (0.79-1.01) 0.09
BMI
<25 kg/m2 1
25-30 kg/m2 0.63 (0.29-1.34) 0.23
>30 kg/m2 0.40 (0.86-1.73) 0.21
Periprostatic fat density (continuous) 1.00 (0.95-1.06) 0.94
Periprostatic fat density
Group 1 1
Group 2 0.69 (0.30-1.59) 0.39
Group 3 1.24 (0.52-2.96) 0.62
Subcutaneous fat thickness 0.80 (0.95-1.05) 0.11
Periprostatic fat area 1.00 (0.96-1.05) 0.93
Table 2b Univariable logistic regression analysis of factors predicting high-risk disease according 
to D'Amico.
fat however, is the abdominal visceral fat. Waist-circumference, as an indicator of 
abdominal obesity may be a better predictor of risk of more aggressive prostate 
cancer than BMI, especially in individuals with a lower BMI. Visceral fat is the most 
metabolic active fat and produces adipokines. Obesity is associated with increased 
levels of several adipokines and studies reported a link between the level of adipokines 
and aggressive prostate cancer.25'27
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A large study by the European Prospective Investigation into Cancer and Nutrition 
(EPIC) group concluded that once general obesity was adjusted for abdominal fat 
distribution it was positively associated with the risk of death. This association 
tended to be stronger among participants with a lower BMI.28 In a large prospective 
cohort of 148,372 men, Pischon et al. found that higher waist-circumference was 
associated with increased risk of advanced prostate cancer and high-grade prostate 
cancer among individuals with lower BMI. The relative risk of advanced prostate 
cancer was 1.06 (95% CI 1.01-1.10) per 5-cm-larger waist circumference.29 Same 
conclusions were drawn in a prospective Swedish study.30 These data suggest that 
especially abdominal adiposity may be associated with an increased risk of advanced 
prostate cancer and waist-circumference is a better way to measure obesity.
Visceral fat can affect both the lean and obese and is more metabolically active than 
subcutaneous fat. By measuring the waist-circumference the discrepancy between 
thin outside (subcutaneous fat) and thick inside (visceral fat) cannot be made. A 
CT scan can distinguish between these two "layers". In our study we measured the 
visceral and subcutaneous fat on a CT to identify if one of these parameters is a 
better marker for tumour characteristics compared with BMI. Possible explanations 
for the lack of this correlation can be: first, there has been less enthusiasm for the 
use of brachytherapy in men with high-risk disease. These patients might be very 
well selected which can be an explanation for these negative findings. Second, the 
fat measurement was performed on one cross-sectional scan. Theoretically the 
accuracy of the fat measurement could be improved by measuring the fat content 
on more cross-sectional scans (volume measurement). However, in this study the 
selection bias of the brachytherapy patients is probable more important than the 
technique of fat measurement. Third, it is possible that the fat around the intra­
abdominal organs are more metabolic active than the periprostatic fat. It would be 
interesting to measure the fat around the intra-abdominal organs, however, this 
scans were not available and it was not possible to measure the intra-abdominal fat 
distribution and body circumference at the level of the umbilicus. Fourth, it would 
be very interesting to correlate the BMI and periprostatic fat density with clinical 
outcome like biochemical recurrence or disease specific survival instead of pre­
treatment Gleason score, because these are better prognostic markers for prostate 
cancer aggressiveness. However, in this study the follow-up was too short to evaluate 
these outcomes.
Our analysis showed a correlation between BMI and subcutaneous fat thickness and 
periprostatic fat density. The correlation between BMI and subcutaneous fat thickness 
was much stronger (Pearson r coefficient=0.71 vs r=0.35). Interestingly, 31% of the 
patients with a normal BMI had a fat-density > 75 percentile, compared with only 
10% of the obese patients who had a fat-density < 25 percentile of the fat-density. 
Thus, what you measure on the outside is definitely not always representative for the
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fat distribution on the inside. It is attractive to speculate that when this study was 
performed in a group of patients with more high-grade tumours, e.g. a group treated 
with external radiotherapy, these parameters could be a better prognostic marker 
for tumour characteristics than BMI, especially in patients with a low BMI. However, 
further studies are needed to identify the real value of these fat measurements on 
CT as correlates with prostate cancer aggressiveness.
Conclusion
Periprostatic fat and fat-density were not of any value to predict prostate cancer 
aggressiveness in patients receiving brachytherapy. However, 31% of the patients 
with a normal BMI had a fat-density of >75 percentile of the periprostatic fat- 
density. More studies, including patients who have more aggressive prostate cancer, 
are needed to identify the true value of fat measurement on a CT as a correlate of 
prostate cancer aggressiveness and/or predictor of treatment failure.
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Abstract
Purpose: To examine if the periprostatic fat measured on computed tomography (CT) 
correlates with advanced disease we examined patients who received radiotherapy 
for localized prostate cancer. Several USA reports found a positive association 
between obesity and prostate cancer aggressiveness. However, in recent European 
studies these conclusions were not confirmed. Studies concerning this issue have 
basically relied on body mass index (BMI), as a marker of general obesity. Visceral fat, 
however, is the most metabolically active and best measured on CT.
Patients and methods: In 932 patients, with T1-3N0M0 prostate cancer, different fat 
measurements (periprostatic fat, subcutaneous fat thickness) were performed on a 
CT. Associations between the different fat measurements and risk of having high-risk 
disease was measured.
Results: Logistic regression analyses revealed a significant association between 
periprostatic fat density (PFD) and high-risk disease.
Conclusion: Patients with a higher PFD had more often aggressive prostate cancer.
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Introduction
In the USA and most countries of Western Europe, prostate cancer is the most 
common cancer among men and the second leading cause of death.1 Although the 
prevalence of prostate cancer at autopsy studies is more or less the same worldwide, 
the reported incidence is highly variable. On the one hand these differences can be 
explained by variation in PSA testing. On the other hand diet has been implicated in 
the aetiology of prostate cancer.2 Obesity, a major and increasing health problem, has 
been correlated with advanced stage at diagnosis and increased risk of biochemical 
recurrence (BCR).3-5 Adipose tissue is not only a storage place of fatty acids but it also 
produces a large number of hormones and cytokines, e.g. tumour necrosis factor-a, 
interleukin-6, leptin and adiponectin. The exact role of these cytokines in prostate 
carcinogenesis, however, is not known. All the studies that found an association 
of obesity with prostate cancer aggressiveness3-5 were performed in the USA. We 
conducted two studies in The Netherlands and could not confirm this relation.6'7 
Neither could another European study by Gallina et al.8 It may be wondered however, 
whether obesity has been measured in the right way, especially in a population that 
is less obese compared to that of the USA. In all studies body mass index (BMI, the 
weight in kilograms divided by the squared height in meters) was used as a marker 
for general obesity. However, the most metabolic active fat is the visceral fat. 
Computed tomography (CT) is a technique which can measure fat at different levels 
in the human body very accurately and can distinguish the contribution of central 
and peripheral fat.9 In a small Portuguese case-control study10 body fat was assessed 
by CT in 63 prostate cancer cases and 63 age-matched healthy community controls. 
Although both groups had the same BMI (26 kg/m2), the prostate cancer group had a 
significantly higher mean visceral fat area compared to the control group. These data 
suggest a role of visceral fat as a risk factor for prostate cancer. We investigated whether 
different fat measurements (periprostatic fat and subcutaneous fat), on CT correlate 
with advanced stage in a group of patients who underwent external radiotherapy or 
brachytherapy for localized prostate cancer. Both treatment modalities were used to 
get a good compilation of patients having both low- and high-risk disease.
Patients and methods
Patients
In our database a CT was available from 363 patients who received five-field intensity- 
modulated three-dimensional conformal radiotherapy (IMRT) and for 725 patients who 
received brachytherapy at the Department of Radiotherapy, University Medical Center 
Utrecht, The Netherlands. All patients had stage T1-T3N0M0 prostate cancer and
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Figure 1 Images dem onstrate our m ethod fo r determ ining d ifferent fa t m easurements. 
Transverse section m ade at th e  level o f the fem oral head and greater trochanter of the 
femur.
The green contour outlines the area, in which attenuation is measured. The line was drawn at the backside 
o f the pubic bone, fo llow ing the obturatorius internus muscle, the gluteus maximus muscle and coccyx 
bone. W ithin the region o f interest the tota l periprostatic fa t area (cm2) and periprostatic fa t density (%, 
dividing periprostatic fa t by the total contour area w ith in the green line) were measured. The blue line 
measures the subcutaneous fat thickness.
were treated between January 2003 and August 2008. Patients who had undergone 
IMRT received 76 Gy in 35 fractions and prostate position was determined daily by 
using three gold markers. Patients, who received brachytherapy, underwent prostate 
implantation by using 125I seeds (144 Gy). Both treatment techniques used have been 
previously described.11'12 Bone scans were obtained and pelvic lymph node dissection 
was performed when clinically indicated. Six months of neo-adjuvant hormonal therapy 
with a LHRH-agonist was given to 120 (19%) brachytherapy patients presenting with 
a prostate volume >50 cm3 to achieve volume reduction. 101 (32.5%) high-risk IMRT 
patients received adjuvant hormonal therapy with a LHRH-agonist for 3 years.
The patients were classified into 3 risk groups according to Ash.13 Tumour stage was 
described according to the 2002, TNM, American Joint Committee on Cancer system.
Fat measurement
BMI was calculated and stratified into three groups according to the WHO, i.e. normal 
weight (<25), overweight (25-30) and obese (>30). A preplanning CT was performed 
in patients who received IMRT and one day after treatment in patients who received 
brachytherapy. In total, 156 patients (N=52 IMRT and N=104 brachytherapy), were
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Risk group
Group 1 
Low Risk
N=260
Group 2 
Intermediate Risk
N=293
Group 3 
High Risk
N=379
p-value
Median (IQR)
Age, years 65.0 (59.6-68.0) 66.5 (62.0-71.0) 69.0 (64.1-73.0) <0.001
Prostate volume, cm3 36.0 (29.0-43.0) 35.0 (30.0-42.5) 35.0 (27.0-44.8) 0.96
Initial PSA, ng/ml 7.2 (5.3-8.5) 9.8 (6.8-13.0) 14.0 (10.0-22.8)
BMI, kg/m2 25.7 (24.2-28.0) 26.0 (24.3-28.4) 25.7 (24.0-28.4) 0.38
Total periprostatic fat, cm2 31.9 (26.8-36.8) 32.0 (25.9-37.2) 35.3 (28.6-41.4) <0.001
Periprostatic fat density, % 32.2 (27.5-36.3) 32.4 (27.1-36.6) 35.6 (29.9-41.0) <0.001
Subcutaneous fat
4.5 (3.8-5.3) 4.7 (3.7-5.7) 4.7 (3.9-5.6)
thickness, cm
0.10
N (%)
Treatment
Brachytherapy 235 (90.4) 265 (90.4) 121 (31.9)
<0.001
IMRT 25 (9.6) 28 (9.6) 258 (68.1)
WHO-classification
Normal weight 94 (38.5) 93 (33.6) 89 (38.7)
0.22
Overweight 123 (50.4) 139 (50.2) 102 (44.3)
Obesity 27 (11.1) 45 (16.2) 39 (17.0)
M iss ing  BMI 16 (6.1) 16 (5.5) 149 (39.3)
Clinical stage
T1 194 (74.6) 197 (67.2) 70 (18.5)
T2 66 (25.4) 96 (32.8) 83 (21.9)
T3 0 0 226 (59.6)
Gleason Score
< 6 241 (93.4) 139 (47.6) 50 (13.3)
7 17 (6.6) 153 (52.4) 250 (66.5)
> 8 0 0 76 (20.2)
Hormonal therapy
Yes 40 (15.5) 60 (20.7) 257 (68.0)
<0.001
No 218 (84.5) 230 (79.3) 121 (32.0)
Table 1 P atien ts ' p a tho log ica l cha rac te ris tics  and fa t m e a su re m e n t cha racte ris tics .
IQR= interquartile range; BMI= body mass index; BCR= biochemical recurrence.
excluded because the CT was of poor quality. This resulted in a study population of 932 
men. Preoperative height and weight data were collected retrospectively by reviewing 
medical records. The CT scans were made with a single slice CT (Aura, Philips Medical 
Systems, Best, The Netherlands) and had an in-plane slice resolution of0.49x0.49 mm2 with 
a slice thickness of 3 mm. We used an in-house developed software tool for delineating 
different regions of the human body.14 Fat measurements were performed on a transverse 
section at the level of the femoral head and greater trochanter of the femur. Figure 1 
shows the method used for determining the different fat measurements. Because there 
are no comparable studies available we chose to delineate along established lines. The 
fat contained within the delineated contours of the CT, was segmented by thresholding
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on the Hounsfield Units (HU). We differentiated between fat (-190 to -30 HU), air (< -500 
HU) and other soft tissue types.15 Since the delineated contours did not contain bony 
structures, we did not include a threshold for segmenting the bones separately.
Statistical analysis
Associations between the predefined risk groups and clinical and pathological 
characteristics or fat measurements were examined by Chi-square tests in case 
of categorical characteristics and Kruskal-Wallis tests in case of continuous 
characteristics. Logistic regression analyses were performed with adjustment for age 
to evaluate the effect of each variable on the risk of having high-risk disease versus 
low- or intermediate-risk. The PSA level before treatment, pathological stage and 
grading were not included in the logistic regression analyses and Cox's proportional 
hazard models, because the risk group (according to Ash) was based on these 
parameters. Differences were considered to be statistically significant if p<0.05. Data 
were analysed using SPSS for Windows (version 15.0).
Results
Table 1 summarizes the clinical, pathological and different fat measurements of the 
study population stratified by Ash risk group. The median age (IQR) was 67.0 years 
(62.0-71.0) and the median BMI (IQR) was 25.8 (24.2-28.3). BMI was missing in 19.4% 
(181) of the cases. Patients in the highest risk group were significantly older. 83.0% of 
the patients who received IMRT had high-risk disease and 80.5% of the patients who 
underwent brachytherapy had low/intermediate-risk disease. Patients in the highest 
risk group had a significantly larger total periprostatic fat area (TPF, cm2) and PFD 
(%) compared with the low and intermediate risk group. Logistic regression analyses 
(table 2), adjusted for age, revealed a statistically association between TPF and PFD 
and increased odds of having high-risk disease.
Variable Hazard Ratio*(95% CI) p-value
BMI (continuous) 1.02 (0.98-1.06) 0.41
BMI
< 25 kg/m2 1
25-30 kg/m2 0.84 (0.60-1.19) 0.34
> 30 kg/m2 1.22 (0.76-1.97) 0.41
Subcutaneous fat thickness, (cm) 1.06 (0.96-1.17) 0.29
Total periprostatic fat, (cm2) 1.04 (1.03-1.06) <0.001
Periprostatic fat density, (%) 1.06 (1.04-1.08) <0.001
Table 2 Logistic regression analysis o f factors predicting high risk disease according to Ash. 
BMI = body mass index; * = after adjustment for age
114
Periprostatic fat and tumour aggressiveness
Discussion
This is the first paper which shows that periprostatic fat measured on CT is directly 
correlated with prostate cancer aggressiveness and is more important than BMI, as a 
measurement of general obesity.
Although the specific biologic processes linking obesity to prostate cancer remain 
to be elucidated completely, previous studies consistently suggested that obesity is 
associated with advanced stage at diagnosis and increased risk of BCR after therapy.3' 
5;17'21 These findings might be important and may indicate that obese patients require 
different treatment considerations. However, these findings could not be confirmed 
in recent European studies.6-' 7;22;23
Several explanations can be given for this discrepancy. First, North America has a 
different population composition than Europe. Second, compared to Europe the 
prevalence and severity of obesity is much higher in North America. In Europe 
only 9 to 14% is obese while in the USA obesity prevalence is as high as 30%.24;25 
Although obesity is less common in Europe, the trend is progressing rapidly.26 In 
all aforementioned studies BMI has been used as a marker for general obesity. In 
a large cohort study among 129,502 men (the European Prospective Investigation 
into Cancer and Nutrition)27 waist circumference and waist-to-hip ratio (as a measure 
of abdominal obesity) were positively associated with risk of advanced disease. The 
relative risk (95% CI) was 1.06 (1.01-1.1) per 5-cm-higher waist circumference and
1.21 (1.04-1.39) per 0.1-unit higher waist-to-hip ratio. Waist circumference and 
waist-to-hip ratio were positively associated with advanced disease among men with 
a lower but not among men with a higher BMI. These data suggest that an increased 
risk of advanced prostate cancer is more strongly associated with abdominal adiposity 
than with BMI, especially in a population that is less obese. A CT scan is an excellent 
technique to distinguish and quantify subcutaneous and visceral fat.
Contrary to BMI and subcutaneous fat thickness, the TPF and PFD significantly increased 
the odds of having high-risk disease in the present study. One percent increases of PFD 
increased the risk of having high-risk disease with 6%. With this in mind, one should 
expect that the patients with the highest PFD are at a greater risk of BCR.
Our study has some limitations. As this was a retrospective study, an abdominal cross­
sectional CT-scan was not available. It would be interesting to have a scan at the level 
of the umbilicus to measure the intra-abdominal fat. It is possible that the intra­
abdominal fat is more metabolic active than the fat around the prostate. Second, in 
order to be able to evaluate a study population that consists of both low/intermediate 
(brachytherapy) and high-risk disease (IMRT) we had to use patients (of whom a CT- 
scan was on hand) who were treated with the two treatment modalities. It would have 
been more ideal if all patients were treated by only one treatment modality.
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Another essential issue that must be considered is the metabolic activity of individual 
fat cells. 'Fat' fat cells, which are more common in obese patients, produce larger 
quantities of cytokines than 'thin' fat cells.28 A CT scan can not distinguish between 
these two different types of fat cells. A future step would be to measure the 
activity of fat by collecting fat from different parts of the body (e.g. during a radical 
prostatectomy) and to determine the cytokine production of the fat cells collected 
from different locations. By linking these data with anthropometric data of the 
patient and its prostate cancer characteristics, a better insight may be gained in the 
exact role of obesity on prostate cancer. A first step is made by Finley et al.29 They 
recently investigated the periprostatic fat quality by analyzing the periprostatic fat 
quality and found that high levels of IL-6 correlated with tumour grade.
Conclusion
In contrast with a higher BMI, patients with a higher PFD had an increased risk of 
having a more aggressive prostate cancer.
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Abstract
Objective: It has been hypothesized that blood lipid profiles are associated with 
prostate cancer risk. However, results are scarce and inconsistent and underlying 
mechanisms are not fully understood. The aim of the present study was to address 
the association between serum total cholesterol, HDL cholesterol, LDL cholesterol, 
triglycerides and prostate cancer risk in a Dutch, population-based cohort study. 
Subjects and methods: The association between blood lipid profiles and prostate 
cancer risk was assessed in a population-based study among 2,862 men. Serum 
total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were evaluated 
as potential risk factors for prostate cancer using age-adjusted proportional hazards 
regression models.
Results: In total, 38 new cases of prostate cancer were identified during a median 
follow-up of 56.4 (IQR: 50.9-59.4) months. Increased risks per mmol/L were observed 
for total cholesterol (HR 1.22, 95% CI: 0.91-1.66), HDL cholesterol (HR 1.83, 95% 
CI: 0.71-4.69) and LDL cholesterol (HR 1.36, 95% CI: 0.97-1.91). Triglycerides were 
associated with decreased prostate cancer risk (HR 0.77 per mmol/L, 95% CI: 0.54­
1.09). However, no statistically significant associations were observed.
Conclusion: The results of this study did not provide strong evidence that blood lipid 
levels are associated with risk of prostate cancer in this cohort. However, statistical 
power is limited due to the relatively small number of prostate cancer cases. Further 
studies are needed to provide additional data.
122
Lipid profile and prostate cancer risk
Introduction
Epidemiological studies suggest that lipid profiles in blood are associated with risk of 
prostate cancer. Although some studies indicated that high serum triglycerides,1,2 low 
serum HDL cholesterol,3 and high total3-5 or LDL cholesterol3 might contribute to the 
development or progression of prostate cancer, results are scarce and inconsistent.
So far, few studies have assessed the relation between serum triglycerides and 
prostate cancer risk.1,6 A case-control study among 504 cases with prostate cancer 
and 565 controls with benign prostatic hyperplasia (BPH) found a positive association 
between serum triglycerides and prostate cancer risk (OR 1.15, 95% CI: 1.00-1.32).1 
A recent, prospective study based on 29,364 Norwegian men (687 incident cases), 
however, did not confirm an association between serum triglycerides and risk of 
incident or fatal prostate cancer.6
Cholesterol has been regarded as a potential risk factor for prostate cancer. Although, 
two case-control studies have shown that hypercholesterolemia increases the risk 
of prostate cancer,3,4 most prospective studies only reported a positive association 
for high-grade disease.5 Other prospective studies did not find any association6-11 
or suggested that risk of prostate cancer decreased with increasing cholesterol
levels.12,13
Supportive evidence for the potential role of cholesterol in prostate cancer 
development has been provided by observations that cholesterol-lowering drugs 
(3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly known as 
statins) might be inversely associated with risk of (advanced) prostate cancer.14-17 A 
recent meta-analysis by Bonovas et al., confirmed that statin use lowers the risk of 
advanced prostate cancer (RR 0.77, 95% CI: 0.64-0.93); however, no effect for total 
prostate cancer risk was found (RR 0.95, 95% CI: 0.73-1.23).18 Others addressed 
that the cholesterol-lowering effects of statins might not be the only reason why 
these drugs are associated with reduced risk of advanced prostate cancer.18 Direct 
pro-apoptotic and anti-inflammatory effects of statins are suggested to inhibit 
development or progression of prostate cancer independent of cholesterol.19,20 
Furthermore, differences in PSA screening patterns between statin users and 
nonusers might be responsible for the observed associations as well.14,18 Since results 
are conflicting and underlying mechanisms have to be elucidated, further research 
is needed to evaluate the effects of cholesterol-lowering drugs on prostate cancer 
prevention, whereas robust studies on serum cholesterol and other blood lipids 
should confirm whether these blood lipids itself are potential risk factors for prostate 
cancer.
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As described above, the relation between blood lipid profiles and prostate cancer 
risk has been previously investigated, but only a few recent and population-based 
prospective studies have been reported.5,6 T ie  aim of the present study was to 
address the association between serum cholesterol, triglycerides and prostate cancer 
risk in a Dutch, population-based cohort study.
Subjects and methods
The Nijmegen Biomedical Study is a survey of the general population in which a 
random, age- and sex-stratified sample was recruited among adult inhabitants of 
Nijmegen, Lent and Oosterhout (eastern part of the Netherlands) between 2001 and 
2003. In total, 21,756 inhabitants received an invitation to participate in this study. Of 
these, 9,350 (43%) subjects agreed to participate and filled out a postal questionnaire 
on lifestyle and medical history at baseline. The majority of the participants (90%) 
in this region were Caucasian. Furthermore, 6,468 (69%) participants donated 
two non-fasting blood samples, which were collected in tubes containing heparin 
(8.5 ml) or EDTA (8.5 ml). Blood samples were processed within two hours after 
withdrawal and aliquots of serum were stored at -40°C. All analyses of blood lipid 
profiles were performed between October 2004 and April 2005. Levels of serum total 
cholesterol, HDL cholesterol and triglycerides were analysed enzymatically using an 
Abbott Aeroset autoanalyser. Levels of LDL cholesterol were estimated using the 
Friedewald formula.21 Since the Friedewald formula only appeared to be accurate up 
to triglyceride levels of 8 mmol/L ,22 we did not calculate LDL levels for participants 
with triglyceride levels above 8 mmol/L (N=8). Criteria of the National Cholesterol 
Education Program were used to define hypercholesterolemia (> 5.17 mmol/L), 
low HDL cholesterol (<1.03 mmol/L), high LDL cholesterol (> 3.36 mmol/L) and high 
triglycerides (> 1.69 mmol/L).23 This study was approved by the Institutional Review 
Board and all participants provided written informed consent.
All 3,050 male participants of the Nijmegen Biomedical Study who provided blood 
samples were initially included in our analyses. Of these, 162 participants were 
excluded since no blood lipid measurements were available and 13 participants were 
excluded because of incomplete follow-up data. Incident cases of prostate cancer 
(N=51) diagnosed between 2002 and 2007 were identified through record linkage 
with the population-based cancer registry of the Comprehensive Cancer Centre 
East (CCCE). The CCCE has a catchment area of 1.3 million inhabitants living in the 
Eastern part of the Netherlands, including Nijmegen and surroundings. Subjects 
with a diagnosis of prostate cancer before blood withdrawal were excluded from the 
analyses (N=13), leaving 38 cases and 2,862 cohort members for final analyses. The
124
Lipid profile and prostate cancer risk
M edian (IQR) or num bers (%) Total cohort
N=2862
Prostate can cer cases
N=38
A ge, years 62.1 (47.3-73.3) 71.7 (68.1-76.3)
Follow -up, m onths 56.4 (50.9-59.4) 26.6 (16.0-45.0)
H e igh t, cm 178 (173-183) 175 (170-178)
W eight, kg 80 (73-88) 79 (71-85)
BM I, kg/m 2 25.2 (23.4-27.5) 26.2 (23.7-27.8)
Sm o kin g , ever, %* 2231 (78) 33 (87)
D iabetes, yes, %* 193 (8) 3 (9)
H ypertension, yes, %* 673 (26) 14 (39)
Use o f ch o lestero l-low erin g  drugs, ever, %* 422 (17) 7 (21)
Serum  to ta l ch o lestero l, m m ol/L 5.6 (4.9-6.3) 5.8 (5.1-6.8)
Serum  HDL cholestero l, m m ol/L 1.2 (1.0-1.4) 1.2 (1.0-1.5)
Serum  LDL cholestero l, m m ol/L 3.5 (2.8-4.1) 3.8 (3.1-4.3)
Serum  trig lyce rid e s, m m ol/L 2.0 (1.4-2.7) 1.7 (1.3-2.3)
Table 1 Baseline characteristics of all cohort m em bers and m em bers with incident prostate 
cancer in th is population-based study.
* = Percentages are based on the number of cohort members and cases without missing values for these 
variables.
follow-up of all participants was defined as the day of blood withdrawal until date of 
death, emigration, prostate cancer diagnosis or the end of follow-up (December 31st, 
2007), whichever came first.
Information on age, height, weight, smoking status (current, former, never), history 
of hypertension (yes, no), history of diabetes mellitus (yes, no), use of cholesterol­
lowering drugs (current, former, never) and use of other drugs (drug names) were 
obtained from the self-reported questionnaires. For the prostate cancer cases, date 
of diagnosis, clinical or pathological tumour stage (TNM based on the 2002 American 
Joint Committee on Cancer guidelines24), Gleason score and PSA levels were obtained 
through the cancer registry, whenever available.
We used age-adjusted proportional hazards regression models to calculate hazard 
ratios (HR) and 95% confidence intervals (95% CI) for prostate cancer incidence. 
Blood lipid levels were all evaluated individually both as categorical variables (high 
versus low) and as continuous measures (per mmol/L) in these age-adjusted models. 
Analyses were repeated after exclusion of participants who ever used cholesterol­
lowering drugs to evaluate whether use of these drugs might have an effect on the 
risk estimates. The Statistical Package of Social Sciences (SPSS, version 16.0, Chicago, 
Illinois) was used for all statistical analyses.
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N o  o f cases HR* 95%  CI
Serum  total cholestero l, per m m ol/L 38 1.22 0.91-1.66
<5.17 10 1.00 -
>5.17 28 1.38 0.67-2.86
Serum  HDL cholestero l, per m m ol/L 38 1.83 0.71-4.69
<1.03 7 1.00 -
>1.03 31 1.64 0.72-3.72
Serum  LDL cholestero l, per m m ol/L 38 1.36 0.97-1.91
<3.36 15 1.00 -
>3.36 23 1.29 0.67-2.47
Serum  trig lyce rid e s, per m m ol/L 38 0.77 0.54-1.09
<1.69 18 1.00 -
>1.69 20 0.71 0.38-1.35
Use o f ch o lestero l-low erin g  drugs, ever vs never 7 vs 27 0.89 0.39-2.04
Table 2 Age-adjusted m odelsfor prostate cancer incidence associated with blood lipid levels.
* = Adjusted for age
Results
Baseline characteristics of the participants are presented in table 1. Among 2,862 
participants, 38 incident prostate cancer cases were identified during a median 
follow-up of 56.4 (IQR: 50.9-59.4) months. Of these, 21 patients were diagnosed with 
low-grade prostate cancer (Gleason <7 at biopsy), while 14 patients had high-grade 
tumours (Gleason >7 at biopsy), and for 3 patients Gleason scores were unknown. 
The median time between blood withdrawal and diagnosis of prostate cancer was 
26.6 (IQR: 16.0-45.0) months. Median age was 62.1 (IQR: 47.3-73.3) years for all 
cohort members and 71.7 (IQR: 68.1-76.3) years for cases. Seventeen percent of 
all men in the cohort reported former or current use of cholesterol-lowering drugs 
(N=422). Median serum levels of total cholesterol, HDL cholesterol, LDL cholesterol 
and triglycerides appear to be fairly similar between the cohort members and 
prostate cancer cases.
As shown in table 2, none of the serum lipid levels (i.e. total cholesterol, HDL cholesterol, 
LDL cholesterol or triglycerides) were significantly associated with prostate cancer risk in 
age-adjusted proportional hazards regression models. For LDL cholesterol (continuous) 
a modest association was found for prostate cancer incidence, although this effect 
was not statistically significant (HR 1.36 per mmol/L, 95% CI: 0.97-1.91). Exclusion of 
subjects who reported ever use of cholesterol-lowering drugs did not change these 
results (for LDL cholesterol, HR 1.47 per mmol/L, 95% CI: 0.96-2.23).
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Discussion
Overall, our study did not provide strong evidence that blood lipid levels are associated 
with prostate cancer risk in this Dutch cohort. We found a positive association with 
prostate cancer risk for high levels of total cholesterol and HDL cholesterol; however, 
these associations did not reach statistical significance. These findings were partially 
consistent with those of Martin and colleagues who assessed blood lipid profiles 
and other components of the metabolic syndrome in a large, population-based 
cohort study among 29,364 Norwegian men.6 They neither did observe a significant 
association between total or HDL cholesterol and triglycerides with prostate cancer 
incidence or mortality.6
Triglyceride levels in our study were inversely related to prostate cancer risk, although 
this association was not statistically significant. Similar results were observed by 
Martin and colleagues who observed triglyceride levels inversely related with 
advanced prostate cancer (HR 0.89 per 1.3 mmol/L, 95% CI: 0.72-1.10). As in our 
study, this finding was based on relatively few cases (N=135) and was not statistically 
significant, therefore raising the possibility of a chance finding.
Findings from our study suggested that increased levels of serum LDL cholesterol might 
be associated with prostate cancer risk, although these results were not statistically 
significant. Our results with respect to LDL cholesterol need to be interpreted with 
some caution, since non-fasting blood samples were used. The Friedewald formula for 
calculating levels of LDL cholesterol is based on the assumption that total cholesterol 
minus HDL cholesterol minus VLDL cholesterol equals LDL cholesterol.21 This method 
requires measurements of total cholesterol, HDL cholesterol and triglycerides (as a 
proxy for VLDL cholesterol) levels.21 Using non-fasting samples might result in abundant 
triglycerides, a subsequent overestimation of VLDL cholesterol and therefore might 
underestimate levels of LDL cholesterol.25 Nevertheless, in our population-based 
cohort we had only eight cohort members with non-fasting triglyceride levels above 8 
mmol/L, which is suggested as the upper level for accurate Friedewald calculations.22 
Since we did not calculate LDL cholesterol levels for these eight patients, we do not 
expect that an underestimation of LDL cholesterol strongly affected our results.
The mechanisms underlying the possible association between blood lipid profiles and 
prostate cancer risk are poorly understood and are most likely related to signaling 
functions of cholesterol. Cholesterol is incorporated into moving platforms in the 
fluid bilayer of cellular membranes, which are referred to as lipid rafts.26 As reviewed 
by others,27-29 these lipid rafts might play an important role in cell signalling (such 
as the EGFR/Akt130 or IL6/STAT331 pathways) and could thereby act on growth and
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survival of prostate cancer cells.30,31 Future experiments focusing on lipid rafts should 
elucidate these and other signaling networks and its effects with respect to prostate 
cancer development or progression. Another hypothesis is based on the theory of 
steroidogenesis, which postulates that prostate cancer cells itself might be able to 
produce androgens which can bind to the androgen receptor and stimulate growth 
and survival.32 It has recently been shown that prostate cancer cells in advanced 
stages could synthesize androgens directly from cholesterol.33 These findings might 
explain the suggested association between serum cholesterol levels and risk of local 
and advanced prostate cancer; however, future studies are needed to confirm the 
exact role of cholesterol and other blood lipids in the development and progression 
of prostate cancer.
It has been previously suggested that associations between blood lipid profiles 
and prostate cancer risk are more pronounced in aggressive or advanced prostate 
cancer.2,5 Hammersten et al. evaluated several features of the metabolic syndrome 
among 299 patients with recently diagnosed prostate cancer. Subjects with poorly 
differentiated prostate cancer had lower HDL cholesterol levels and higher triglyceride 
levels compared to those with well differentiated disease.2 Furthermore, Platz et al., 
had previously demonstrated that use of statin drugs lowers the risk of advanced 
prostate cancer (RR 0.51, 0.30-0.86), whereas no association for total prostate 
cancer risk was found.14 Recently, they have evaluated the association between 
plasma cholesterol and prostate cancer risk in a nested case-control study to address 
whether cholesterol-lowering properties might explain the effects of statins on 
prostate cancer risk.5 Low cholesterol levels were not associated with total prostate 
cancer risk (OR 0.93; 0.72-1.20), however an inverse association was found for high­
grade disease (OR 0.61; 0.39-0.98).5
Unfortunately, we were not able to distinguish between localized and advanced 
or aggressive disease due to the relatively small number of cases in our study. 
Therefore, it was not possible to perform subgroup analyses for prostate cancer 
grade or stage. Despite this small number of cases in our study, a-posteriori power 
calculations demonstrated that we would have been able to detect a difference in 
serum cholesterol levels of 0.5 mmol/L between cases and members of the cohort 
(power of 80%). Since median cholesterol levels in our population were 5.6 mmol/L, 
a difference of 0.5 mmol/L could have made the distinction between desirable (<5.17 
mmol/L) and borderline high (>5.17 mmol/L) cholesterol levels.
Potential limitations of the present study were the non-fasting blood samples, the 
relatively short follow-up (median 56 months) and the incapability to stratify for 
localized and advanced disease. Strengths of this study are the prospective design
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and the analyses of total cholesterol, HDL cholesterol and triglycerides in blood 
samples from a population-based cohort.
Conclusion
This study did not provide strong evidence that blood lipid levels are associated with 
prostate cancer risk in a Dutch cohort. Larger, prospective, population-based studies 
are needed to verify whether blood lipids might have more pronounced effects on 
advanced or aggressive prostate cancer risk or mortality. Knowledge of these and 
other specific metabolic factors associated with prostate cancer risk might be relevant 
with respect to preventive strategies or even therapeutic options.
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General Discussion
Globally, prostate cancer is highly prevalent. It is the most common non-cutaneous 
cancer in men. An estimated 782,600 new cases and 254,000 deaths caused by 
the disease occurred in 2007 worldwide.1 Interestingly, autopsy studies worldwide 
show that approximately 60% of men in their sixth and seventh decade of life have 
prostate cancer.2'3 Although the prevalence of prostate cancer is similar across 
different populations, enormous differences in prostate cancer incidence and 
mortality between the United States and Asia are seen. Age-adjusted incidence 
rates in China are 3 per 100,000 men as compared with 108 for white and even 
184 per 100,000 for African-American men.4 The incidence of prostate cancer in 
Chinese men, however, increases substantially after migration to the United States.5 
This epidemiological relationship between incidence and geography supports a 
major contribution of environmental factors to the progression of prostate cancer. 
One of these environmental factors related to westernization is obesity, which is a 
common and rapidly growing epidemic in the United States and in Western European 
countries.6 With the aging male, increased use of PSA, and increasing trend of obesity 
the physician will be confronted more and more with obese patients having prostate 
cancer. Although the relation of obesity and prostate cancer has gained popularity 
in the field of scientific research most of these studies are performed in the United 
States. This thesis focused on the clinical implications of obesity on prostate cancer 
in the Dutch population.
Localized prostate cancer can be treated with surgery (open or laparoscopic) 
or radiotherapy (external or brachytherapy). Thus, when an obese patient with 
localized prostate cancer visits the outpatient clinic, the urologist and/or radiation 
oncologist can offer this patient different treatment options. But which of those fit 
the obese patient best in terms of cure and, not less important, morbidity? Obesity 
makes many urological procedures technically more difficult. A proper preparation 
of the striated sphincter and a good apical dissection as well as the reconstruction 
in a deep pelvis is challenging. Besides technical difficulties during an operation, 
obesity itself may have a negative impact on healing, especially at the vesico-urethral 
anastomosis. However, data are lacking on the exact role of obesity on the different 
surgical techniques and the existing studies consist of a small number of patients. 
The incidence of postoperative urinary incontinence, differs between 2.5% and 
87%.7-9 Three studies, all using self-administered and non-validated questionnaires, 
investigated the impact of obesity on postoperative incontinence after open radical 
prostatectomy and found no association between obesity and postoperative 
incontinence.10-12 In our series (chapter 3) however, the postoperative incontinence 
rate of obesity was much higher in the obese men compared to the non-obese men 
(25.8% vs. 8.7%, p=0.009) in patients who underwent an open radical prostatectomy.
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Different operation techniques and various definitions of incontinence as well as 
the retrospective nature of the studies, make comparisons between these series 
not easy. In the same chapter we also described that obese men were at higher 
risk of developing vesico-urethral strictures postoperatively compared with non- 
obese men (45.2% vs. 12.3%, p<0.005). Only one other study drew the same 
conclusion.13 These days the robotic assisted/laparoscopic radical prostatectomy is 
becoming more popular in the urological field. Theoretically, the magnification of a 
laparoscope and better vision in the deep pelvis may help the urologist performing a 
prostatectomy more precisely compared to the open approach. Despite the different 
and improving surgical techniques, it is particularly the co-morbidity of the patient 
that determines the recovery and healing process of an obese patient. Limitations 
of the study presented in chapter 3 was that the absolute number of obese patients 
was small, making multivariable analysis to adjust for potentially significant co­
variables impossible in any meaningful way. Besides, the functional outcomes were 
not obtained by validated questionnaires.
The risk of obesity in developing prostate cancer is controversial.14-18 However, more 
agreement exists on the increased risk of biochemical recurrence in obese men who 
underwent a radical prostatectomy.19-23 Of note, all studies were done in the United 
States. Compared to The Netherlands not only the prevalence of obesity is different, but 
also the composition of the population.24'25 We conducted a study (chapter 4) in which 
we retrospectively analysed 1,302 men with clinically localized prostate cancer who 
underwent a radical prostatectomy in one of two Dutch academic hospitals (Nijmegen 
and Rotterdam). In this study BMI did not appear to have any prognostic value for 
biochemical recurrence. One of the explanations for this discrepancy may be that 
American men are more obese and have more 'fatter' fat cells which produce larger 
quantities of adipokines. These adipokines may be responsible for more aggressive 
prostate cancer and higher biochemical recurrence rates. In chapter 4, although not 
significant, obese men had more often positive margins (40.8% vs. 34.9%) compared 
with normal-weight men. However, this resulted not in a higher risk of biochemical 
recurrence in the obese men. A question that may present: are these positive surgical 
margins a consequence of the technical difficulty during dissection of the prostate or 
is this due to adverse pathological features seen in obese men? In chapter 4, obese 
patients were not at risk of having more aggressive prostate cancer compared with 
non-obese men. It is tempting to speculate that the higher rate of positive margins 
seen in the obese group was caused by surgical difficulties. Interestingly, to determine 
whether the higher biochemical recurrence rates seen in an American study21 were due 
solely to the higher positive margin rate, Freedland et al.26 examined whether obesity 
was an independent predictor for biochemical recurrence among men with negative 
surgical margins. After controlling for preoperative characteristics, moderately and 
severely obese men (BMI >35 kg/m2) had a nearly a 4-fold increased risk of biochemical
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recurrence. Thus, in that study the surgical technique did not fully explain the worse 
outcomes among obese men, suggesting that obesity was associated with a more 
aggressive form of prostate cancer. A limitation of the study presented in chapter 4 
was that biochemical recurrence was used as an end-point. It would be more ideal to 
use cancer-specific survival.
To date, only a few studies reported the risk of biochemical recurrence in obese 
patients who underwent brachytherapy.27-29 In all studies obesity was not shown to 
be a risk factor for biochemical recurrence compared with non-obese patients. In 
chapter 5, 1,530 Dutch patients who had localized prostate cancer were treated with 
brachytherapy and were retrospectively evaluated. To the best of our knowledge 
this was the first and the largest European study investigating the relation between 
BMI and prostate cancer outcome. BMI was not a risk factor for biochemical 
recurrence after brachytherapy. Because biochemical recurrence is a surrogate 
for prostate cancer progression, we also examined the relation between BMI and 
cancer specific survival. BMI did not appear to have any prognostic value also for 
cancer specific survival. Compared with external radiotherapy27'30'31 where obese 
patients are at risk to develop biochemical recurrence, non of the brachytherapy 
studies found a correlation between obesity and worse treatment outcome. The 
following question arises: is this the result of a better technique or is this due to 
selection bias?
It is conceivable that a greater chance of daily setup uncertainties and excessive intra­
abdominal adipose tissue, which may increase organ motion, may lead to external 
beam treatment uncertainties and in their turn lead to increased failure rate seen 
in obese patients. In a study by Wong et al.32 severe obese patients who underwent 
external radiotherapy tended to have a greater magnitude of left-right prostate shifts 
compared to their non-obese counterparts. The technical aspects of brachytherapy, 
where radioactive seeds are brought into the prostate with real-time ultrasound 
imaging, may bypass the daily setup errors seen in external radiotherapy. However, 
there has been less enthusiasm for brachytherapy in patients with high-risk disease 
which may result in a more homogeneous group of patients with a better prognostic 
profile. Theoretically, obese patients with high-risk disease might be treated by 
other treatment modalities like surgery or external radiotherapy and thereby the 
differences seen in treatment failure in obese patients is not a matter of technique 
but due to selection bias. More studies are needed to clarify this.
In most studies investigating obesity in relation to prostate aggressiveness and 
biochemical recurrence, BMI is used as a criterion for general obesity. Although 
scientists have used BMI as a reliable indicator of overweight, new insights are now 
rapidly undermining this consensus. Terms such as 'fat' and 'thin' tell us much less 
about health than we assumed.33 The most metabolic active fat is the abdominal 
visceral fat. Although the specific biologic processes linking obesity to prostate
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cancer remain to be elucidated completely, several studies (as mentioned before), 
consistently suggest that obesity is associated with the advanced stage at diagnosis 
and the increased risk of biochemical recurrence in patients who undergo surgery 
or external radiotherapy.19-21'23'30'34-36 These findings, however, were not observed in 
recent European studies.37'38 (chapter 4 &5)
One of the reasons of this discrepancy may be clarified by the fact that we do not 
measure obesity (read: visceral fat) in the right way by using only BMI as a marker 
for general obesity. Especially in a population where obesity is less prevalent and 
less severe as compared with the USA. Pischon et al.39 found in a large European 
prospective cohort that greater waist circumference, as a measure of abdominal 
fat distribution, was associated with increased risk of advanced disease among 
individuals with lower BMI. One disadvantage of using waist circumference is that it 
cannot distinguish between a thin subcutaneous and a thick visceral fat layer or a thick 
subcutaneous and a thin visceral fat layer. A computed tomography (CT) scan is a very 
accurate technique, which can distinguish between these two "layers". A possible 
clarification of discrepancies seen between the European and North American studies 
on the risk of BCR may be resolved by measuring fat distribution more precisely on a 
CT. In chapter 6 we used a CT scan to measure the visceral fat and subcutaneous fat 
of 725 men who underwent brachytherapy for localized prostate cancer in relation to 
pathologic baseline characteristics. No association between periprostatic fat density 
(%, dividing periprostatic fat area by the total contour area measured around the 
prostate) and prostate aggressiveness was found. This is probably caused by the fact 
that patients with aggressive prostate cancer were not treated with this modality 
resulting in selection. Interestingly we found that 31% of the patients with a normal 
BMI had a >75 percentile of the periprostatic fat density. Thus, what one measures 
on the outside is definitely not representative for the fat distribution on the inside. 
The patient population in chapter 6 consisted mainly of patients with low and 
intermediate risk prostate cancer. To get a greater insight into the true value of fat 
measurement on a CT scan in relation to prostate aggressiveness and to overcome 
the problem that the study population mainly consisted of low/intermediate risk 
prostate cancers, we performed a similar study in a more heterogeneous group of 
patients. In chapter 7 we evaluated 932 patients who had undergone brachytherapy 
(mainly low/intermediate-risk patients) or external radiotherapy (mainly high-risk 
patients) for localized prostate cancer. In this chapter the periprostatic fat density 
was strongly associated with the risk of having a high-risk disease. One percent 
increase of the periprostatic fat density increases the risk of having high-risk disease 
with 6% (HR 1.06 95% CI 1.04-1.08, p<0.001). Unfortunately the follow-up was too 
short to determine the risk of biochemical recurrence in this population. It would be 
more ideal if all patients were treated by only one treatment modality. Studies with a 
longer follow-up and patients who are treated with only one treatment modality are
138
General Discussion & Future Perspectives
warranted to evaluate if patients with a higher periprostatic fat density are at greater 
risk to die from their prostate cancer.
Although results are still inconsistent and biochemical mechanisms have to be 
elucidated, lipid profiles in blood have been associated with prostate cancer risk.40-45 
It is very plausible that the signalling function of cholesterol plays an important role 
in prostate cancer aggressiveness. The cholesterol is packed and moved into moving 
platforms in the fluid bilayer of cellular membranes, which are called lipid rafts.46 
These rafts might play a central role in cell signalling (such as the EGFR/Akt147 or IL6/ 
STAT348 pathways) and could thereby act on growth and survival of prostate cancer 
cells. Another hypothesis is based on the theory of steroidogenesis, which postulates 
that prostate cancer cells themselves might be able to form androgens directly 
from cholesterol. The aforementioned hypothesis could explain the association 
between serum cholesterol levels and risk of (advanced) prostate cancer. Two case- 
control40'42 studies demonstrated that hypercholesterolemia increased the risk 
of prostate cancer and one prospective study44 reported a positive association for 
high-grade disease, while others found no43'49'50 or even a decreased51 association. 
Supplementary evidence of the role of cholesterol in prostate cancer has been 
provided by cholesterol-lowering-drugs (statins) studies. A recent meta-analysis by 
Bonnovas et al.52 addressed that statins were associated with an increased risk of 
having advanced prostate cancer. Besides the direct cholesterol-lowering effect of 
statins by statin-users, it is assumable that differences in PSA screening patterns 
between statin users and non-users also have contributed to the increased risk of 
having advanced prostate cancer. The other component in blood serum which is 
associated with prostate cancer is triglyceride.41'45
Although the relation between blood lipid profiles and prostate cancer risk has 
been investigated, only a few recent and population-based prospective studies have 
been reported. In chapter 8 we studied the association between serum cholesterol, 
triglycerides and prostate cancer risk in a Dutch, prospective population-based 
cohort among 2,862 men. After a median follow-up (IQR) of 56.4 (50.9-59.4) months, 
38 new cases of prostate cancer were identified. In this study, no strong evidence 
regarding blood lipid levels and risk of having prostate cancer was found. In contrast 
with other studies triglyceride levels, although not significant, were inversely related 
to prostate cancer risk. Our study, however, was based on relatively few cases, raising 
the possibility of a chance finding. Because of this we were not able to distinguish 
between localized and advanced or aggressive prostate cancer. Larger, prospective, 
population-based studies are needed to verify whether blood lipids might have more 
pronounced effects on advanced/ aggressive prostate cancer risk or mortality.
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Future Perspectives
Due to the ongoing obesity epidemic and increasing incidence of prostate cancer 
a relatively new topic 'obesity and prostate cancer' has gained more and more 
popularity among urologists and radiation oncologists in recent years. Although this 
thesis has shed light on this subject, there are still various issues that have to be 
resolved in the future. In this paragraph several of these issues will be addressed 
briefly.
Most of the issues concerning this subject have been focussed on epidemiological 
studies, tumour characteristics and oncological outcome. However, to date there 
is no consensus which of the different treatment modalities (surgery, external 
radiotherapy or brachytherapy) gives the obese patient suffering from prostate 
cancer the best oncological and functional outcome and quality of life. Although 
randomised controlled trials would be ideal to study outcome of therapy in obese 
and non-obese patients, this will be impossible to do. Therefore, data of patients 
who are treated for prostate cancer patients must be collected prospectively and 
validated questionnaires and uro-dynamic investigations are needed in order to 
achieve this goal. Without these trials making an assumption on which technique is 
the best for the obese patient suffering from prostate cancer cannot be made. 
Obese men undergoing external radiotherapy for localized prostate cancer may be at 
a greater risk of biochemical recurrence compared with their thinner counterparts. 
Besides tumour characteristics technical issues may also contribute to this discrepancy. 
In obese patients who undergo external radiotherapy daily setup errors can occur 
due to excessive intra-abdominal adipose tissue. These prostate shifts may result 
in not receiving the intended dose and leads to increased treatment failures if not 
corrected. Gold seeds and real time image-guided radiation therapy may be useful 
to improve the prostate targeting during radiotherapy, especially in obese patients. 
Comparative trials are needed to investigate whether gold seeds or image-guided 
radiation therapy can improve the oncological and functional outcome of obese 
patients suffering from prostate cancer
Besides BMI to determine obesity we also used CT to measure different fat entities 
in patients having prostate cancer. One of the disadvantages of using a CT is that it 
can only measure fat quantity. In addition to its lipid-storage capacity, adipose tissue 
is a highly active endocrine and metabolic organ. A very important question that 
must be answered is how metabolically active is that fat at the different locations 
of the human body? 'Fat' fat cells, those common in obese patients, produce 
larger quantities of cytokines (messengers to the rest of the body) than their 'thin' 
counterparts. However, a CT cannot distinguish between those two different types 
of fat cells. It may be assumed that some 'fat compartments' of the body produce 
more quantities of cytokines than other 'fat compartments'. So far we do not know
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if the abdominal fat which is wrapped around the intestines produces more or less 
cytokines than the fat which is located around the prostate. The fat around the 
prostate may act in a paracrine way by releasing the cytokines near the prostate 
while the abdominal fat releases the cytokines into the blood. To measure the fat 
activity it would be very interesting to collect fat at the different anatomical parts 
of the body during e.g. a radical prostatectomy. After the fat of different anatomical 
locations is collected, the fat cells can be brought into a medium where they are 
stimulated. The amount of cytokines produced by each of the fat cells at different 
parts of the body may represent its metabolic activity. By linking these data with the 
different anthropometric data of the patients and its prostate cancer characteristics 
and oncological outcome, a better insight may be gained in the exact role of obesity 
on prostate cancer. In contrast with the USA, different European studies did not find 
a higher rate of biochemical recurrence in obese patients who were treated for their 
prostate cancer compared with their thinner counterparts. Therefore, it would be 
very interesting to perform this study in Europe and America to determine if there 
are differences between the two continents that can explain this discrepancy.
Most of the studies concerning the risk of obesity on developing prostate cancer, high­
risk disease and biochemical recurrence after treatment were based on just one BMI 
measurement in adulthood. However, the following questions may arise: can an obese 
patient in whom prostate cancer is diagnosed improve his prognosis by losing weight? 
Is childhood obesity of greater risk of developing aggressive prostate cancer than 
adulthood gained obesity? Besides better definitions of obesity, where mostly BMI is 
just a marker for general obesity, further research should investigate the role of not 
just obesity at one point but rather lifelong obesity. Analogous to smoking where pack- 
years (i.e. number of cigarette packages smoked per year multiplied by the number 
of years of smoking) is used we should use the "obesity years duration" in oncological 
research to get a better insight in the real effect of obesity on cancer.
Finally, although better understanding of the link between obesity and prostate cancer 
and their molecular pathways might provide therapeutic targets, preventing overweight 
and obesity still remains number one priority. It is a bitter irony that as developing 
countries continue their efforts to reduce hunger, some are also facing the opposing 
problem of obesity. Besides the fact that obesity is related with a higher incidence of 
chronic illness including diabetes, heart disease and cancer, it could place significant 
financial burdens on the health care systems all over the world. In the European Union 
it is estimated that 113 million adult males and 98 million adult females have either 
overweight or are obese, while the prevalence is still increasing. Important measures 
to slow down the increasing prevalence among adults and children might be e.g. good 
education about healthy behaviour, lifestyle modifications, stimulation of exercise and 
removing television advertising of high-fat and/or high-sugar food and beverages or 
fast-food commercials at the children's peak viewing times.
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Closing Remarks
Obesity is a growing health problem that is increasingly affecting numerous aspects 
of medical care. This thesis focused on the effect of obesity on prostate cancer 
among Dutch patients. However, we need to realize that there are still many 
unresolved issues and more data regarding the effect of obesity on prostate cancer 
outcomes with the various treatment modalities are emerging. Based on the data 
presented in this thesis, I conclude the following: In a Dutch cohort of men who 
underwent a radical prostatectomy for prostate cancer, obese men were at risk for 
developing vesicourethral strictures and incontinence compared to their non-obese 
counterparts. Obese patients who underwent brachytherapy or surgery were not 
at higher risk for developing biochemical recurrence compared with the non-obese 
patients. In this thesis we measured the periprostatic fat density by CT. 31% of the 
patients with a normal BMI who received brachytherapy for their prostate cancer 
had a periprostatic fat density of > 75 percentile. In a group of patients with low 
and high-grade localized prostate cancer an increase of the periprostatic fat density 
was significantly correlated with the odds of having a high-risk disease. In a Dutch, 
prospective population-based cohort study among 2,862 men, no strong evidence of 
a relation regarding blood lipid levels and risk of having prostate cancer was found.
I would suggest that future research on the topic of obesity and prostate cancer must 
not simply focus on BMI, as a marker for general obesity but rather on correlating 
visceral obesity and adipocyte dysfunction. People with a healthy weight and even 
people with a very low BMI can still be too 'fat'. Although BMI does correlate with 
many health factors, it is not the amount of fat, but its location that matters for 
health. Therefore, a better definition of adiposity may expose clearer and perhaps 
new associations with prostate cancer and other diseases as well. Future research 
needs to evaluate the role of central versus peripheral obesity in epidemiologic 
studies.
Finally, the clinician must approach a prostate cancer patient in a holistic manner and 
educate the patient about the relation between the early all-cause morbidity and 
mortality associated with obesity.
"To prevent is better than to cure!"
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Summary
The aim of this thesis was to investigate the clinical implications of obesity on disease 
aggressiveness and treatment outcome in prostate cancer patients.
Chapter 1 presents a general introduction and outline of the thesis. The general 
introduction provides a short overview of the epidemiology and aetiology of prostate 
cancer. It sheds light over the definition of obesity, the different clinical aspects and 
the epidemiology of both obesity and prostate cancer. In this chapter the relation 
between obesity and prostate cancer and its clinical implications are described 
briefly. The chapter ends with an outline of the thesis.
Chapter 2 is a review of the literature about the possible impact of obesity on 
prostate cancer development, its clinical implications and effect on treatment 
outcome. The chapter starts with potential biochemical mechanisms related to 
obesity, which may act on prostate cancer development or progression. Alteration 
of hormone profiles and different adipokines are described. Obesity is associated 
with increased levels of estradiol and decreased serum concentrations of free 
testosterone and sex-hormone-binding globulin. At first sight this might seem 
protective for prostate cancer, however, several reports have shown a correlation 
between higher pathological disease stage at the time of surgery and lower levels of 
serum testosterone. Besides hormonal changes, obesity is associated with increased 
levels of several adipokines, like leptin, insulin-like growth factor-1, tumour necrosis 
factor a, interleukin 6, vascular endothelial growth factor and decreased levels of 
adiponectin. The available literature about each adipokine in relation with prostate 
cancer is discussed separately. The relation between different adipokines and 
prostate cancer progression is more consistent than the relation between different 
adipokines and prostate cancer development. However, most studies evaluated the 
adipokines individually, while a cumulative effect of all adipokines together may be 
of greater importance in prostate cancer progression.
The chapter continues with an overview of the literature about the influence of 
obesity on the risk of developing prostate cancer. Also, the relation between obesity 
and the prevalence of aggressive vs. non-aggressive prostate cancer is discussed. 
Although the relation between obesity and the risk of having prostate cancer is 
inconsistent, the existing evidence suggest that obesity is associated with a higher 
risk of having a more aggressive prostate cancer at the time of diagnosis.
The detection rate of prostate cancer in an obese patient may be influenced 
because obesity lowers the PSA level, enlarges the prostate and makes a digital 
rectal examination more difficult to perform. In this section, possible explanations 
why obese patients are at higher risk for biochemical recurrence are given. It is
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undisputed that obesity influences outcome, both functionally and oncologically. 
However, it is questionable whether higher recurrence rates seen after surgery and 
external beam radiotherapy are driven by worse biological features or caused by 
technical difficulties during the therapy or a combination of both. A short summary 
of the available literature that describes the relation between obesity and different 
treatment outcome is given.
Chapter 3 reports on a historical cohort study including 252 men who underwent a 
radical retropubic prostatectomy at the Canisius-Wilhelmina Hospital, Nijmegen to 
gain more knowledge about the effects of obesity on treatment outcome. Compared 
to non-obese men (N=221, 88%), obese men (N=31, 12%) were at a significantly 
higher risk of developing wound infections (16.1% vs. 4.5%), urinary incontinence 
(25.8% vs. 8.7%) and vesico-urethral strictures (45.2% vs. 12.3%). Obese patients 
were not at increased risk of having worse pathological features or biochemical 
recurrence after surgery.
Chapter 4 compares obese and non-obese patients with localized prostate cancer 
who have been operated in one of the following Dutch university hospitals: Radboud 
University Medical Centre, Nijmegen or Erasmus University Medical Center, 
Rotterdam. Although epidemiological studies of obesity in relation to prostate 
cancer development have provided conflicting results, recent studies from the USA 
suggested that a higher body mass index (BMI) is associated with an increased risk 
of biochemical recurrence after a radical prostatectomy. A total of 1,368 patients, of 
whom 600 (43.9%) were classified as having normal weight, 665 (48.6%) as overweight 
and 103 (7.5%) as obese, were included. To determine the risk of biochemical 
recurrence, 1,302 patients were analyzed. After a median follow-up of 59 months, 
297 patients developed biochemical recurrence. The 10-year risk (95% confidence 
interval) of biochemical recurrence was 31.9% (26.6%-37.2%), 30.5% (25.8%-35.2%) 
and 23.9% (14.9%-32.9%) for patients in the normal, overweight and obese group, 
respectively (p=0.84). In this study, BMI appeared to have no significant prognostic 
value for biochemical recurrence in Dutch patients with clinically localized prostate 
cancer treated with radical prostatectomy.
Chapter 5 reports a study on the impact of obesity on treatment outcome in patients 
who underwent brachytherapy at the University Medical Center Utrecht. In total, 
1,530 patients with clinically localized prostate cancer were evaluated retrospectively. 
The study included 617 (40.3%) normal-weight patients, 754 (49.3%) over-weight 
patients and 159 (10.4%) obese patients. The focus of this study was on biochemical 
recurrence, cancer-specific survival and overall survival. After a median follow-up 
of 47.0 months, 249 (16.3%) patients developed biochemical recurrence and 193
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(12.6%) patients died. The Kaplan-Meier 8-year risk of biochemical recurrence (95% 
confidence interval) was 33.3% (27.2%-39.4%), 29.2% (23.5%-34.9%) and 29.3% 
(12.4%-46.2%) for patients in the normal, overweight and obese group, respectively. 
The Kaplan-Meier 8-year cancer-specific survival (95% CI) was 88.2% (83.1%-93.3%), 
88.6% (83.7%-93.5%) and 90.6% (79.9%-100.0%) for patients in the normal, overweight 
and obese group, respectively. Multivariable proportional hazard regression analyses 
of BMI and established prognostic factors for biochemical recurrence confirmed the 
absence of any prognostic value of BMI on biochemical recurrence, cancer-specific 
survival and overall survival.
From the three previous chapters we can conclude that BMI seems to be related 
to functional outcome of a radical prostatectomy, but BMI has no prognostic 
value when oncological outcome is analysed after local therapy with curative 
intent. However, in these chapters BMI is used as a general marker of obesity. 
Computed tomography (CT) can measure the fat distribution very accurately and 
can distinguish the contribution of central and peripheral fat. In chapter 6 a CT was 
used to measure the subcutaneous fat distribution and the fat around the prostate, 
the so-called periprostatic fat. To investigate whether the amount of periprostatic 
fat correlates with prostate cancer aggressiveness, 725 CT scans of patients who 
were treated with brachytherapy were evaluated. 237 (37.2%) of the patients were 
classified as having normal weight, 320 (50.2%) as overweight and 80 (12.6%) as 
obese (from 88 patients the BMI was not available). The patients were stratified into 
3 groups: <25, 25-75 and >75 percentile of the periprostatic fat density. There was a 
significant association between BMI and periprostatic fat density and subcutaneous 
fat thickness. The strongest correlation was seen between BMI and subcutaneous 
fat thickness (Pearson coefficient=0.71). Logistic regression analysis revealed no 
statistically significant association between periprostatic fat density and prostate 
cancer aggressiveness. However, the study population consisted exclusively of low 
and intermediate grade and T1 to T2 prostate cancers. Interestingly, 31% of the 
patients with a normal BMI were above the 75thpercentile of the periprostatic fat 
density. Thus, what is measured on the outside is definitely not always representative 
of the fat distribution around the prostate.
Chapter 7 describes 932 patients with T1-T3N0M0 prostate cancer who underwent 
radiotherapy (brachytherapy (N=621) and external beam radiotherapy (N=311)) for 
their localized prostate cancer. Their CT scans were evaluated and the periprostatic 
fat and subcutaneous fat thickness was measured. A possible association between 
these fat measurements and the risk of having high-risk disease was examined. 
Logistic regression analyses revealed a significant association between periprostatic 
fat density and the risk of having high-risk disease.
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Chapter 8 represents a population-based cohort study among 2,862 men. It has 
been hypothesized that blood lipid profiles are associated with prostate cancer 
risk. In this chapter we addressed serum total cholesterol, HDL cholesterol, LDL 
cholesterol and triglycerides as potential risk factors for prostate cancer using age- 
adjusted proportional hazards regression models. During a median follow-up of 
56.4 months, 38 new cases of prostate cancer were identified. Non-significantly 
increased risks (95% CI) per mmol/L were observed for total cholesterol (HR 1.22, 
0.91-1.66), HDL cholesterol (HR 1.83, 0.71-4.69) and LDL cholesterol (HR 1.36, 0.97­
1.91). Triglycerides were associated with decreased prostate cancer risk (HR 0.77, 
0.54-1.09). Unfortunately, the follow-up was too short and the population size too 
small to reach sufficient statistical power for any definitive conclusion.
Chapter 9 provides a general discussion of the various investigations of the present 
thesis in light of the relevant literature. Future perspectives for further research are 
outlined and the closing remarks bring this thesis to an end.
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Samenvatting
Het doel van dit proefschrift is om een aantal verschillende klinische aspecten 
van obesitas te onderzoeken in relatie tot de agressiviteit van de ziekte en de 
behandelingsresultaten van patiënten met prostaatkanker.
Hoofdstuk 1 bestaat uit een algemene introductie en uiteenzetting van het 
proefschrift. De algemene introductie geeft een kort overzicht over de epidemiologie 
en etiologie van prostaatkanker. Tevens behandelt het de definitie van obesitas en de 
verschillende klinische en epidemiologische aspecten. Ook komen de relatie tussen 
obesitas en prostaatkanker en in het kort de klinische implicaties daarvan aan de 
orde. Tot slot wordt een uiteenzetting van dit proefschrift gegeven.
Hoofdstuk 2 is een literatuuroverzicht waarin de mogelijke invloed van obesitas op 
de ontwikkeling van prostaatkanker, klinische implicaties en behandelingsresultaten 
worden beschreven. Het hoofdstuk begint met de potentiële biochemische 
mechanismen die worden gezien bij obesitas, welke op haar beurt invloed kunnen 
uitoefenen op zowel de ontwikkeling van prostaatkanker als ook op de progressie. 
Daarna volgt een beschrijving van hormonale veranderingen en verschillende 
adipokines. Obesitas is geassocieerd met verhoogde oestradiol spiegels en verlaagde 
serumconcentraties van het vrije testosteron en sex-hormoon-bindend globuline. 
Op het eerste gezicht lijkt deze verandering juist beschermend tegen prostaatkanker. 
Verschillende studies bevestigen een correlatie tussen een slechter pathologisch 
stadium en een lage testosteronspiegel ten tijde van de operatie. Naast hormonale 
veranderingen is vetzucht ook geassocieerd met verhoogde concentraties van 
verschillende adipokines zoals leptine, insulin-like growth factor-1, tumor necrose 
factor a, interleukine 6, vascular endothelial growth factor en verlaagde concentraties 
van adiponectine. De beschikbare literatuur over elk adipokine in relatie tot 
prostaatkanker worden separaat besproken. De relatie tussen de verschillende 
adipokines en progressie van prostaatkanker is minder inconsistent dan de relatie 
tussen de verschillende adipokines en het risico op het krijgen van prostaatkanker 
Echter, de meeste studies bestuderen de adipokines individueel terwijl een cumulatief 
effect van alle adipokines bij elkaar mogelijk een grotere invloed zouden hebben op 
prostaatkanker progressie.
Het hoofdstuk gaat verder met een literatuuroverzicht over het risico van obesitas op de 
ontwikkeling van prostaatkanker. De relatie tussen obesitas en een verhoogde kans op 
het hebben van een agressieve vorm van prostaatkanker vergeleken bij een niet obese 
man wordt ook besproken. Hoewel de relatie tussen obesitas en het risico op het krijgen 
van prostaatkanker niet duidelijk is, bestaat er meer bewijs over de rol van obesitas ten 
tijde van behandeling en het hebben van een meer agressieve vorm van prostaatkanker.
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De detectiegraad van prostaatkanker bij patiënten met obesitas kan worden beïnvloed 
omdat obesitas de PSA waarde verlaagt, de prostaat vergroot en rectaal onderzoek 
bemoeilijkt. Mogelijke verklaringen waarom obese patiënten een hoger risico lopen 
op het krijgen van een biochemisch recidief komen ook in het hoofdstuk aan bod. 
Het is onomstreden dat obesitas invloed heeft op de behandelingsresultaten in 
functionele en oncologische zin. Het is echter niet duidelijk of de hogere recidiefkans, 
die valt waar te nemen na chirurgie en uitwendige bestraling, wordt veroorzaakt 
door slechtere biologische tumorkenmerken, technische problemen tijdens de 
behandeling of een combinatie van beiden. Het hoofdstuk eindigt met een korte 
samenvatting van de beschikbare literatuur die de relatie beschrijft tussen obesitas 
en verschillende behandelingsresultaten.
Hoofdstuk 3 rapporteert een historisch cohortstudie bestaande uit 252 mannen 
die een radicale prostatectomie hebben ondergaan in het Canisius-Wilhelmina 
Ziekenhuis in Nijmegen. Om meer kennis te krijgen over het effect van obesitas 
op de behandelingsresultaten, werden de patiënten retrospectief geanalyseerd. 
Vergeleken met niet-obese mannen (N=221, 88%), hadden mannen met obesitas 
(N=31, 12%) een significant hoger risico op het ontwikkelen van wondinfecties 
(16.1% vs. 4.5%), urine incontinentie (25.8% vs. 8.7%) en vesico-urethrale stricturen 
(45.2% vs. 12.3%). Obese patiënten hadden geen verhoogd risico met betrekking tot 
slechtere pathologische kenmerken of biochemisch recidief.
Hoofdstuk 4 vergelijkt obese en niet obese patiënten met gelokaliseerde prostaat­
kanker, die zijn geopereerd in het Radboud Universitair Medisch Centrum 
Nijmegen, danwel het Erasmus Universitair Medisch Centrum Rotterdam. 
Alhoewel epidemiologische studies over obesitas in relatie tot de ontwikkeling van 
prostaatkanker tegenstrijdige uitkomsten laten zien, tonen recente Amerikaanse 
onderzoeken aan dat een hogere body mass index (BMI) is geassocieerd met een 
hoger risico op een biochemisch recidief bij patiënten die een radicale prostatectomie 
hebben ondergaan. In totaal werden er 1368 patiënten geïncludeerd van wie er 
600 (43.9%) een normaal gewicht hadden, 665 (48.6%) hadden overgewicht en 
103 (7.5%) waren obees. Om het risico op biochemisch recidief vast te stellen 
werden 1302 patiënten geanalyseerd. Na een mediane follow-up van 59 maanden 
ontwikkelden 297 patiënten een biochemisch recidief. Het 10-jaar risico (95% 
betrouwbaarheidsinterval) op de ontwikkeling van biochemisch recidief was 31.9% 
(26.6%-37.2%), 30.5% (25.8%-35.2%) en 23.9% (14.9%-32.9%) voor patiënten 
met respectievelijk een normaal gewicht, overgewicht en obesitas (p=0.84). In dit 
proefschrift blijkt de BMI, bij Nederlandse patiënten met een klinisch gelokaliseerde 
prostaatkanker en die behandeld zijn met een radicale prostatectomie, niet van 
prognostische waarde te zijn voor het krijgen van een biochemisch recidief.
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Hoofdstuk 5 betreft een studie over de invloed van obesitas op de 
behandelingsuitkomsten van patiënten die brachytherapie hebben ondergaan 
in het Universitair Medisch Centrum Utrecht. In totaal werden 1530 patiënten 
met klinisch gelokaliseerde prostaatkanker retrospectief geanalyseerd. De studie 
bestond uit respectievelijk 617 (40.3%) patiënten met een normaal gewicht, 754 
(49.3%) met overgewicht en 159 (10.4%) met obesitas. In deze studie werd de relatie 
tussen obesitas enerzijds en biochemisch recidief, kanker specifieke overleving en 
totale overleving anderzijds bekeken. Na een mediane follow-up van 47.0 maanden 
ontwikkelden 249 (16.3%) patiënten een biochemisch recidief en overleden 193 
(12.6%) patiënten. Het Kaplan-Meier 8-jaarsrisico op biochemisch recidief (95% 
CI) was 33.3% (27.2%-39.4%), 29.2% (23.5%-34.9%) en 29.3% (12.4%-46.2%) voor 
patiënten met respectievelijk een normaal gewicht, overgewicht en obesitas. In 
dezelfde volgorde bedroeg de Kaplan-Meier 8-jaar kankerspecifieke overleving (95% 
CI) respectievelijk 88.2% (83.1%-93.3%), 88.6% (83.7%-93.5%) en 90.6% (79.9%- 
100.0%). De multivariabele proportionele hazard regressie-analyse tussen BMI en de 
bekende prognostische factoren voor biochemisch recidief bevestigde de afwezigheid 
van enige prognostische waarde van de BMI op het voorspellen van biochemisch 
recidief, kankerspecifieke overleving en totale overleving.
De conclusie uit de vorige drie hoofdstukken is dat BMI wel is gerelateerd aan de 
functionele uitkomsten na een radicale prostatectomie, maar de BMI heeft geen 
voorspellende waarde met betrekking tot de oncologische resultaten na lokale, in 
opzet curatieve therapie. Echter, in de vorige drie hoofdstukken is BMI als generale 
maat voor vetzucht gebruikt. Computed tomography (CT) kan de distributie van vet 
erg nauwkeurig bepalen en een onderscheid maken tussen centraal en perifeer vet. 
In hoofdstuk 6 wordt met behulp van een CT de subcutane vetdikte en het vet rond 
de prostaat, verder genoemd het periprostatisch vet, berekend. Om te onderzoeken 
of de hoeveelheid periprostatisch vet correleert met prostaatkankeragressiviteit 
werden 725 CT's geëvalueerd van patiënten die waren behandeld met brachytherapie 
voor gelokaliseerd prostaatkanker. Geclassificeerd zijn er onder deze 725 patiënten, 
237 (37.2%) met normaal gewicht, 320 (50.2%) met overgewicht en 80 (12.6%) met 
obesitas (bij 88 patiënten kon de BMI niet worden bepaald). De patiënten werden in 
3 groepen ingedeeld, te weten: <25, 25-75 en >75 percentiel van de periprostatische 
vetdichtheid. Er was een significante associatie tussen BMI en periprostatische 
vetdichtheid en subcutane vetdikte. De sterkste correlatie werd gevonden tussen 
BMI en subcutane vetdichtheid (Pearson-coëfficiënt= 0.71). Logistieke regressie­
analyse leverde geen statistisch significante associatie op tussen periprostatische 
vetdichtheid en prostaatkankeragressiviteit. Echter, de studiepopulatie bestond 
hoofdzakelijk uit patiënten met een tumor van een lage en intermediaire graad van 
agressiviteit, met een klinisch stadium T1 of T2. Interessant genoeg hadden 31% van
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de patiënten met een normale BMI een periprostatische vetdichtheid van hoger dan 
de 75ste percentiel. Concluderend is wat je aan de buitenkant meet niet automatisch 
representatief voor de vetverdeling rond de prostaat.
Hoofdstuk 7 beschrijft 932 patiënten met T1-3N0M0 prostaatkanker die radiotherapie 
(brachytherapie (N=621) en externe radiotherapie (N=311)) voor gelokaliseerde 
prostaatkanker hebben ondergaan. De CT's van deze mannen zijn geëvalueerd en het 
periprostatisch vet en de subcutane vetdichtheid gemeten. Een mogelijke associatie 
tussen deze verschillende vetbepalingen en het risico op het hebben van een hoog 
risico prostaatkanker werden bestudeerd. Logistische regressie-analyse laat een 
significante associatie zien tussen de periprostatische vetdichtheid en het risico op 
het hebben van een agressieve vorm van prostaatkanker.
Hoofdstuk 8 gaat over een populatie-gebaseerde cohortstudie van 2862 mannen. 
Er wordt verondersteld dat vetprofielen die meetbaar zijn in het bloed geassocieerd 
zijn met het risico op het krijgen van prostaatkanker. In dit hoofdstuk behandelen we 
het totale serum cholesterol, HDL cholesterol, LDL cholesterol en triglyceriden als 
potentiële risicofactoren voor prostaatkanker. Hierbij hebben we gebruik gemaakt 
van een voor leeftijd gecorrigeerde proportionele hazard analyse. Gedurende 
een mediane follow-up van 56.4 maanden werd bij 38 mannen prostaatkanker 
vastgesteld. Een niet significant toegenomen risico (95% CI) per mmol/L werd 
gevonden voor totaal cholesterol (HR 1.22, 0.91-1.66), HDL cholesterol (HR 1.83, 
0.71-4.69) en LDL cholesterol (HR 1.36, 0.97-1.91). Triglyceriden (HR 0.77, 0.54­
1.09) werden geassocieerd met een verminderde kans op het diagnosticeren van 
prostaatkanker. Ongelukkigerwijs was de follow-up te kort en het aantal patiënten 
met prostaatkanker te laag om voldoende statistische power te verkrijgen om tot een 
definitieve conclusie te komen.
Hoofdstuk 9 bediscussieert de resultaten van de bovenstaande studies in het licht van 
relevante literatuur. Verder worden enkele slotopmerkingen gemaakt en suggesties 
gedaan voor verder onderzoek.
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Dankwoord 'Jullie waren de motor voor dit succes!!'
Een aantal jaar geleden had ik niet kunnen voorspellen dat, na een avondje tv kijken 
en wederom de nodige dikke, snackende mensen te hebben gezien, mijn onschuldige 
nieuwsgierigheid zou uitgroeien tot het proefschrift wat nu voor u ligt. Ik vroeg me 
daadwerkelijk af wat de gevolgen van de steeds dikker wordende mens zouden zijn 
op mijn vakgebied. Ook al ben ik de inspirator en initiator van de onderzoeken in 
dit proefschrift, zonder de steun, zonder gebruik te mogen maken van verschillende 
databasen, zonder patiënten en zonder morele ondersteuning was het me absoluut 
niet gelukt. Iedereen die op welke manier dan ook een bijdrage heeft geleverd die 
geleid heeft tot dit proefschrift ben ik dan ook zeer veel dank verschuldigd. Een aantal 
mensen wil ik nog persoonlijk bedanken:
Lieve, lieve Roos, mijn allessie, voor mij ben jij DE motor geweest om het proefschrift 
spoedig af te schrijven. Gelukkig heb je nog mogen meemaken dat mijn proefschrift 
is goedgekeurd door de manuscriptcommissie en wist je zelfs mijn promotiedatum. 
Helaas liet de geneeskunde anno 2010 jou in de steek, terwijl er voor jou daar 
juist een mooie toekomst was weggelegd. Ik ben je niet alleen dankbaar voor de 
onvoorwaardelijke steun, maar ook voor al die mooie momenten die we samen 
hebben mogen beleven. De dagen met jou waren een groot feest! Deze mooie 
herinneringen en onvergetelijke ervaringen die ik koester zijn de wind die ik nodig 
heb om door te varen. Lieverd, wat heb ik van je genoten. Ik mis je enorm, maar op 
de avond van mijn promotie heffen we SAMEN het glas!
Prof. dr. J.A. Witjes, beste Fred, in de eerste weken van mijn academische opleiding 
vroeg ik je of het mogelijk was om onder jouw vleugels te mogen promoveren. Je 
antwoordde redelijk resoluut: "Veel assistenten willen graag bij me promoveren, 
maar hun verzoek blijft vaak onaangeroerd in de la liggen." Gelukkig ben ik niet één 
van de velen en heb ik de daad bij het woord gevoegd. Spoedig kreeg ik mijn eigen 
mapje. Zie hier het resultaat. Ik wil je enorm bedanken voor jouw enthousiasme en 
betrokkenheid gedurende het onderzoekstraject. Stukken die ik naar je opstuurde 
ter correctie waren in mum van tijd weer bij me terug. Daarnaast ben ik je veel dank 
verschuldigd voor de vele leermomenten tijdens mijn opleiding. Het was altijd een 
groot genoegen om met jou aan de operatietafel te staan. Je nam altijd de tijd om 
dingen uit te leggen. Je hebt de gave om je assistent het gevoel te geven dat hij of 
zij de operatie geheel zelfstandig heeft uitgevoerd. Als assistenten noemden we dat 
"knippen over de stippellijn". Als jonge klare zelfstandig aan tafel is het soms wel 
eens zoeken naar die stippellijn!
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Prof. dr. L.A.L.M. Kiemeney, beste Bart, tijdens de beginfase van mijn proefschrift 
kwam ik bij jou langs voor statistische adviezen. Vaak bleef het niet bij louter en 
alleen statistische adviezen, maar had jij ook inhoudelijk en taalkundig de nodige 
op- of aanmerkingen. Hiervoor nam je altijd ruimschoots de tijd en je was erg 
laagdrempelig in het maken van een afspraak. De manier waarop jij complexe 
statistische vraagstukken weet te simplificeren, zodat het ook voor een leek duidelijk 
wordt, spreekt mij zeer aan. In jouw enthousiasme heb je zelfs een uitleg op een 
white-board vereeuwigd door er per ongeluk met een watervaste stift op te schrijven. 
Ook jouw niet-medische kijk op verschillende stukken was zeer verhelderend. Je hebt 
me de nodige statistische kennis verschaft en ik kan nu zelfs met SPSS al aardig uit de 
voeten. Veel dank hiervoor.
Prof. dr. J.L.H.R. Bosch, beste Ruud, na mijn opleiding ben ik als fellow oncologie/ 
laparoscopie op de afdeling urologie in Utrecht terecht gekomen. Ik heb met veel 
genoegen op jouw afdeling gewerkt. Naast de urologische werkzaamheden gaf je 
me alle ruimte om mijn proefschrift te voltooien en heb je een aantal artikelen van 
kritisch commentaar voorzien. Veel dank hiervoor.
Dr. M. van Vulpen, beste Marco, al snel heb ik je met mijn obesitasvirus besmet en 
werd je steeds enthousiaster over het onderwerp. Vele uren hebben wij bij elkaar 
op de kamer zitten brainstormen. Jij bijtend in je Grannysmith, ik achter een kop 
koffie. Niet alleen hebben we veel artikelen in een relatief korte periode geschreven 
over het onderwerp van dit proefschrift, ook heb je me betrokken bij het lopende 
onderzoek van jouw afdeling. Dit heb ik altijd enorm gewaardeerd. Heel veel dank 
voor je onaflatende support.
Dieuwertje Kok, dank voor jouw hulp bij het samenvoegen van de Rotterdamse en 
Nijmeegse database. Daarnaast ben je ook nog actief betrokken geweest bij het 
schrijven van twee artikelen. Ik heb met veel plezier met je samengewerkt. Helaas 
liep jouw promotietraject niet zoals je graag had gewild, maar ik ben er van overtuigd 
dat het jou gaat lukken. Dank voor al het werk wat je hebt verricht.
Karel Hinnen, als coassistent raakte je betrokken bij mijn onderzoek en zette je een 
database voor me op. Dit onderzoek leidde ertoe dat je nu zelf een onderzoekstraject 
doorloopt waaruit al veel artikelen zijn voortgevloeid. Ik wens je veel succes met het 
afronden van je promotie en je urologische carrière. Dank voor al je inspanningen.
Dr. J.P. van Basten, beste Jean-Paul, niet vermoedend dat dit het begin zou zijn van 
het werk wat nu voor je ligt, schreef ik samen met jou mijn eerste artikel. "Schrijven is 
schrappen" was je devies. Ik heb me dit zeer ter harte genomen. Dank voor je hulp!
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Collega's van het UMC Utrecht, Ruud, Arto, Tycho en Laetitia, Tom, Pieter, Aart, 
assistenten, verpleegkundigen en secretaresses wil ik hartelijk danken voor de fijne 
tijd die ik heb gehad op de afdeling urologie. Met veel plezier heb ik op de afdeling 
gewerkt.
Arto, vele uren hebben we samen op de operatiekamer gestaan en jij hebt me onder 
andere verder wegwijs gemaakt in de wereld van de laparoscopie. Het was niet alleen 
leerzaam, maar ook de prettige sfeer die we samen wisten te creëren met gelukkig 
de nodige dosis humor, heb ik als zeer aangenaam ervaren. Dank!!
Kamergenoten, Esther en Laetitia, zittend tussen 2 gepromoveerde dames kon ik 
natuurlijk niet achter blijven. Krassen jullie die 's' maar weg! Naast het lenen van 
woordenboeken, nietapparaten en andere kantooraccessoires was het vooral 
de gezelligheid die me tussen mijn werk door veel afleiding heeft bezorgd. Dank 
hiervoor.
Opleiders en assistenten met wie ik samen de opleiding heb gedaan wil ik hartelijk 
bedanken voor de gezellige en leerzame tijd tijdens mijn opleiding tot uroloog.
Matthijs dank voor je hulp bij de lay-out van dit proefschrift!
Mijn paranimfen, collega's maar vooral vrienden, Mark en Lennard. Mark, die middag 
achter de snijtafel met dat kleine levenloze biggetje voor ons was het begin van onze 
vriendschap. Ik hoop dat die vriendschap nog lang mag duren. Ik ben trots om getuige 
te mogen zijn op jouw aanstaande huwelijk. We gaan er een mooi feest van maken. 
Lennard, ook al hebben we maar kort als assistent-chirurgie samengewerkt, vanaf 
het begin hadden we een klik en zagen we elkaar ook na het werk. Geweldig dat we 
samen in Brabant gaan werken. Super dat jullie beide mijn paranimfen willen zijn!
Last, but zeker niet least wil ik mijn dierbare (schoon)familie en Wouter, Matthia, 
Rutger, David en vriend(inn)en bedanken voor al hun belangstelling. Ondanks 
de roerige tijd die we samen hebben doorgemaakt, waren jullie altijd oprecht 
geïnteresseerd in het wel en wee van mijn proefschrift. Ik hoop dat jullie nu een 
beetje begrijpen waarmee ik me de afgelopen periode heb beziggehouden. Daarnaast 
wil ik jullie enorm danken voor de vele ontspannen avondjes, gezellige etentjes en 
borrels. Dit waren voor mij dè kersen op de taart! Hierdoor kon ik de motor weer 
opladen en het gaf me nieuwe inspiratie om dit proefschrift af te schrijven. Beide 
Harry's en Mark, dank voor het kritisch doornemen en becommentariëren van mijn 
manuscript.
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Lieve Rolf en Marleen, wat fijn dat we als broers en zus zo veel plezier hebben. Ik ben 
trots op jullie!
Lieve mama, vroeger zei je altijd: "Als Joep iets in zijn kop heeft zitten dan...."
Waarschijnlijk is dit een van de belangrijke eigenschappen geweest die er voor 
gezorgd heeft dat dit boekje nu geschreven is. Helaas mam, kan ik je het proefschrift 
niet persoonlijk overhandigen. Ik ben je heel erg dankbaar voor alle liefde, warmte, 
steun en betrokkenheid die je me al die jaren hebt gegeven. Ik had erg graag nog vele 
jaren met je willen lachen, maar helaas is ons dat niet gegund.
Lieve papa, jij weet als geen ander wat ik nu doormaak en vice versa. Ik ben enorm 
trots op je hoe jij je leven weer hebt opgepakt na het overlijden van mama. Daarin 
ben je absoluut een lichtend voorbeeld. Samen met mama hebben jullie mij alle 
mogelijkheden gegeven en jullie liefde en nooit aflatende steun en vertrouwen heeft 
me daar gebracht waar ik nu ben. Niet alleen in carrière-technisch opzicht, maar zeker 
ook op het persoonlijke vlak. Ik ben jullie daarvoor eeuwig dankbaar! Dit proefschrift 
draag ik uit dankbaarheid aan jullie op.
165
Curriculum Vitae
C u R R iC U L U M  V i t a e
Joep van Roermund werd op 28 februari 1974 geboren in 
Nijmegen. Op jonge leeftijd verhuisde hij met zijn ouders 
naar Roosendaal te Noord-Brabant. Daar behaalde hij in 
1993 zijn VWO diploma aan het Norbertus college. In dat 
zelfde jaar verliet hij het mooie Brabantse land om de studie 
Geneeskunde te beginnen aan het UMC St Radboud (Destijds 
Katholieke Universiteit Nijmegen).
Voor de aanvang van zijn coschappen liep hij een aantal weken 
mee op de afdeling urologie van het Catharina Ziekenhuis 
in Eindhoven, onder leiding van dr. A.J.M. Hendrikx. Zijn enthousiasme voor het 
vakgebied werd daar geboren. In eerste instantie zou hij er 2 weken blijven maar 
uiteindelijk bleef hij een half jaar. In die tijd kwam hij voor het eerst in aanraking met 
wetenschappelijk onderzoek. Daarna verbleef hij 2 maanden in Helsinki op de afdeling 
transplantatie en hepatobiliaire chirurgie (prof. dr. K. Höckerstedt). In september 
2000 behaalde hij zijn arts-examen. Nadat hij driekwart jaar had gewerkt als arts­
assistent op de afdeling urologie in het Canisius Wilhelmina Ziekenhuis te Nijmegen, 
werd hij in 2001 aangenomen voor de opleiding urologie. Voor zijn vooropleiding 
heelkunde, die hij volgde in het Medisch Spectrum Twente (opleider prof. dr. P.A.M. 
Vierhout), verhuisde hij naar Enschede. Daar leerde hij Rosanne van Lingen kennen, 
met wie hij in 2007 trouwde. Na zijn vooropleiding deed hij zijn perifere deel van 
zijn opleiding urologie in het Canisius Wilhelmina Ziekenhuis (opleider dr. H.F.M. 
Karthaus). De laatste 2 jaar van zijn opleiding vervolgde hij op de afdeling urologie 
in het Universitair Medisch Centrum St Radboud te Nijmegen (opleider prof. dr. J.A. 
Witjes). Tijdens deze jaren van zijn opleiding begon hij met het onderzoek dat heeft 
geleid tot dit proefschrift. Nadat hij zijn opleiding tot uroloog eind 2007 had afgerond, 
is hij als fellow oncologie/laparoscopie gaan werken op de afdeling urologie in het 
Universitair Medisch Centrum Utrecht (prof. dr. J.L.H.R. Bosch). In juli a.s. zet hij zijn 
urologische carrière voort in het Catharina Ziekenhuis te Eindhoven.
Ter gelegenheid van het 100-jarig bestaan van de Nederlandse Vereniging voor 
Urologie, nam hij deel aan het ludieke lustrum cabaret.
In 2009, enkele weken na haar eigen promotie, werd bij zijn vrouw Acute Myeloïde 
Leukemie vastgesteld. Een jaar later overleed ze aan de gevolgen van deze ziekte.
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